TREATMENT TARGETING ONCOLOGY AND NEURODEGENERATION

Abstract

The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools.

Description

CROSS REFERENCE TO RELATED APPLICATION

[0001] This application is a continuation of U.S. patent application Ser. No. 13/681,164 filed on Nov. 19, 2012, which is a continuation in part application of U.S. patent application Ser. No. 12/282,117 filed on Sep. 8, 2008 and which is also a continuation in part application of International Patent Application Serial No. PCT/FR2011/000155 filed on Mar. 18, 2011.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools.

[0003] The inventor highlights the mechanisms of molecular interactions and the interest of biochips dedicated according to cancers with a multi-therapy added with therapeutic additives to slow down the formation of these lesions.

[0004] The comprehension of the plays of balance between under-expression and over-expression of genes according to their localization in a cellular compartment allows to open a field of finer differential analysis and to adapt a multi-therapy with siRNA and peptides by molecular targeting.

DESCRIPTION OF THE STATE OF THE ART

[0005] Age-related neurodegenerative diseases and cancers both involve a modification of the physiological process of programmed cell death or apoptosis. Neuronal death is abnormally accelerated during neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease etc . . . . On the other hand, the cancerization process corresponds to a blocking of apoptosis, which results in an uncontrolled multiplication of cells. The link between these two processes has currently become a major field of investigation in research on aging. The control of the balance between cell division (mitosis), differentiation and programmed cell death (apoptosis), is fundamental during normal physiological processes, including embryonic development, tissue regeneration and aging. An impairment of this balance can lead to major pathological situations such as the formation of tumors or some neurodegenerative diseases.

[0006] Cancer is one of the principal causes of mortality throughout the world. While, over the course of the last generation, the percentages of deaths related to cardiac and cardiovascular diseases and a large number of other diseases has decreased, the number of deaths related to the various forms of cancer has increased.

[0007] Despite the rapid advance in our understanding of the various forms of cancer, the low survival rates can generally be attributed to inadequate diagnosis and inadequate treatment. Most tumors can only be detected when they reach a size of approximately 1 cm. Since a continuously developing tumor takes a relatively short period of time to evolve to a stage which is incompatible with survival, this leaves little time for a therapeutic intervention. Early diagnosis therefore becomes the key to success for the treatment of cancer. Skin cancer for example, is the most widespread cancer in Canada. In 1992 alone, 50 300 new cases of skin cancer were reported, compared with 19 300 cases of lung cancer, 16 200 cases of colorectal cancer and 15 700 cases of breast cancer. In other words, skin cancer is as common as the three main types of cancer combined. Its incidence continues to increase, with 64 200 new cases thereof in 1997, corresponding to an increase of 14 000 cases in 5 years. In particular, the incidence of malignant melanoma is increasing at a rate of 2% per year. Early diagnosis remains the key to an effective treatment. A malignant tumor is readily accessible and can be removed with minor surgery. In fact, recovery is 100% if skin cancer is detected early enough. Early diagnosis of skin cancer remains however difficult . . . . It thus becomes important to be able to distinguish these two types of skin cancers. A final diagnosis of skin cancer requires a biopsy and a histological analysis. However, the decision to send a biopsy for analysis (or even if a patient must be referred with a dermatologist) becomes very subjective. There are several biopsies which are not taken whereas they would have being.

[0008] Colon cancer is the third most common cause of cancer-related mortality in men and women in North America (16 200 cases per year). Early detection, leading to an early intervention, has demonstrated that treatment success and survival rate can be improved. For example, the 5-year survival rate is 92% for a patient whose disease was detected at an early stage, whereas the rate drops to approximately 60% in patients with a localized cancer, and to approximately 6% in those with metastases. However, only a third of colon cancers are detected at an early stage. One of the reasons for this delay in diagnosis is the absence of a sensitive, relatively inexpensive and non-invasive screening test. Breast cancer is one of the most common cancers in women, together with colon cancer. The mortality rate is the highest among cancers affecting women. There are very few diagnostic markers allowing the detection of breast cancer and they only have a predictive value of 20%, There are no markers, either, which can detect or determine the invasiveness or the aggressiveness of metastatic cancer cells or which permit therapeutic monitoring.

[0009] For a multitude of reasons, early diagnosis remains illusory for most forms of cancer. For certain forms of cancer, disease-specific markers are not available or are only available at an advanced stage of the disease, making diagnosis difficult. In other forms of cancer, the markers are available but are not always specific for the disease or they may be associated with its benign form.

[0010] A hope this year with the marker who is the receiver with FSH is possible. As one of our markers of the LIV21 complex (cf. figure) it is common to several cancers and allows an early diagnosis, it also appears in the vessels as ours which one can see in Alexa revealed on the level of the endothelial cells, but in more we observe a marking of the erythrocytes and also collagen. During the last years, considerable progresses were made in the comprehension of the means implemented by the oncogenes and tumor suppressor genes to control cell proliferation and the apoptosis. One of the main targets of these regulators is the family of E2E-type transcription factors in the E2F and RB protein signaling pathway.

[0011] In other cases still, the techniques exist hut the prohibitory cost to in general implement them to the population makes them inappropriate.

[0012] These cancers may find it beneficial to be studied and diagnosed by biochip including the bio-markers of the major pathways of regulation to allow an adjustment of the multi-therapy according to the results of under expression and over-expression of genes of the complex Liv21.

[0013] Thus the processing by standard molecular targeting siRNA or monoclonal antibodies combined or not with chemical therapeutic assets is of a greater effectiveness.

[0014] The neuroblastes are neuronal precursors resulting from the splitting of the neuro-epithelial cells. There are immature embryonic neurons which can still divide contrary to the mature neurons which cannot enter in mitosis.

[0015] The neuroblastoma, also called sympathoblastome, is a malignant tumor developed at the expense of the cells of the neural crest, which give rise to the sympathetic nervous system. It is of the solid tumor most frequent in the child (8 to 10% of cancers before 15 years) and in particular about the very young child (average age 4 years with 90% which have less than 5 years). Its incidence is from 1 to 3 cases for 100 000 older children from 0 to 14 years. There are no causes nor of recognized mailmen which support occurred of a neuroblastoma.

[0016] The neuroblastoma is discovered starting from symptoms due to the primary neoplasm (mass tumoral, in particular abdominal, or compression of a nearby part, such spinal-cord), to metastases or an endocrine secretion (deterioration of the general state, diarrhea, arterial hypertension . . . ). The neuroblastoma can develop starting from an unspecified component of the system highly-strung person sympathetic nerve, generally at the abdominal level. At the time of the diagnosis, the tumor can be localized on the level of one only part, the local or regional level, or be from the disseminated start. The metastatic sites most frequent are the bone, bone marrow, the liver and the skin. Thus, the majority of the localized tumors have an excellent forecast. It is the same for those of the children of less than one year, independently of the stage of the tumor, Some of these tumors regress even spontaneously. On the contrary, approximately 60% of the children of more than one year forward a metastatic neuroblastoma from the start of poor prognosis.

[0017] The variety of the clinical presentation is in relation to the expression of certain biochemical markers and molecular (DNA ploidy, amplification of the oncogene n-myc, Trk receptor expression, loss of the chromosome 1p, excess of the 17q . . . ). Thus, diffuse tumors occurring in the child of more than 1 year and on-expressing the oncogene myc are often chemo-resistant and have a poor prognosis (Berthold and A1, 1990; Schweigerer and A1, 1990). In the same way, the TrkB receptor expression and of BDNF allows a system of survival autocrine neuroblastic cells and induces the neuritic growth. It is also associated with the amplification of N-Myc and thus with a poor prognosis (Nakagawara and A1, 1994). On the contrary, the TrkA receptor expression, which induces the differentiation of the neuroblastoma (Borrello and A1, 1993; Eggert and A1, 2000), and TrkC (Yamashiro and A1, 1996) are rather associated with a good forecast. Thus, it is common to say that the TrkA receptor expression is conversely correlated with the amplification of the oncogene n-myc.

[0018] During the development, the gliaux precursors give rise to the astrocytes, oligodendrocytes, microglial cells, choroidal cells and ependymaires cells in the SNC, and with the Schwann cells in the peripheral nervous system. Thus, the cells gliales play a crucial role in differentiation (Lemke, 2001) and the survival of the neurons (Bar, 2000). These cells ensure the nutrition of the neurons, manage connected them inter-neuronal, control the neurotransmitters.

[0019] The glioblastomas are the malignant tumors astrocytaires (grade IV according to the classification of the World Health Organization) most undifferentiated of SNC and they are generally found on the level of the cerebral hemispheres. In the adult, they are the most frequent brain tumors (20% of all the intracranial tumors) with an angle of attack of about 3 new cases a year and for 100.000 inhabitants, that is to say approximately 2400 new cases a year in France. They occur at any age but in 70% of the cases between 45 and 70 years.

[0020] The glioblastomas form soft masses, rich in blood-vessels, from 3 to 10 cm in diameter, of vinous color, heterogeneous with active compact areas and areas of necroses wide, strewn with vessels thromboses and which infiltrate brain tissue. However, these tumors are not practically ever associated with the appearance of metastases. There are surrounded by a edema which increases the suffering of the brain. Typically, they are expressed by signs of intracranial hypertension which often joins changes of the behavior, with crises comitiales, focal neurologic deficits.

[0021] This tumor evolves quickly, in 2-3 month, and even after surgery, radiotherapy then chemotherapy, its forecast remains dark except if the glioblastoma comes from the the tumor can be localized on the level of one only part, the local or regional level, or be from the disseminated start. The metastatic sites most frequent are the bone, bone marrow, the liver and the skin. Thus, the majority of the localized tumors have an excellent forecast. It is the same for those of the children of less than one year, independently of the stage of the tumor. Some of these tumors regress even spontaneously. On the contrary, approximately 60% of the children of more than one year forward a metastatic neuroblastoma from the start of poor prognosis. The variety of the clinical presentation is in relation to the expression of certain biochemical markers and molecular (DNA ploidy, amplification of the oncogene n-myc, Trk receptor expression, loss of the chromosome 1p, excess of the 17q . . . ). Thus, diffuse tumors occurring in the child of more than 1 year and on-expressing the oncogene myc are often chemo-resistant and have a poor prognosis (Berthold and A1, 1990; Schweigerer and A1, 1990). In the same way, the TrkB receptor expression and of BDNF allows a system of survival autocrine neuroblastic cells and induces the neuritic growth. It is also associated with the amplification of N-Myc and thus with a poor prognosis (Nakagawara and A1, 1994). On the contrary, the TrkA receptor expression, which induces the differentiation of the neuroblastomata (Borrello and A1, 1993; Eggert and A1, 2000), and TrkC (Yamashiro and A1, 1996) are rather associated with a good forecast. Thus, it is common to say that the TrkA receptor expression is conversely correlated with the amplification of the oncogene n-myc.

[0022] The receivers of the superfamily of TNF-R were studied in the neuroblastic cells. Thus, the Fas receiver could be highlighted at the level of certain neuroblastic cells (Gross et al., 2001), cells which can be (Barthlen et al., 1999; Riffkin et al., 2001) or not (Bian et al., 2004) resistant to the apoptosis induced by Fas. The sensitivity of the neuroblastic cells does not depend only on the Fas receptor expression but on the presence or not of the caspase-8 in cells (Kisenge et al., 2003). The receptors of TRAIL are also expressed in the neuroblastic cells.

[0023] The neuroblastoma is one of most common in the child. Death rate is the highest of all cancers assigning the children.

[0024] There are very few diagnostic markers able to detect the neuroblastoma. There are no either markers which can detect or determine the invasivity and the aggressiveness of the metastatic cancerous cells or which allows a therapeutic follow-up.

[0025] During the last years, considerable progresses were made in the comprehension of the means implemented by the oncogenes and tumor suppressor genes to control cell proliferation and the apoptosis. One of the main targets of these regulators is the family of the mailmen of transcription of the type E2Fs (E2F1, E2F2, E2F3, E2F4 etc . . . ) in the channel of indication of the proteins E2Fs and RB. These proteins play a central role in the control of cell division by coupling the regulation of genes necessary to the cell cycle progression with the extracellular signals (mitogenes, inhibitors of the proliferation). It behaves as an oncogene by stimulating tumor cell proliferation. Myc N and Aurora kinase are also oncogenes implied in the proliferation of the neuroblastoma. E2F3 modulates the form of the RNA m of Aurora during the cell cycle. In addition, certain data suggest that the mailmen of transcription E2F are critical for total activation and the repression of Myc N in the neuroblastoma. The combination of the dosages of genes of Myc N and the Survivin by RTPCR is correlated at the stage of the clinical change of the neuroblastoma.

[0026] Among the expressed genes are found:

[0027] over-expression of the E2F4 transcription factor and the c-myc oncogene which induce apoptosis of post-mitotic cells by accumulation of oxygenated reactants (Tanaka, 2002) and the N Myc which is amplified in 35% of the cases of neuroblastoma, gene ALK, DDX1 and CRABP II too. HGMA1 and the Survivin also. The repression of HGMA1 by RNA interference reduces the cell proliferation of the neuroblastoma. N Myc induces the expression of FAK. N Myc down reguls the expression mRNA of many genes having a role in cellular architecture.

[0028] the gene p53, which belongs to the tumor suppressor gene family, blocks the cell cycle in the case of DNA lesion. It has now been demonstrated that this gene is also involved in the progression of apoptosis (Oren, 1994; Yonish-Rouach, 1996);

[0029] the cyclin D1, one of the proteins constituting the regulatory subunits of cell cycle kinases, which is essential for cell cycle progression. This protein is also expressed during apoptosis in various cell types (Han et al, 1996; Pardo et al, 1996).

[0030] A transcription factor Zinc finger can stop the activity of the D1 cyclin and lock the cycle. Data suggest that the mailmen of transcription E2F are critical for total activation and the repression of MYCN in the neuroblastomas.

[0031] chk1 and 2, crb2, p21 and other oncogenes and cytokines such as TNF alpha etc . . . . It would be of great interest to have novel diagnostic methods detecting the Presence of cancer with greater specificity and making it possible to distinguish between aggressive cancer cells with the tendency to metastasize and those which are more localized and have a lower probability of metastasizing. A marker capable of revealing cell proliferation would therefore be of great use. The works of the professor Jean Louis Mendel about the glial markers and in particular on the GFAP and the NF70 advanced the diagnosis, the expression of the synemine in the glial tumors is an important way of research like the study of the mutations of the Ras/MAPK channel. The deletion of chromosome 1 in the area 1p36 and the amplification of gene MYC N sign the state of proliferation, a forecast of neuroblastoma and an unfavourable histology. In 35% of the cases, MYC N is amplified, in 58% of the cases it is chromosome 17 in q23 and in 35% of the cases chromosome 1 in p36 is deleted.

[0032] Complex LIV21 will be studied by RT PCR and biochip and its cytoplasmic markers of interest and the membrane protein of the complex Liv 21 too.

[0033] 21 additional markers and new sequences of complex LIV21 compared to the first and with the second patent deposited will allow a notable improvement and an improvement of the pharmaco diagnostic tests which we propose.

[0034] It is thanks to this improvement that the therapeutic adjustment in multi-therapy will be able to allow a greater effectiveness of processing and as it is thanks to this improvement as the diagnosis of the glial tumors will be done more precisely with a thorough knowledge on the forecast, the grade and the development of these tumors. Another improvement made it possible to have a larger precision in the study of the expression levels of various important genes for the diagnosis of glial tumor, it is the troubleshoot of a standardization of the tissue samples like punctures of the cerebrospinal fluid. Thus the comparisons of profiles of expression are more reliable and undergo less fluctuations due to skews of observation. All these new parameters which do not increase the number of variables but which decrease the background noise largely improve the diagnosis and the processing of the gliales tumors. ki 67 and Cafl are nuclear markers indicating the proliferation state of many cancers (Almouzny; Curie Institut). Liv21 complex genes will be the cytoplasmic markers at least equal and complementary to the previously identified nuclear ones.

SUMMARY OF THE IN VENTION

[0035] The present invention concerns new polypeptide, ribonuclotidic and nucleotidic sequences to integrate into a novel test for screening for reinduction of the cell cycle targeting oncology and the use of some of these same functionalized sequences, like auxiliary processing by molecular targeting. It is about a major improvement without which the diagnosis and the test pharmaco diagnostic could be only partial. The consequence would be a less effective processing and of less broad implementation according to the heterogeneity of cancers. It is thus about a diagnostic test and a prognostic test for various cancers. More particularly, the invention concerns the use of the genes or proteins of the Liv21 complex and of their derivatives as therapeutic tools or as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 gene or LIV21 protein with a kit comprising LIV21-specific antibodies or LIV21 specific probes. The present invention also consist in using all the proliferation markers and transcription factors which play a role in the cancerization and in some cases, neurodegeneration process. The invention lies in the use of quantitative RT PCR and the PCR (QPCR) twinned at the manufacture of diagnostic DNA biochips, proteins biochips and antibody arrays including known antibodies directed against various proteins of the LIV21-associated complex according to the phases of the cell cycle, that is, without restriction thereto: peptides and antibodies specific for RBP2, E2F4, E2F1, SUMO, HDACl, crb2, Int2, cmd2, cycE/cdk2, cdk1, CREB1 and p300, Rb, pl07 and pl30 of the pocket protein family. In addition, antibodies specific for NFkB, cdc2A, mdm2, p21, p53, p65, BRCA1, TNFalpha, TGF beta. The new sequences are the poly-nucleotidic and polypeptide sequences of Liv21F, Liv21H, etc . . . (list additional of the sequences: SEQ ID NO.degree. 171 to 185) and the sequences of genes, proteins, and corresponding antibodies lately integrated in the pharmaco-diagnostic biochips are: Myc N, ALK, HMGA1, DDX1, GFAP, NF70, AD7cNTP, FAB3, Serin C2, Synemine, PDX1, HDAC6, TPX2, DKK1, DKK3, HUD, ID2, SKP2, TP53INP1, VEGF, NLRR1, PAX3-FKHR, NDP kinase A, Bora ?, Aurora A, Survivin

[0036] The protein arrays will make it possible to study the proteinic interactions and the post traductional modifications, more particularly the phosphorylations and methylations of certain proteins which sign a state characteristic of the sick cell different from the proteinic interactions and metabolism of the healthy cell. The state of expression and silencing of certain genes being different. The rate of expression of each biomolecule in front of being observed distinctly in each cellular compartment to be able in the second time controlled being (under expressed or on expressed by a standard auxiliary processing biomolecule or siRNA or vectorized peptides). The biochips with nucleotidic sequences will make it possible to study in nuclear cellular extracts and in addition cytoplasmic or membran, under expressions or on gene expressions and the ratios between genes as between proteins of complex Liv21 and its associated partners, the analysis of the interactions within the metabolic complexes is a key of the diagnosis and also passes by the study of the functional fields.

[0037] A first objective of the present invention is to demonstrate a method for the detection and prognosis of cancer and of its metastatic potential which makes it possible to adjust a multitherapy targeted. Preferably, the cancer is selected from breast cancer on cerebral cancers and more particularly the glioblastoma, the neuroblatoma, without being limited thereto.

[0038] One aspect of the present invention consists of the use of LIV21 complex new sequences as prognostic indicator for cancer and his therapeutic monitoring.

[0039] Indeed, when Liv21 is localized in the cytoplasm, the cancer cells in tissues are aggressive. Conversely, when the product of gene expression Liv21F is preferentially localized in the cellular core, this is a prognostic indicator that the tissue cells are differentiated and quiescent and thus noninvasive. We define the Liv21 complex by the protein extract and peptides studied by mass spectrometry such as Maldi and ESIMSMS or Maldi Tof Tof. The said extract has been obtained by binding of the Liv21 complex to one of its polyclonal antibodies described in the patent (PCT/FR2006/000510).

[0040] The Liv21 complex is defined by its mass spectrometry global profile (FIG. 5) and the number and the molecular weight of protein extracts bands obtained on the acrylamide gels of FIGS. 1A and IB as a function of temperature at which the sample is submitted and of described migration conditions. In fact, when for example Liv21F peptide is located in the cytoplasm and we reveal directly for example by in situ hybridization or by biochip analysis its higher expression in the cytoplasm, the cancer cells in the tissues are aggressive. Conversely, when the LIV21 gene expression product or the expression of Liv21F peptide is preferentially located in the cell nucleus, this is a prognostic indicator that the cells of the tissue are differentiated and quiescent and therefore noninvasive. This observation is associated under investigation with expression, phosphorylation and localization of the other factors of complex Liv21 and with these partners of interaction. The effectiveness of a cancer treatment can also be monitored by the traceability of new sequences and of these proteins Liv21F and Liv21K, of this Liv21 protein complex, and of its derivatives and ratios with the associated proteins but also by Diagmicroarray and sensorchip including among others this protein and its Liv21 associated complex (FIG. 12 and FIG. 14).

[0041] Moreover, detection of protein kinase C epsilon (PKCs) is also advantageous since it has been determined that PKCs phosphorylates the LIV21 protein in order to maintain it in the cytoplasm. Thus, a significant increase in PKCs is indicative of the presence of cancer cells. Moreover, the LIV21/PKCS ratio increases in the cytoplasmic fraction of cancer cells. The same is true of the detection of HDAC1, which has been shown to be involved in PML/SUMO/Rb/HDAC-1. More generally, the HDACs family plays a key role in the regulation of gene expression, when the HDACs are overexpressed, they induce tumor suppressor gene silencing, hence the advantage of using HDAC inhibitors in therapy, combined with other inhibitors which regulate the metabolic pathway involving the protein complex which contains Liv21.

[0042] In addition, the detection of the E2F1, E2F2, E2F3 and/or E2F4 proteins is advantageous. In fact, the LIV21 protein forms a complex with E2F4, which is capable of inhibiting the expression of the E2F1 gene in the nucleus, E2F1 gene expression being a sign of cell proliferation. Thus, a decrease in the association of LIV21 with the E2F4 protein is indicative of the presence of cancer cells. Similarly, the presence of the E2F1 protein in the nucleus is indicative of the presence of cancer cells.

[0043] Consequently, the present invention concerns a method for the detection of cancer cells in a biological tissue sample (for example, breast, ovary, endometrium, bladder, melanoma, prostate, glioblastoma, etc.) from patients, this method comprising the detection of the products of expression of the LIV21 complex genes in the nucleus comparatively to the same products in the cytoplasm and the membranes of the cells in the biological tissue sample from said patient, this method comprising detection of the product of expression of liv21F gene in the core and/or the cells cytoplasm in the biological tissue sample from said patient, a localization of said products of expression of the LIV21F gene in the cytoplasm is indicative of the presence of cancer cells and a localization of said products of expression of the LIV21 complex genes in the nucleus is indicative of the presence of noncancer cells. Preferably, a localization of said products of expression of the LIV21 gene in the cytoplasm is indicative of the presence of invasive and/or metastatic cancer cells, the localizations of the products of expression of the LIV21 complex genes and its associated partners described in the examples of biochips shows or not the cancer cells presence. Optionally, the method according to the present invention also comprises the detection of the product of expression of at least one gene selected from the group consisting of the protein kinase C epsilon (PKCs) gene, the E2F1 gene and the E2F4 gene. The method can in particular comprise the detection of the product of expression of two of these genes or of the three genes. Moreover, at least one of the ratios LIV21/PKCS, LIV21/E2F4 and LIV21/E2F1 can be determined in the present method. This ratio can be determined in the cytoplasm and/or in the nucleus preferably separated. Preferably, these ratios are determined in the nucleus. Preferably, these ratios are compared with those obtained in a normal cell. The level of expression of each enzyme or polypeptide of the SUMO/Rb/HDAC complex or, for certain cell types, of the PML/SUMO/Rb/HDAC complex is an additional indicator of the proliferative state of the cell.

[0044] These ratios of expression or silencing can be detected via the protein expression or inhibition level themselves in the protein arrays (biochips) fabricated according to conventional methods described (Lubman David M, QIAO TIECHENG Alex, Mathew ABY J etc.) or novel tools for the automation of hybridization and of reading, US2004152212 and Yu Xinglong US 2005019828 and novel supports which attach polypeptides (patents US 2008 213130 and US 2005/0157445 or US 2006170925 or WO 2005 016515, Klages Claus Peter and example figure).

[0045] Before describing the principle of these biochips, which are well known by man skilled in the art, we will give the following definitions: The biological sample can be in particular sample of blood, serum, saliva, tissue, tumor, bone marrow, circling cells from the patient. The biological sample can be recovered by any type of sampling know by those skilled in the art. According to the present invention, we consider a biological sample any material allowing the detection of expression of a target gene. The biological material can include in particular proteins, or nucleic acids such as desoxyribonucleoic acid (DNA) and rybonueleic acid (RNA). The nucleic acid can in particular be an RNA (rybonucleic acid). According to a preferred embodiment of the invention, the biological material comprises nucleic acids, in particular RNAs and even more specifically total RNAs. Total RNAs include transfer RNAs, messenger RNAs (mRNAs), such as mRNAs transcribed from the target gene, but also transcribed from any other gene, and ribosomal RNAs. This biological material includes specific material of the target gene, such as in particular mRNAs transcribed from the target gene or proteins issued from these RNAs, but it can also include material unspecific to the target gene, such as in particular mRNAs transcribed from a gene different from the target gene, tRNAs, rRNAs issued from other genes than the target gene. When the extracts to be studied consist of cell cultures, they will preferably be analyzed on fresh cultures (with or without previous treatment) that underwent an extraction protocol separating cellular compartments. This type of kit known by those skilled in the art allows the specific extraction of membranes or solely the cytoplasmic or nuclear or cytoskeletal content in a differential fashion by using different solutions. For instance, the kit Proteo extract (ref 539790) from Calbiochem can be used.

[0046] The other aspect of the present invention is the use of the genes and the proteins mentioned above as markers for the invasiveness and the metastatic aggressiveness of cancer cells of the prostate, -colon, bladder, melanoma, ovary, endometrium and cervix, and cancers in neurobiology or in ORL etc . . . . In fact, sequential pharmacodiagnostic tests during treatment monitoring will permit to observe, by comparing at different lime points, variations of the expression level or of their silencing and therefore to better evaluate the treatment efficiency, to readjust these treatments in the case of a suitable multitherapy in such a way that the physiological equilibrium of the different products of genes involved in metabolic complexes are maintained. The plasticity of these equilibriums justifies the use of diagnostic biochips and for the therapeutic monitoring with the most pertinent genes of metabolic complexes involved in the physiology of anarchic proliferation in the case of breast cancer, which is highly heterogeneous. Therefore each individual or each phenotypic subgroup of individuals will show an under or over expression profile of genes of the metabolic complexes which is specific to him.

[0047] In one embodiment, the expression product of the genes is detected at the mRNA level. mRNA can be detected by RT-PCR analysis (i.e. following examples). It can also be detected by Northern blotting analysis or by SPR if the RNAm and DNA are functionalized at the surface of electroapplied on a support of biochip (techniques described therefore in the patents US 2008 213130 and US 2005 0157445 or US 2006 170925 or WO 2005 016515). The MICAM technique which uses the electric piezo effect in its biochips can be also used for the above mentioned invention of pharmaco diagnostic biochip dedicated to the cerebral neuroblastoma and other cerebral cancers, of biochips diagnostic dedicated to the epidermoid cancers and more specifically dedicated to the breast, ovarian and prostate cancers.

[0048] In an alternative mode of realization, the product of gene expression is detected on the level of protein or peptides characterizing complex liv21 and its partners of interaction. Preferably, the protein and/or proteinic complex Liv21 associated, are detected using an specific antibody. For example, the protein can be detected by analysis Western Blot and SPR, a system of biochip using a wave of transverse propagation (evanescent wave) of surface plasmonic resonance (SPR). The interaction can be done with an electronic surface, conducting semi surface creates an exiton by luminescence or fluorescence. In a mode of preferred embodiment, it is detected by immuno histochimy, immuno cytochemistry, microfluidic, radiography or peroxidase labeling or any other means of optical, sonic imagery or of spectroscopy.

[0049] In one specific embodiment of the method comprising the detection of the expression product of the PKC.epsilon. gene, a significant increase in PKC.epsilon. is indicative of the presence of cancer cells. Moreover, the method can also comprise the determination of the LIV21/PKC.epsilon. ratio in 5 the nucleus, the membranes and the cytoplasm. This ratio can be compared with the one observed in a normal cell. An increase in the LIV21/PKC.epsilon. ratio in the cytoplasmic fraction is indicative of cancer cells.

[0050] In another specific embodiment of the method comprising the detection of the expression product of the E2F4 gene, the method comprises the detection of the association of LIV21 with the E2F4 protein, a decrease in this association in the cell nucleus being indicative of the presence of cancer cells. Moreover, the method can also comprise the determination of the LIV21/E2F4 ratio in the nucleus and/or the cytoplasm. This ratio can be compared with the one observed in a normal cell.

[0051] In an additional embodiment of the method comprising the detection of the expression product of the E2F1 gene, the presence of the E2F1 protein in the nucleus is indicative of the presence of cancer cells. Moreover, the method. can also comprise the determination of the LIV21/E2F1 ratio in the nucleus and/or the cytoplasm. This ratio can be compared with that observed in a normal cell.

[0052] In a specific embodiment, the method comprises the detection of a labelled small interfering RNA (siRNA) in order to target its specific sequence and therefore signal the locus of messenger RNA expression of the gene of interest. In this way, the specific small interfering RNA can be used as a diagnosis marker similarly to an antibody. The specific siRNA would allow to locate in a specific case such as in extamporaneous tissues or any kind of sample from a patient, such as cancer tissues sample, the fluorescence signal or any other marker used on the siRNA is found in a cellular compartment on the sample, An siRNA targeting the E2F1, E2F4 and PKC epsilon would allow a complementary diagnosis.

[0053] The method according to the present invention allows in particular the detection of metastasized cancer, therapeutic monitoring and/or recurrences following treatment.

[0054] A second aspect of the invention concerns the human LIV21 protein and also the fragments thereof. More particularly, the present invention concerns a purified or recombinant isolated human LIV21 protein. It concerns in particular an isolated polypeptide comprising a peptide sequence selected among SEQ ID Nos 1 to 5 and more broadly selected among the peptide sequences characterizing it and obtained by MALDI (FIGS. 3, 4 and 5) arid NanoLC-ESI-MS. In a preferred embodiment, the polypeptide comprises the three peptide sequences SEQ ID Nos 1 and 2 and 3. Preferably, the LIV21F protein and certain proteins of the Liv21 complex comprises a leucine zipper motif, a basic domain characteristic of DNA binding domains (FIG. 2), and a nuclearization sequence.

[0055] In an even more preferred embodiment, the present invention concerns the polypeptides with peptide sequences characterized by spectrograms of FIGS. 3, 4, 5 of gel bands 1, 2 and 3, selected among SEQ ID Nos 1 and 2 and 3 and 4 and 5 and a hundred additional non ordered sequences supplement (i.e. listing sequences in annex), the other sequences of the proteins must being checked compared with their homologies with contaminants and order during spectrometries of mass MSMS on the unmatched fragments identified in the Maldi Tof analysis (i.e. FIGS. 3, 4, 5), these unmatched fragments corresponding to the masses M (H+) untagged characterized in part the Liv21 protein and some elements of the Liv21 protein complex. A third aspect of the invention concerns an antibody, which the present invention. More particularly, the antibody can bind specifically to a polypeptide comprising a peptide sequence selected from SEQ ID N.degree.s 1-180, preferably from SEQ ID N.degree.s 1 and 2 or 3 and/or 5 or 51, or a sequence having more than 80% identity to said sequences. The present invention concerns in particular an anti-LIV21 serum produced by immunizing an animal or a human with a polypeptide according to the present invention, in particular a polypeptide comprising a peptide sequence selected from SEQ ID N.degree.s 1-180, preferably from SEQ ID N.degree.s 1-5 and 51, or a sequence having 70%, 80% or 90% identity to said sequences.

[0056] A fourth aspect of the invention concerns a kit for the detection of cancer cells in a biological sample from a patient, this kit comprising one or more elements selected from the group consisting of an antibody which binds specifically to human LIV21F according to the present invention and an anti-LIV21F serum according to the present invention, a specific oligonucleotide mRNA probe of Liv21F and a pair of primers specific of mRNA. In a specific embodiment of the invention, the kit also comprises means for detecting the product of expression of a gene or a specific oligonucleotide mRNA probe of factors selected from the group consisting of the protein kinase C epsilon (PKC.epsilon.) gene, the E2F1 gene and the E2F4 gene. But also the antibodies in a specific antibodies microarray from the antibodies group consisting of RBP2, SUMO, HDAC, TNFalpha, crb2, cycE/cdk2, cdkl, CREB1, p300, Rb, pl07, pl30, NFkB, cdc2A, mdm2, p21, p53, p65. It also comprises Microarray with said proteins above and specific peptides known by a person skilled in the art, their antigens being referenced. The combination of these different peptides corresponding to the specific interactions of protein complexes acting in metabolic deregulation, induces anarchical proliferation, which is a specific feature of cancer or neurodegeneration. The invention concerns the use of an antibody specific for human LIV21 for the diagnosis of cancer, and antibodies specific for its protein complex, but also specific antibodies for RBP2, SUMO, HDAC, TNFalpha, crb2, cycE/cdk2, cdkl, CREB1 and p300, Rb, p107, pl130, NFKB, cdc2A, mdm2, p21, p53, p65, p73. Also, the invention concerns the used of primers pair or LIV21 specific probe for the cancer diagnosis. Preferably, the diagnosis is performed ex vivo on samples from a patient (puncture of the cerebral spinal fluid, blood test, biopsy, ground cellular material, bronchial aspirations, DNA/protein/antibodies arrays, plasmionics (SPR), hydrophobic or ion metal supports, etc). Method according to claim 15, characterized in that in addition, it implements at least any of the specific probes of the sequences of known as said complex liv21 and these associated partners. The method is characterized in that the aforementioned biochip is: a biochip with protein, or a biochip with nucleotidic antibodies or a biochip with acids, or a biochip with mRNA, or a biochip with SiRNA.

[0057] Method is characterized in that the aforementioned biochip with protein, or the aforementioned biochip with antibody, consists of a biochip of fluidic microcomputer and for which the aforementioned stage of detection consists of a detection by SPR.

[0058] Method is characterized in that it understands a stage of amplification/retro-transcription by RT-PCR of at least a nucleotidic sequence of the known as human Liv21 complex according to claim 1 or 2 or of the known as Liv21 complex and its associated partners.

[0059] Method is characterized in that it understands a pharmaco-diagnostic test for diagnosis of the cancer or the follow-up of the development of a cellular proliferation, the aforementioned cancer being preferentially choose in the group consisted the neuroblastome, the glioblastomas and other cancers touching tissues of the nervous system.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

[0060] FIG. 1A: one-dimensional gel (acrylamide gradient 12%) revealing after three hours thirty of migration 11 tapes with certain triplets and doubled tapes and a two-dimensional gel SDS Page of total cellular extracts with spots between 15 and 20 KD and to 29-32 kD and 35 KD approximately with basic pH and of the spots with 190-180 and to 100 kD with acid pH;

[0061] FIG. 1B: diagram of the interactions of the bio-markers of complex Liv21 and the surrounding metabolic pathways;

[0062] FIG. 2: scheme of nuclear and cytoplasmic protein with domain DNA binding and effects on the study of therapeutic targeting the core and the cell cytoplasm;

[0063] FIG. 3A: The listing of monoisotopic peaks of the band 1 at 50 kD and the band 2 between 49 and 50 kD

[0064] FIG. 3B: LIV21 protein profile by mass spectrometry (Maldi) M (H.sup.+) for the one-dimensional gel band corresponding to the band 2 migrating at 49-50 kD wherein the peptides derived from the digestion are solubilized in a solvent: acetonitrile/water (1/1) containing 0.1% of TFA (trifluoroacetic acid);

[0065] FIG. 4A is a profile of the spectrogram of the band 6 named 6FC;

[0066] FIG. 4B: monoisotopic of certain peaks from FIG. 4A;

[0067] FIG. 5 is the third spectrogram corresponding to the one-dimensional 12% acrylamide gel band migrating at 52 kD and revealed with coomassie blue and the LIV21 antibody;

[0068] FIG. 6: analysis on the data banks the listings of monoisotopic peaks;

[0069] FIGS. 7A and 7B relate to SEQ ID NO 217;

[0070] FIG. 8: RNA pool;

[0071] FIG. 9: PCR with housekeeping genes and analysis of molecular masses;

[0072] FIG. 10: PCR with the primers showing a band of 1400 bp;

[0073] FIGS. 11A & 11B: Gel 2 with analysis of molecular masses;

[0074] FIG. 12: Gel 3 at 55.degree. and analysis of molecular masses;

[0075] FIG. 13: Gel 4 at 45.degree. and at 55.degree. and analysis of molecular masses;

[0076] FIG. 14: screening ligation of 400 pb band, clones 131 to 1310;

[0077] FIG. 15: screening ligation of 1400 pb band, clones CI to C10;

[0078] FIG. 16: Gel 5: ligation screening on the five new clones;

[0079] FIG. 17: Gel 6: Screening of the S55T and S55M recombinant clones and analysis of molecular masses;

[0080] FIG. 18: examples of comparison of nucleotide sequences between the sequenced clones;

[0081] FIGS. 19A & 19B: Si RNA design;

[0082] FIGS. 20A-20D: Protein biochip (array) from Yeretssian hut in addition with peptides named of the proteins of the interested complex studied in the invention;

[0083] FIG. 21: Two biochips standard microfluidic of four shafts x2 with a control and three biomarkers;

[0084] FIG. 22: Example of biochip of 20 spots with 16 biomarkers of interest and four controls) fixed on the sensorchip allowing to see by SPR on-expression and the under-expression of certain genes of complex LIV21 and its partners of interactions for example;

[0085] FIGS. 23A & 23B: Biochip with RNA allowing to explore mini RNA of complex LIV21; and

[0086] FIG. 24: Example of biochip with DNA resulting from above mentioned genes of interest targeting pathology.

DETAILED DESCRIPTION OF THE INVENTION

[0087] FIG. 1A: one-dimensional gel (acrylamide gradient 12%) revealing after three hours thirty of migration 11 tapes with certain triplets and doubled tapes and a two-dimensional gel SDS Page of total cellular extracts with spots between 15 and 20 KD and to 29-32 kD and 35 KD approximately with basic pH and of the spots with 190-180 and to 100 kD with acid pH. Spots between 49 and 51 KD and to 64 KD. Into monodimensional: Tapes with ISO kD approximately (TOFC), 100 KD, 64 kD, 51 a49 kD, 49 kD, 35 kD, 29 kD, 15 to 17 kD.

[0088] FIG. 1B: diagram of the interactions of the bio-markers of complex Liv21 and the surrounding metabolic pathways.

[0089] FIG. 2: scheme of nuclear and cytoplasmic protein with domain DNA binding and effects en the study of therapeutic targeting the core and the cell cytoplasm.

[0090] FIG. 3A: The listing of monoisotopic peaks of the band 1 at 50 kD and the band 2 between 49 and 50 kD. FIG. 3B: LIV21 protein profile by mass spectrometry (Maldi) M (H.sup.+) for the one-dimensional gel band corresponding to the band 2 migrating at 49-50 kD. The peptides derived from the digestion are solubilized in a solvent: acetonitrile/water (1/1) containing 0.1% of TFA (trifluoroacetic acid). A saturated solution of the alpha-cyano-4-hydroxycinnamic acid matrix is prepared in the same solvent. The same volume of the two solutions is taken and mixed together, and 1 microliter is deposited onto the Maldi plate for analysis.

[0091] FIG. 4 is a profile of the spectrogram of the band 6 named 6FC.

[0092] The de novo analysis (MS MS Maldi Tof Tof) makes it possible to propose the sequences: RYLVTPVNA (SEQ ID NO: 13), RYVPSSNLP (SEQ ID NO: 12), RYVLSPVK (SEQ ID NO: 14), RYVPSSNPL (SEQ ID NO: 11), RYLPSANPD (SEQ ID NO: 342).

[0093] FIG. 4bis: monoisotopic of the peak 1032.58 MSMS analyzes: R (SEQ ID NO: 206), RYVPSSNPL (SEQ ID NO: 12)

[0094] The peak monoisotopic 944.6 is a sequence: FAVAFPVGR (SEQ ID NO: 323)

[0095] The peak monoisotopic 1603.7: KPSHPKPSTK (SEQ ID NO: 15)

[0096] The peak 1328.69: KAHNLFKT (SEQ ID NO: 17), TFKNLC (SEQ ID NO: 16)

[0097] The common peaks monoisotopic between the first 2004 (230304 imagenium 03_H11_a_001 and the peak 6FC from 2008 are;

[0098] Following peaks monoisotopic: 1135.563, 1151.545; 1167.604; 1206.589; 1324.634; 1336.658; 1507.735; 1604.710; 1800.940; 2087.034.

[0099] The variation of the protocol is due only to three different stages: the first is the purification of the antibody used, the second is the separation of the fractions cytoplasmic and nuclear, the third is the heating two minutes with 100.degree. of the sample before migration on freezing of acrylamide.

[0100] FIG. 5 is the third spectrogram corresponding to the one-dimensional 12% acrylamide gel band migrating at 52 kD and revealed with coomassie blue and the LIV21 antibody.

[0101] FIG. 5 bis is a table of the monoisotopic peaks of the third spectrogram corresponding to the one-dimensional acrylamide gel band migrating at 51 kD 52 kD and revealed with coomassie blue and the LIV21 antibody.

[0102] The monoisotopic peaks with a value M H+. The masses are give with three numbers after the decimal point by the proteomic platforms since they estimate that this is the acquisition precision limit of MALDI TOF machines. The FIGS. 3-5 describe the MALDI analyses giving a set of polypeptides that can be assigned to the LIV21 protein and its complex and contaminants sometimes different according to the observers from the various platforms of proteomics under discussing.

[0103] FIG. 6: analysis on the data banks the listings of monoisotopic peaks. Example of the histatine 3. The Mascot search parameters are: trypsin enzyme, variable modifications: carbamethylation and oxidation of methionins, without molecular mass limit, without isoelectric point restriction.

[0104] FIG. 7 idem but the second example:

[0105] Type of mass: monoisotopic. Mass error (MS): according to the observer 50 ppm or 100 ppm. Non-cleavage with trypsin: 1 The masses captured are M (H.sup.+)/real masses. For spectrogram 1, the cysteins are blocked with iodoacetamide. The possibility of digestion with Promega bovine trypsin may be incomplete with cleavage oversight.

[0106] Sequences common with Gallus gallus (gi 50732569), the 30 Mouse Syntaxin, the histatin variant HIS3-2 (P15516-00-01-00), the ZN575-Human, the G6P translocase, the HSP60 chaperonin, the deiminase, ferrodoxin NADP(+) reductase, pseudomonas polyribonucleotide nucleotidyltransferase, the clathrin, the dehydrolipoamide dehydrogenase.

[0107] FIG. 8: RNA pool

[0108] FIG. 9: PCR with housekeeping genes and analysis of molecular masses.

[0109] FIG. 10: PCR with the primers showing a band of 1400 bp.

[0110] FIG. 11: Gel 2 with analysis of molecular masses FIG. 12: Gel 3 at 55.degree. and analysis of molecular masses

[0111] FIG. 13: Gel 4 at 45.degree. and at 55.degree. and analysis of molecular masses.

[0112] FIG. 14: screening ligation of 400 pb band, clones B1 to B10.

[0113] FIG. 15: screening ligation of 1400 pb band, clones CI to C10.

[0114] FIG. 16: Gel 5: ligation screening on the five new clones. FIG. 17: Gel 6: Screening of the S55T and S55M recombinant clones and analysis of molecular masses.

[0115] FIG. 18: examples of comparison of nucleotide sequences between the sequenced clones.

[0116] FIG. 19: Si RNA design.

[0117] FIG. 20: Protein biochip (array) from Yeretssian but in addition with peptides named of the proteins of the interested complex studied in the invention.

[0118] FIG. 21: Two biochips standard microfluidic of four shafts x2 with a control and three biomarkers.

[0119] An on-expression of DDX1, MYCN and CRABPII is observed whereas one observes by testing the second sensorship an under-expression of HUD, TP53 INP1 and a major under-expression of p21.

[0120] FIG. 22: Example of biochip of 20 spots with 16 biomarkers of interest (and four controls) fixed on the sensorchip allowing to see by SPR on-expression and the under-expression of certain genes of complex LIV21 and its partners of interactions for example.

[0121] An under-expression of DKK1, SKP2, DKK3, ID2, p21, SKP2, TP53INP1, ID2, P73 is observed whereas an on-expression of MYC N, ALK, NLRR1 (the leucine rich neuronal repeat is transactivated), CRABPII, DDX1, LIV21K, AURORA kinase A is observed.

[0122] FIG. 23 Biochip with RNA allowing to explore mini RNA of complex LIV21 and more particularly those resulting from genes of the polypeptides LIV21F and LIV21K added in Mir RNA, microRNA known to be implied in pathology ((miR (=MIR) 34A. MIR9. MIR125A.125B.MIR128 MIR 184 MIR221)).

[0123] We study also regulator PTEN and factors

[0124] TR AIL.

[0125] FIG. 24: Example of biochip with DNA resulting from above mentioned genes of interest targeting pathology.

[0126] The invention relates to the identification of antigens in cell lysates by immunoprecipitation. The analysis of the physical interaction of various proteins associated in the LIV21 complex as E2F4 and E2F1 has been studied by coimmunoprecipitation of protein complexes. This analysis has made it possible to demonstrate novel 10 markers, which has a diagnostic and prognostic use for cancer (i.e. PCT/R2006/000510). Begin by using the one dimensional and two dimensional gel electrophoresis analysis (FIGS. 1 and 2), the protein samples corresponding to the putative protein and to the elements of the complex were extracted from the gels and digested with trypsin (Promega) in order to be analysed by MALDI (FIGS. 3 to 5) and ESI MS/MS mass spectrometry. The results, when put up against proteomic databanks, made it possible to reveal several peptide sequences of interest, including some given as an example (FIGS. 6 and 7), some being found in humans with very significant scores (splicing of histatin, etc., FIGS. 8 and 9), these sequences were used as primers (once reverse-transcribed to cDNA) for screening a library formed from breast cancer-specific MCF7 cells (FIGS. 10 to 17).

[0127] The cloning made it possible to bring to the fore about twenty clones out of the 150 clones obtained, of which ten clones were sequenced and characterize the new LIV21 gene LIV21F and the gene LIV21K (FIG. 1B and FIG. 2). Based on these sequences, siRNAs were determined in order to allow regulation of silencing type within this metabolic complex of interest so as to develop therapeutic applications (FIG. 18).

[0128] In post-mitotic cells, apoptosis could correspond to an aborted attempt at mitosis. It is in this context that the application of LIV21 has been developped. The inventor has identified sequences of the LIV21 gene. Using the LIV21 antibody on affinity columns he has been able to extract peptides of the LIV21 protein; it has also used a second approach by means of a coimmunoprecipitation kit (Pierce) in order to have larger amounts of proteins (Example 1). Based on peptide sequences of the LIV21 protein, obtained by mass spectrometry (Example 2), primers which make it possible to amplify a cDNA fragment were designed (Example 3). After culturing and amplification of MCF7 line cells, extraction and purification of RNAs, RT PCRs and cloning in a shuttle vector were carried out, and then screening of the resistant colonies and sequencing made it possible to reveal sequences characterizing the genes LIV21F and LIV21K (Examples 4 and 5). More than twenty characteristic clones out of 150 clones were studied. The cDNA of these clones was used to screen a library prepared from the total mRNA of MCF7 cells.

[0129] The sequence of this new products arc new transcription factors, the nuclear translocation of which change their role and their function, that being correlated for some of them with the establishment of the cellular quiescence such as for example LIV21F, E2F4. In addition it is linked to the DNA role and function. Furthermore, it forms heterodimers with other transcription factors and certain bind to DNA.

[0130] Using Northern blotting, the inventor then followed the expression of this new product during development, from the embryonic stage. It was observed that the amount of the LIV21 protein increases as development progresses, i.e. as a quiescent cell state becomes established. Through the same strategy, the inventor showed that the LIV21/E2F4 complex inhibited the expression of E2F1. This complex could correspond to a new checkpoint in the arrest of cell proliferation. LIV21 complex and associated metabolic complex:

[0131] The present invention relates to the LIV21 complex and its new nucleotide sequences SEQ ID No. 171 to SEQ ID N.degree. 217 also used for some of them in the form of siRNA for diagnostic and therapeutic applications and also LIV21F and LIV21K polypeptides and derivatives and fragments and isoforms thereof (SEQ ID No 215).

[0132] LIV21 human complex, characterized in that it comprises:

[0133] the nucleotide sequences SEQ ID N.degree.171 to 175, and

[0134] siRNA sequence derived from one of the RNA sequences SEQ ID N.degree. 120 and SEQ ID N.degree. 121, and 171 to 175

[0135] a protein fraction comprising at least sequence SEQ ID N.degree. 1 and 181 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said SEQ ID N.degree. 1 and 181.

[0136] LIV21. human complex, characterized in that it comprises:

[0137] The nucleotide sequences SEQ-ID N.degree. 171, 172, and the protein fractions comprising at least sequence SEQ ID N.degree. 1 or a sequence having 181 or 70, 10 80 or 90% identity with said SEQ ID NO 1 or 181 and SEQ ID N.degree. 183 or a sequence having 70, 80 or 90% identity with said SEQ N.degree. 183.

[0138] LIV21 complex human, characterized in that it also comprises:

[0139] nucleotide sequences SEQ ID N.degree. 123, 124 and 127, and the protein fractions comprising at least sequence SEQ ID No. 1 or a sequence having 70, 80 or 90% identity with said SEQ ID NO 1 and the sequence from 181 to 185 or a sequence having 70, 80 or 90% identity with said SEQ ID NO 181 to 185.

[0140] LIV21 complex human characterized in that it further comprises:

[0141] Any of the nucleotide sequences or ribonucleic SEQ ID N.degree. 119, 120, 121, 122, 123, 124, 125, 126 or 127 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID N.degree. 119 to 127, or

TABLE-US-00001 (SEQ ID NO: 306) UUGGUAACGACCAUGCCAC, or (SEQ ID NO: 307) UUCACUUAGAAUAAUGUCC, or (SEQ ID NO: 308) UCUUUGUGAAUUUGACAAC, or (SEQ ID NO: 309) UCAAGGUCCAGGCUACAAC, or

[0142] Any of the siRNA following:

TABLE-US-00002 (SEQ ID NO: 310) GUGGCAUGGUCGUUACCAA dTdT (SEQ ID NO: 311) dTdT CACCGUACCAGCAAUGGUU (SEQ ID NO: 312) GGACAUUAUUCUAAGUGAA dTdT (SEQ ID NO: 313) dTdT CCUGUAAUAAGAUUCACUU (SEQ ID NO: 290) GGAAGAAUCUCAUCUCAGAUUCAA ) UUCCUUCUUAGAGUAGAGUCUAG AG- (SEQ ID NO: 112) GCAGAUCAUGAGGUCAAGAUUCAA ) UUCGUCUAGUACUCCAGUUCUAG AG- (SEQ ID NO: 113) GAAGAAUCUCAUCUCAGAAUUCAA ) UUCUUCUUAGAGUAGAGUCUUAG AG- (SEQ ID NO: 114) GUGUGAGACUCCAUCUGAAUUCAA ) UUCACACUCUGAGGUAGACUUAG AG- (SEQ ID NO: 115) GAUCAUGAGGUCAAGAGAUUUCAA ) UUCUAGUACUCCAGUUCUCUAAG AG- (SEQ ID NO: 291) GAGAGUCAUCUUACUCAGAUUCAA ) UUCUCUCAGUAGAAUGAGUCUAG AG- (SEQ ID NO: 292) GCUGGGUGUGGUAGUGCAUUUCAA ) UUCGACCCACACCAUCACGUAAG AG- (SEQ ID NO: 293) GUCAAGAGAUCGAGACCAUUUCAA ) UUCAGUUCUCUAGCUCUGGUAAG AG- (SEQ ID NO: 294) GUCAUCUTACUCAGAGCAUUUCAA ) UUCAGUAGAAUGAGUCUCGUAAG AG- (SEQ ID NO: 116) GGCUGAGGCAGGCAGAUCAUUCAA ) UUCCGACUCCGUCCGUCUAGUAG AG- (SEQ ID NO: 295) GGAGUAUAGGAAUCUCCUAUUCAA ) UUCCUCAUAUCCUUAGAGGAUAG AG- (SEQ ID NO: 117) GGUAGUGCAUGCCUGUAGUUUCAA ) UUCCAUCACGUACGGACAUCAAG AG- (SEQ ID NO: 280) GAGAUGGCGCCACUGUACUUUCAA ) UUCUCUACCGCGGUGACAUGAAG AG- (SEQ ID NO: 296) GCCUGGCGACAGUGUGAGAUUCAA ) UUCGGACCGCUGUCACACUCUAG AG- (SEQ ID NO: 297) GCCUGUAGUCCCAGCUACUUUCAA ) UUCGGACAUCAGGGUCGAUGAAG AG

[0143] LIV21 complex and associated metabolic complex:

[0144] The present invention relates to the LIV21 complex and its new nucleotide sequences SEQ YD No. 171 to SEQ ID N.degree. 217 also used for sonic of them in the form of siRNA. for diagnostic and therapeutic applications and also LIV21F and LIV21K polypeptides and derivatives and fragments and isoforms thereof SEQ ID No 215).

[0145] LIV21 human complex, characterized in that it comprises:

[0146] the nucleotide sequences SEQ ID N.degree. 171 to 175, and

[0147] siRNA sequence derived from one of the RNA sequences SEQ ID N.degree. 120 and SEQ N.degree. 121, and 171 to 175

[0148] a protein fraction comprising at least sequence SEQ ID N.degree. 1 and 181 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said SEQ ID N.degree. 1 and 181.

[0149] LIV21 human complex, characterized in that it comprises:

[0150] The nucleotide sequences SEQ-ID N.degree. 171, 172, and the protein fractions comprising at least sequence SEQ ID N.degree. 1 or a sequence having 181 or 70, 10 80 or 90% identity with said SEQ ID NO 1 or 181 and SEQ ID N.degree. 183 or a sequence having 70, 80 or 90% identity with said SEQ ID N.degree. 183.

[0151] LIV21 complex human, characterized in that it also comprises:

[0152] nucleotide sequences SEQ ID N.degree. 123, 124 and 127, and the protein fractions comprising at least sequence SEQ ID No. 1 or a sequence having 70, 80 or 90% identity with said SEQ ID NO 1 and the sequence from 181 to 185 or a sequence having 70, 80 or 90% identity with said SEQ ID NO 181 to 185.

[0153] LIV21 complex human characterized in that it further comprises:

[0154] Any of the nucleotide sequences or ribonucleic SEQ ID N.degree. 119, 120, 121, 122, 123, 124, 125, 126 or 127 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID N.degree. 119 to 127, or

TABLE-US-00003 (SEQ ID NO: 306) UUGGUAACGACCAUGCCAC, or (SEQ ID NO: 307) UUCACUUAGAAUAAUGUCC, or (SEQ ID NO: 308) UCUUUGUGAAUUUGACAAC, or (SEQ ID NO: 309) UCAAGGUCCAGGCUACAAC, or

[0155] Any of the siRNA following:

TABLE-US-00004 (SEQ ID NO: 310) GUGGCAUGGUCGUUACCAA dTdT (SEQ ID NO: 311) dTdT CACCGUACCAGCAAUGGUU (SEQ ID NO: 312) GGACAUUAUUCUAAGUGAA dTdT (SEQ ID NO: 313) dTdT CCUGUAAUAAGAUUCACUU

[0156] LIV21 complex human (FIGS. 1 et 2) characterized in that it further comprises at least:

[0157] Any one of the nucleotide sequences SEQ ID N.degree. 123, SEQ ID N.degree. 124 and SEQ ID N.degree. 127 to 149, or SEQ ID N.degree. 217

[0158] any one of amino acid sequences SEQ ID N.degree. 1 to 148 and SEQ ID N.degree. 150 to 170 and SEQ ID NO 180 to 185, or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID N.degree. 180 to 185 and SEQ ID 1,2,5 and SEQ ID N.degree. 215

[0159] LIV21 Complex human characterized in that said protein fraction further comprises any of the following proteins: E2F1, E2F4, p130, p300, p107, Liv21F, HDAC-1, PML, SUMO et PKC epsilon, Aurora A, Survivin, BCAS4, BCAS3, RFSH.

[0160] LIV21 complex human characterized in that it interacts with at least one of its associated partners, at least one of its associated partners are selected from the group consisting of:

[0161] any one of the following proteins: RBP2, TNFalpha, crb2, cycE/cdk2, cdkl, CREB1, p300, p107, NFkB, cdc2A, mdm2, p21, p53, p65, p73 MYC, NMYC, TGEbeta, Chlatrin, Aurora, AKT, BRCA1, F0X04 or cyclin A et D1, CHUK, HMGA2, IKBKB

[0162] an antibody of anyone of the following proteins: RBP2, E2F4, E2F1, SUMO, HDAC-1, crb2, Int2, cmd2, cycE/cdk2, cdkl, CREB1 et p300, Rb, p 107, p 130 of the family of pocket proteins NFkB, cdc2A, mdm2, p21, p53, p65, p73, the cyclin A and D1, CHUK, MYC, NMYC, TGF Beta, Chlatrin (2), Aurora, AKT, BRCA1, F0X04, HMGA2, BCAS3, BCAS4, solute carrier.

[0163] in that it comprises an extract of proteins and peptides obtained by latching to a polyclonal antibody of the LIV21, and

[0164] in that its electrophoretic profile acrylamide gel comprises at least three bands: band of 50 kD, 51 kD band, and the band of 52 kD.

[0165] Complex human LIV21 is also characterized in that, after trypsin digestion, the profile of MALDI includes at least mono isotopic peaks following:

[0166] 1135.563; 1151.545; 1167.604; 1206.589; 1324.634; 1336.658; 1507.735; 1604.710; 1800.940; 2087.034.

[0167] Method of detecting the complex human LIV21, characterized in that it comprises the implementation of at least one probe specific for at least one sequence of said complex LIV21 according to claim 1 or 2.

[0168] Method of detecting the complex human LIV21, characterized in that it further comprises the implementation of at least one probe specific for at least one sequence of the LIV21 said complex and its associated partners.

[0169] Method of detection of the complex and its partners LIV21 in that it is comprises at least the steps of:

[0170] A step of extracting biological material from a biological sample taken from a patient,

[0171] A step of contacting said biological material with at least said probe specific for any of the sequences of said human or complex LIV21 or LIV21 said complex and its content partners, and at least one control and

[0172] A step of detecting the expression of the expression products of the genes of said complex of said human or LIV21 LIV21 complex and its content partners, said products being comprised of expression of messenger RNA, or peptides, or proteins.

[0173] Detection method is characterized in that it also aims to screen a candidate compound, said candidate compound is capable of modulating the activity of the complex human LIV21, and that it also includes:

[0174] a step of contacting said biological material with said candidate compound, and a step of selecting said candidate compound.

[0175] Method is characterized in that said biological sample is taken from a cancer patient and in a healthy patient, and in that said biological material comprises cell nuclear extracts, and cytoplasmic cell extracts, cell membrane extracts, and in that it further comprises a step of determining of the under-expression and overexpression of the gene products of said complex of said human or LIV21 LIV21 human complex and its content partners said biological extracts.

[0176] Method is characterized in that it further comprises a step of determining the ratios of said sub-expression and overexpression of said gene products: cell nuclear extracts, and cytoplasmic cell extracts, cell extracts or membrane, and in that it further comprises a step of such analysis combined ratios of said biological material taken from a cancer patient and in a healthy patient.

[0177] Method is characterized in that said probe comprises a sequence specific siRNA labeled with rhodamine.

[0178] A method according to any one of the above approaches is, characterized in that it implements a biochip, on which is deposited at least one sequence-specific probes from said complex human LIV21.

[0179] Method is characterized in that, in addition, it implements at least one specific probe sequences LIV21 said complex human and associated partners

[0180] Method is characterized in that said biochip is a protein biochip, or a biochip antibody, or a nucleotide acid microarray, or a RNAm biochip, or a siRNA biochip.

[0181] Method is characterized in that said detecting step implements any means of optical imaging, or any means of sonic or any means of spectroscopy.

[0182] FIG. 1 characterizing the protein complex, and its PI and its PM are dependent on the temperature and conditions of migration and its observation in total extracts or in extracts of cellular compartments.

[0183] FIGS. 1, 2, 3). It gives more than 54 peptides following digestion with Promega trypsin (FIG. 7). The characteristics of the LIV21F protein are also described in FIGS. 1, 2, 3, 4. Twenty specific peptides of LIV21 have been described: LIV2ta (SEQ ID No 1) and LIV21b (SEQ ID No 2) at the sequence 180.

[0184] The gene of this protein is characterized by two main sequences (i.e. patent in listing) and sequences representing an alternate splicing.

[0185] LIV21K corresponds to a sequence of strong homology (of more than 60%) with AD7cNTP, the neural thread protein in N terminal (position 193 to 299) of (060448_Human). NO: 180)

TABLE-US-00005 (SEQ ID NO: 180) SVAQAGVQWRNLGSLQALPPGFMPFSCLSLLSSWDYRRLPPRPATFLYFP RQGFTVLARMVSISPRDPPASASQSVGIAYISNFFFFEMESRSVAQAGVQ WHNLGSLQALPPGFMPFSCLSLLSSWDYRRLPPRPATFLYFPR

[0186] With variable ones within peptide in position (i.e. figure . . . ):

[0187] The structure of LIV21K is like that of the AD7C NTP, i.e. repeated regions that can be also analyzed under regions which correspond to functional fields.

TABLE-US-00006 (SEQ ID NO: 314) SVXQAGVQWXNLGSLQXLPPGXXXFSCLSLXSSWDYXXLPPXPAXF

[0188] Or a variable one:

TABLE-US-00007 (SEQ ID NO: 315) SVXQAGVQWXNLGSLQXLPPGFXXFSCXSLSSWDYRRXPPRXA

[0189] Between these two repeated reasons, there is a peptide of 40 amino-acids with a reason also preserved:

TABLE-US-00008 (SEQ ID NO: 316) ISPXDXPASASQSXGIXXXSX (SEQ ID NO: 317) THE LIV21I: FLYFPRQGFTVLARMVSISPRDPPASASQSVGIAYISN

[0190] With alternatives in position:

[0191] For example for LIV21I

[0192] In position 31, an A instead of the V and in position 34 a T instead of the amino-acid A.

[0193] Thus: the amendment of the end PASASQSAGIT (SEQ ID NO: 318) but also an alternative where the A becomes T in position 25: DPPTSASQS VGI (SEQ ID NO: 319)

[0194] Item for LIV21F or K:

[0195] SEQ NO 320: FSCLSLLSSWDYRRLPPRPATFLYF where the amino-acid in position 7 here becomes a praline (P instead of L) and/or in position 15 too (with the possibility of an alternative Alanine; sometimes the position 14 changes of a R in H and/or in position 21 where an amino-acid T becomes N.

TABLE-US-00009 SEQ ID NO 321: FSCLSL P SSWDYRR P PPRPA N FLYF

[0196] Moreover, two other peptides of LIV21 are also described: the peptide LIV21c (SEQ ID No 3) and the peptide LIV21d (SEQ ID No 4). The peptide LIV21e (SEQ ID No 5), KFFVFALILALMLSMCGADSHAKR (SEQ ID NO: 322) with which the final section is homologous with a sequence with LIV21K.

[0197] Other specific peptides of L1V21 are described in the additional list.

[0198] A homology with a functional segment of the protein zinc finger 575 (ZN575-Human): score 13 to 48 and 91% of recovery

[0199] A homology of sequence 6 and 56 and with the field MF MR which is the bzip field of a transcription factors containing a signal of nuclear localization and a trans-regulating activity in TAF1.

[0200] For the purposes of the invention, a preferred protein comprises at least one sequence chosen from SEQ ID Nos 1-180 or a sequence having 70%, 80% or preferably 90% homology with said sequence (SEQ ID N.degree. 215).

[0201] The LIV21 complex comprises proteins including 3D helices structures, which have a major functional role for their interactions with the rest of the Liv21 complex.

[0202] The present invention concerns a purified or recombinant, isolated human polypeptide having a sequence comprising the sequence SEQ ID No 1 and/or SEQ 5 ID No 2 and/or SEQ ID No 3 and/or SEQ ID No 4 and/or SEQ ID No 5. Preferably, the polypeptide LIV21F comprises the sequences SEQ ID Nos 1, 2 and 5. In a preferred embodiment, the complex is studied based on a sequence selected among the peptide sequences obtained by MALDI (FIGS. 3, 4 and 5). The invention also concerns the three peptides LILV21a (SEQ ID No 1), LIV21b (SEQ ID No 2) and LIV21c (SEQID No 5). It also concerns peptides comprising at least 10 consecutive amino acids of human LIV21, preferably at least 20, 30 or 50 consecutive amino acids of LIV21 peptides (i.e. sequences list 1-215 in annexes).

[0203] The present invention also relates a polynucleotide encoding for the human protein Liv21, Liv21 a and/or Liv21b, generally a polynucleotide encoding for a polypeptide according to the present invention. The polynucleotide encoding for Liv21F and this one encoding for LIV21K may be an mRNA, a cDNA or a genomic DNA. The polynucleotides according to the present invention may be isolated from cells and more particularly from human cells or from human cDNA libraries. They can also be obtained by a polymerase chain reaction (PCR) carried out on the total DNA of the cells or else by RT-PCR carried out on the total cellular RNAs or by chemical synthesis. Probes and primers described in the present invention may be used to isolate and/or prepare a polynucleotype encoding for a protein of the Liv21F. It relates also a cloning or expression vector comprising such polynucleotide.

[0204] Such vector may include the elements required for the expression (expression vector) and eventually for the secretion of the protein in a host cell (signal peptide of secretion). Preferably the said vectors comprise: a promoter, signals of initiation and termination of translation, as well as adapted regions for transcription regulation. The vector can be a plasmid, a cosmid, a BAC, a phage, a virus, or other. The invention relates to a host cell or a non-human transgenic animal including a vector or a polynucleotide according to the present invention.

[0205] The invention also concerns derivatives of interest of LIV21F or LIV21K which are for example proteins of merger in which is amalgamated with proteins markers like the GFP. In addition, the LIV21F or LIV21K protein and all described peptides (i.e. patent in listing) can be marked by any known means of those skilled in the art. The siRNA too (SEQ ID N.degree. 91 to 118).

[0206] The present invention also relates to an antibody which is linked specifically to a polypeptide according to the present invention, preferably human LIV21, a fragment or a derivative of this one. In a specific mode of realization, the antibody is linked specifically to a LIV21a or LIV21b peptide or LIV21F or LIV21K polypeptides.

[0207] The method can in particular comprise the detection of the product of expression of two of these genes or of the three genes. Moreover, at least one of the ratios LIV21/PKCS, LIV21/E2F4 and LIV21/E2F1 can be determined in the present method. This ratio can be determined in the cytoplasm and/or in the nucleus. Preferably, these ratios are determined in the nucleus. Preferably, these ratios are compared with those obtained in a normal cell.

[0208] In one embodiment, the expression product of the genes is detected at the mRNA level, it being possible for the mRNA to be detected. by any means known to those skilled in the art.

[0209] Thus, the method according to the present invention also relates to the detection of a polynucleotide encoding the human LIV21 protein or a fragment thereof, for example LIV21a and/or LIV21b. The polynucleotide encoding LIV21 may be an mRNA, a cDNA or a genomic DNA. The polynucleotides may be isolated from cells of the biological sample. They may also be obtained by a polymerase chain reaction (PCR) carried out on the total DNA of the cells or else by RT PCR carried out on the total RNA of the cells or polyA RNAs.

[0210] The mRNA may be detected by an RT PCR analysis. For this, the method uses a pair of primers specific for the expression product to be detected, in particular LIV21, PKC.epsilon., E2F1 or E2F4. The term "specific pair of primers" is intended to mean that at least one of the primers is specific for the expression product to be detected, i.e. that this pair of primers makes it possible to specifically amplify a fragment of the desired mRNA. Preferably, the RT PCR analysis carried out on nuclear and/or cytoplasmic extracts of the cells contained in the sample from the patient. Optionally, the RT PCR analysis may be a quantitative analysis. A pair of primers specific for LIV21 can be prepared on the basis of the teachings of the present application. For example, the pair of primers may comprise the primers described in the sequences listing 5 SEQ ID Nos 3 and 4, and additional sequences of the list obvious thus numbered from 119 to 149 and 171 to 180 with optionally all the additional nucleotidic sequences of the additional list.

[0211] The pairs of primers specific for PKCs, E2F1 and E2F4 are well known by those skilled in the art (Cara J S 2000; Mundle S D 2003; Stevaux 0 2002; Cheng T 2002; Opalka B 2002). The mRNA may also be detected by Northern blotting analysis. For this, the method uses a probe specific for the expression product to be detected, in particular LIV21, PKCs, E2F1 or E2F4. A probe specific for LIV21 can be prepared on the basis of the teachings of the present application. An example of a specific probe comprises the sequence SEQ ID No 5. Preferably, the Northern blotting analysis is carried out on nuclear and/or cytoplasmic extracts of the cells contained in the sample from the patient. The nucleic probe is labelled. The oligonucleotide labelling technique is well known to those skilled in the art. The labelling of the probes according to the invention can be carried out with radioactive elements or with non radioactive molecules. Among the radioactive isotopes used, mention may be made of .sup.32P, .sup.33P or .sup.3H. The non radioactive entities are selected from ligands such as biotin, avidin, streptavidin or digoxigenin, haptens, dyes and luminescent agents such as radioluminescent, chemoluminescent, bioluminescent, fluorescent or phosphorescent agents. The probes specific for PKCs, E2F1 and E2F4 are well. known to those skilled in the art. In a preferred embodiment, the expression product of the genes is detected at the protein level. Preferably, the protein is detected using a specific antibody. Thus, the method comprises a step of bringing the cells of the biological sample into contact with an anti-human LIV21 antibody. The antibodies can be monoclonal or polyclonal. The antibody can for example be a serum anti-LIV21. When the product of expression of one of the genes PKCs, E2F1 and E2F4 must be detected, the method can use antibodies specific for the PKCs, E2F1 and E2F4 proteins, respectively. Polyclonal and monoclonal antibodies directed against PKCs, E2F1 and E2F4 are commercially available. By way of example, mention may be made of, for PKCs, a rabbit polyclonal antibody (Santa Cruz Technology, sc-214), for E2F1, a rabbit polyclonal antibody (Santa Cruz Technology, sc-860), and for E2F4, a rabbit polyclonal antibody (Santa Cruz Technology, sc-866). Preferably, the antibodies are labelled, directly or by means of a secondary antibody. The antibody labelling techniques are well known to those skilled in the art. In a specific embodiment, the protein can be detected by Western blotting analysis. The Western blotting analysis can be carried out on nuclear and/or cytoplasmic extracts of the cells contained in the sample from the patient. Briefly, the proteins are migrated in a gel and then blotted onto a membrane. This membrane is then incubated in the presence of the antibodies and the binding of the antibodies is optionally revealed using labelled secondary antibodies. In another embodiment, the protein is detected by immunohistochemistry, immunocytochemistry or immuno-radiography. These techniques are well known to those skilled in the art. The immunocytochemical analysis can be carried out on whole cells originating from the sample or which are derived there from, for example by cell culture. It can also be carried out on isolated nuclei. The immunohistochemical analysis can be carried out on mammary, nerve tissue sections etc . . . . By way of illustration, an immunocytochemical analysis can include the following steps. However, it is understood that other preparatory methods can be carried out. Cells originating from the biological 5 sample are cultured, preferably on slides (Lab Tek, Nunc, Germany), and then washed with buffer and fixed with paraformaldehyde (for example, 4%). A saturation step is preferably carried out by incubating the cells with buffer S (PBS-0.1% Triton X100-10% FCS). The cells are then incubated with a primary antibody and are then washed and incubated with a fluorescent secondary antibody, if necessary. The nuclei can be labelled with propidium iodide (Sigma). The slides are mounted in moviol for observation by fluorescence microscopy. Moreover, isolated nuclei sampled during a nuclear extraction can be fixed with paraformaldehyde (for example, 4%). The suspensions of nuclei are deposited between a slide and cover slip and the observation is carried out by fluorescence microscopy and by confocal microscopy. The primary antibodies are, for example, rabbit antibodies and the secondary antibodies are labelled antibodies directed against rabbit IgGs. The biological samples originate from a patient potentially suffering from cancer or for whom it has been established that said patient is suffering from cancer. "Biological sample" is intended in particular to mean a sample of the biological fluid, living tissue, tissue fragment, mucosity, organ or organ fragment type, or any culture supernatant obtained by means of taking a sample. The method according to the present invention can comprise a step of taking a biological sample from the patient. The detection step can be carried out directly on a tissue section of the sample, or on a culture of cells originating from the sample, or on total cell extracts, nuclear extracts and/or cytoplasmic extracts. In a specific embodiment of the method comprising the detection of the product of expression of the PKCe gene, a significant increase in PKCs is indicative of the presence of cancer cells. More specifically, the amount of PKCs in normal cells is compared with the amount of PKCs in the cells of the sample, and the significant increase is determined by means of this comparison. The method according to the present invention can optionally comprise the measurement of the LIV21/PKCS content. This LIV21/PKCS ratio increases in the cytoplasmic fraction of cancer cells compared with normal cells. In another specific embodiment of the method comprising the detection of the product of expression of the E2F4 gene, the method comprises the detection of the association of LIV21 with the E2F4 protein, and a decrease in this association is indicative of the presence of cancer cells. The detection of the association of LIV21 with the E2F4 protein can be carried out by concurrent detection of LIV21 and of E2F4. The method according to the present invention can optionally comprise the measurement of the E2F4/LIV21 content. This E2F4/LIV21 ratio decreases in the nucleus of cancer cells compared with normal cells. In an additional embodiment of the method comprising the detection of the product of expression of the E2F1 gene, the presence of the E2F1 protein in the nucleus is indicative of the presence of cancer cells. The method according to the present invention can optionally comprise the measurement of the E2F1/LIV21F content. This E2F1/LIV21F ratio increases in the nuclear fraction of cancer cells compared with normal cells. The method according to the present invention allows in particular the detection of metastasized cancer, therapeutic monitoring and/or recurrences following treatment and makes it possible to determine the degree of invasiveness of a cancer or neurodegenerative disease or Alzheimer disease. The specificity of the detection can be related to the crossing over of information obtained through the existence and the topography of LIV21 by all imaging and spectroscopy means and obtained by combination with other known cancerological indicators via protein arrays or microarrays. Thus, the detection based on LIV21 can be combined with the detection of other cancer markers, in particular breast cancer markers, known to those skilled in the art and nerve cancers. In fact, the present invention concerns a method for the therapeutic monitoring of an anticancer treatment in a patient suffering from cancer, comprising the administration of the anticancer treatment to said patient and the detection of cancer cells in a biological sample from the patient, according to the method of the present invention. A decrease in cancer cells will be indicative of the effectiveness of the treatment. The detection of cancer cells in a biological sample from the patient, according to the method of the present invention, can be carried out once or several times over the course of the anticancer treatment or after the anticancer treatment. Preferably, the biological sample originates from the tissue affected by the cancer treated.

[0212] Moreover, the present invention also concerns a method for the detection of recurrences subsequent to an anticancer treatment of a cancer in a patient, comprising the detection of cancer cells in a biological sample from the patient, according to the method of the present invention. The detection of cancer cells in a biological sample from the patient, according to the method of the present invention, can be carried out once or several times after the anticancer treatment. The detection of cancer cells is indicative of recurrences. Preferably, the biological sample originates from the tissue affected by the cancer treated. The present invention also describes a kit for carrying out a method according to the invention. More particularly, the invention concerns a kit for the detection of cancer cells in a biological sample from a patient, comprising one or more elements selected from the group consisting of an antibody which binds specifically to human LIV21 according to the present invention and an anti-LIV21 serum according to the present invention, an oligonucleotide probe specific for the LIV21 mRNA and a pair of primers specific for the LIV21 mRNA. In a preferred embodiment, the kit comprises antibodies, which bind specifically to human LIV21. In another preferred embodiment, the kit comprises an oligonucleotide probe specific for the LIV21 mRNA. It may also comprise a probe specific for a "housekeeping" gene. The kit according to the present invention can comprise reagents for the detection of an LIV21-antibody complex produced during an immunoreaction. Optionally, the kit according to the present invention also comprises means for detecting the product of expression of at least one gene selected from the group consisting of the protein kinase C epsilon (PKCs) gene, the E2F1 gene and the E2F4 gene. This detection means can be antibodies specific for the protein, oligonucleotide probes specific for the mRNA concerned and/or a pair of primers specific for the mRNA. The present invention also relates to a diagnostic composition comprising one or more elements selected from the group consisting of an antibody according to the present invention and a serum according to the present invention, an oligonucleotide probe specific for the LIV21 mRNA and a pair of primers specific for the LIV21 mRNA.

[0213] Anticancer Therapy

[0214] In the context of an anticancer therapy, it is possible to envision increasing the amount of LIV21 present in the nucleus. For this, the nuclear localization in cancer cells of LIV21 expression could be promoted. Liv21 being able to translocate in the nucleus by itself, one could envisage the construction of an expression vector including a polynucleotide coding for human Liv21 in order to over express these protein in the cell nucleus for that we wish regulate the proliferation (SEQ ID N.degree. 215). The expression vector encoding Human Liv21 can be administrate in vivo to the patient by any mean known by those skilled in the art, SEQ ID N.degree. 215 for example and inhibitor peptide of Liv 21. For example, the expression vector can be administrated as naked DNA (for example EP 465529), The microinjection, electroporation, phosphate of calcium precipitation techniques and formulations using nanocapsules or liposomes are other techniques available (SEQ ID N.degree. 217). The expression vector may also be in the form of a recombinant virus, including, a polynucleotide encoding human Liv21 inserted into its genome. The viral vector can be selected for example from an adenovirus, a retrovirus, in particular a lentivirus, and a virus adeno-associated (AAV), a herpes virus (HSV), a cytomegalovirus (CAW), a vaccine virus, etc . . .

[0215] So advantageous, the recombinant virus is a defective virus.

[0216] Preferably, the expression vector permits a cellular targeting. So this vector could target cancer cells or a particular cell type that is affected by cancer. Targeting of particular cellular type can be realized by placing the polynucleotide coding Liv21 under the control of a promoter tissue-specific. In another alternative the expression vector may be targeted, for example, in association with a specific molecule of a particular tissue or cancer cells, for example a specific antibody to a molecule expressed specifically by the particular tissue or the cells of cancer. Also the choice of expression vector may also influence the cellular targeting. Indeed, if the vector is a virus, the virus tropism natural or amended may also allow a certain target.

[0217] The present invention concerns a pharmaceutical composition comprising a polynucleotide encoding for Liv2l (SEQ ID N.degree. 215), more particularly an expression vector coding for Liv21. It also concerns the use of a pharmaceutical composition comprising a polynucleotide encoding for Liv21, in particular an expression vector encoding for Liv21 as medicament. Preferably, the present invention concerns the use of a pharmaceutical composition comprising a polynucleotide encoding for Liv21, in particular an expression vector encoding for Liv21, for the preparation of a medicament for use in treating cancer. Finally, it concerns a method for treating cancer in a patient, comprising the administration to the cancer cells of a polynucleotide encoding for Liv21, Liv21 expression making it possible to reduce or abolish the cancerous phenotype of the treated cells. Preferably, cancer is selected from breast cancer, bladder cancer, ovarian cancer, uterus cancer lung cancer, skin cancer, prostate cancer, colon cancer, a glioblastoma, without being limited thereto. Moreover, the nuclear localization of LIV21 could be promoted, for example by decreasing the activity of PKCs in the cancer cells and by using HDAC inhibitors.

[0218] In another specific embodiment of anticancer therapy, it is possible to envision decreasing the activity of PKCs in the cancer cells. This decrease in activity can be produced by decreasing the activity of the PKCs protein or by decreasing its expression. A decrease in the activity of the PKCs protein can be obtained by administering PKCs-protein inhibitors to the cancer cells. The PKCs-protein inhibitors are well known to those skilled in the art. A decrease in the expression of the PKCs protein can be obtained by using antisenses or siRNA specific for the PKCs gene. Kits are commercially available. Moreover, the techniques concerning inhibition by means of antisense or siRNA are well known to those skilled in the art (Arya R 2004, Lee W 2004, Sen A 2004, Platet N 1998, Hughes 1987) (SEQ ID N.degree. 215 and SEQ ID N.degree. 216).

[0219] The next siRNA can be also used:

TABLE-US-00010 (SEQ ID NO: 108) GCUGAGGCAGGCAGAUCAUUUCAA ) UUCGACUCCGUCCGUCUAGUAAGAG- (SEQ ID NO: 109) GUACCAUUUCACAACAACUUUCAA ) UUCAUGGUAAAGUGUUGUUGAAGAG-

[0220] The present invention therefore concerns a pharmaceutical composition comprising a PKCs-protein inhibitor. It also concerns the use of a pharmaceutical composition comprising a PKCs-protein inhibitor as a medicament, in particular for the preparation of a medicament for use in treating cancer. Finally, it concerns a method for treating cancer in a patient, comprising the administration to the cancer cells of a PKCs-protein inhibitor, the pKCs-protein inhibitor making it possible to reduce or abolish the cancerous phenotype of the treated cells. In a first embodiment, the PKCs-protein inhibitor decreases the activity of the PKCs protein. In a second embodiment, the PKCs-protein inhibitor decreases the expression of the PKCs protein. Preferably, cancer is selected from breast cancer, bladder cancer, ovarian cancer, uterus cancer lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, a sarcoma, a leukaemia and glioblastoma, without being limited thereto. PKC epsilon inhibitors are published and commercially available for other applications.

[0221] In the context of a therapy for a neurodegenerative disease, it is possible to envision decreasing the amount of LIV21 present in the nucleus. For that, the Liv21 expression could be decreases or blocked in nuclear of the diseased cells of neurodegeneration. The cells affected by the neurodegenerative disease are generally neurons, motorneurons, etc.

[0222] In a preferred embodiment, the neurodegenerative disease is chosen from Alzheimer's disease, Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). The inhibition or the blocking of LIV21 expression can be carried out by any means known to those skilled in the art. In particular, by way of illustration, mention may be made of the antisense strategy, siRNA and ribozymes. Thus, an antisense oligonucleotide or an expression vector encoding this antisense oligonucleotide could be prepared and used to block the translation of the mRNA encoding LIV21F in vivo. Moreover, a ribozyme can be prepared for cleaving and destroying, in vivo, the mRNA encoding LIV21. It is also possible to envisage a triple-helix strategy in which an oligonucleotide is designed so as to hybridize with the gene encoding LIV21 and to thus block the transcription of this gene.

[0223] Moreover, for this, the nuclear localization of LIV21 could also be hindered, for example by increasing the activity of PKCs in the cells affected by the neurodegenerative disease. In one particular therapeutic method against neurodegenerative diseases, it is possible to envision increasing PKC epsilon activity in the cells affected by the neurodegenerative disease. This increase in activity can be produced by increasing the activity of the PKCs protein or by increasing its expression. An increase in the activity of the PKCs protein can be obtained by administering PKCs-protein activators to the cells affected by the neurodegenerative disease. The PKCs-protein activators are well known to those skilled in the art (Toma 0(2004), Activation of PKCs by DAG, AGPI: oleic acid, linoleic acid, arachidonic acid, etc . . . .

[0224] Activation and proteolysis of PKCs in gonadotropic cells: Communication 2004 by Macciano H, Junoy B, Mas J L, Drouva S V, UMR6544 Marseille). An increase in the expression of the PKCs protein can be obtained by using expression vectors encoding the PKCs protein and which make it possible to overexpress it in the cells affected by the neurodegenerative disease.

[0225] Thus, the present invention concerns a pharmaceutical composition comprising a PKCs-protein activator or an expression vector encoding the PKCs protein. It also concerns the use of a PKCs-protein activator or of an expression vector encoding the PKCs protein, for the preparation of a medicament for use in the treatment of a neurodegenerative disease.

[0226] Screening Method

[0227] The invention concerns methods for the selection, identification, characterization or optimization of active compounds, which decrease cell proliferation, based on the measurement of the nuclear versus cytoplasmic localization of LIV21, or of the binding of the LIV21 protein to the E2F4 protein,

[0228] In a first embodiment, the selection, the identification, the characterization or the optimization of active compounds of therapeutic interest comprises bringing a candidate compound into contact with a cell and determining the nuclear versus cytoplasmic localization of the LIV21 expression product. An increase in the nuclear localization of LIV21 indicates that the candidate compound is active in terms of decreasing or abolishing cell proliferation. A decrease in the nuclear localization of LIV21 indicates that the candidate compound is active in terms of treating or preventing a neurodegenerative disease.

[0229] In a second embodiment, the selection, the identification, the characterization or the optimization of active compounds of therapeutic interest comprises bringing a candidate compound into contact with a cell and determining the level of expression of the gene encoding the PKCs protein. A decrease in the expression of PKCs indicates that the candidate compound is active in terms of decreasing or abolishing cell proliferation. An increase in the expression of PKCs indicates that the candidate compound is active in terms of treating or preventing a neurodegenerative disease.

[0230] In a third embodiment, the selection, the identification, the characterization or the optimization of active compounds of therapeutic interest comprises bringing a candidate compound into contact with a cell and determining the level of LIV21/E2F4. complex. An increase in the level of LIV21/E2F4 complex indicates that the candidate compound is active in terms of decreasing or abolishing cell proliferation. A decrease in the level of LIV21/E2F4 complex indicates that the candidate compound is active in terms of treating or preventing a neurodegenerative disease. In a fourth embodiment, the selection, the identification, the characterization or the optimization of active compounds of therapeutic interest comprises bringing a candidate compound into contact with a cell and determining the level of expression of the gene encoding the E2F1 protein. A decrease in the expression of E2F1 indicates that the candidate compound is active in terms of decreasing or abolishing cell proliferation. An increase in the expression of E2F1 indicates that the candidate compound is active in terms of treating or preventing a neurodegenerative disease.

[0231] The invention also relates to a method of screening for a compound capable of interacting in vitro, directly or indirectly, with LIV21, characterized in that: in a first step, the candidate compound. and LIV21 are brought into contact and, in a second step, the complex formed between said candidate compound and LIV21 is detected. by any appropriate means.

[0232] The present invention also relates to a method of screening for a compound capable of modulating (activating or inhibiting)the activity of the LIV21 protein, characterized in that: in a first step, cells of a biological sample expressing the LIV21 protein are brought into contact with a candidate compound, in a second step, the effect of said candidate compound on the activity of said LIV21 protein is measured by any appropriate means, and in a third step, candidate compounds capable of modulating said activity are selected. The activity of LIV21 can, for example, be estimated by means of evaluating the ability of the cell to divide, by measuring the expression of the E2F1 gene or by the cytoplasmic and/or nuclear localization of LIV21.

[0233] The candidate compound can be a protein, a peptide, a nucleic acid (DNA or RNA) , a lipid, or an organic or inorganic compound. In particular, the candidate compound could be an antibody, an antisense, a ribozyme or an siRNA.

[0234] Other advantages and characteristics of the invention will appear in the examples and the figures which follow, and which are given in a non limiting manner.

EXAMPLES

Example 1

[0235] Extraction of proteins of the Liv21 complex.

[0236] The MCF-7 cell line

[0237] The MCF-7 line is a non clonal human line of breast denocarcinoma cells. During their differentiation induced by exogenous factors, these cells develop a hypertrophy, membrane protrusions and a tendency to dissociate from one another. They acquire a secretory phenotype which is characterized by the appearance of numerous granules and of secretory canaliculi. In vivo, these cells are relatively non metastatic and this low invasiveness is thought to be due to a low constitutive activity of the protein kinases C (PKCs) and to a relatively low level of expression of protein kinase C alpha.

[0238] This line is used in many studies on proliferation, differentiation and apoptosis. These studies use appropriate drags, such as TNF for the induction of apoptosis, or TPA (12-0-tetradecanoyl phorbol-13-10 sumoate) for the induction of differentiation and therefore for the study of departure from the cell cycle.

[0239] Extraction of proteins of the Liv21 complex.

[0240] After culture cells MCF7 (ATCC passage 15) and cell extraction, 5 mg of protein are centrifuged after homogenization in 10 ml RIPA buffer, antiprotease added. These protein extracts went loop for seven hours at a peristaltic pump on a column of affinity (HITRAP NHS ACTIV HP 1.times.5 ml: Article and catalog 17071701) which was set Liv21 antibody. Wash 3 times, 10 ml in RIPA buffer and then a half-eluting fractions of 500 nl in a buffer glycine PH2/HCL, then control gel SDS Page 10% (deposit of 25 nl of the fraction) followed by a 25 western blot to verify. Revelation of a band on gel at 51 kD flanked by two other bands at 50 and 52 kD respectively and a lower trace of a band 80 kD and 100 kD in gel mono dimensional (FIG. 1A). Moreover revelation of 12 spots between 50 kD and 70 kD in bidimensional gel (FIGS. 1B and 2), idem cultures of SHSY5Y (i.e. FIG. 7).

TABLE-US-00011 SEQ ID No 1 Peptide LIV21a RVYGPLTNPKPQ SEQ ID No 2 Peptide LIV21a PLMIIHHLDDCPHSQALK SEQ ID No 3 Peptide LIV21c SYMSMFLLLMAISCVLAK SEQ ID No 4 peptide LIV21d CYRSILHTKV SEQ ID No 5 Peptide Liv21b KFFVFALILALMLSMCGADSHAKR

Example 2: Mass Spectrometry

[0241] A mass spectrometry (MALDI) was realized for the LIV21 protein and its complex. The LIV21 protein (polynucleotide Liv21F) was digested with trypsin. The peptides derived from the digestion are solubilized in a solvent: acetonitrile/water (1/1) containing 0.1% of TFA (trifluoroacetic acid). A saturated solution of the alpha-cyano-4-hydroxycinnamic matrix was prepared in the same solvent. The same volume of the two solutions was taken and mixed together and 1 .mu.l was deposited onto the MALDI plate for analysis. The mass spectrometry showed that the LIV21 protein and its complex digested with trypsin reveals hundred peptides following the band of gel extracted between 49 and 54 kD (i.e. FIGS. 3-5). The LIV21 protein was characterized by a molecular weight of 50 kD revealed by Western blotting and by a two-dimensional SDS PAGE gel (FIG. 2). But we find a product of 100 kD at 130 kD which could be a Liv21 dimer. (I.e description FIGS. 4,5 and 6)

[0242] When it changes cell compartment and when it is sumoylated, the LIV21 protein has a molecular weight of approximately 60 kD. When it is phosphorylated in the cytoplasm, it exhibits two forms which differ by a few kilobases. A doublet is then observed.

Example 3: Analysis of Sequences in the Proteomic Databases

[0243] Several peptides in the patent in listing of the patent characterize it:

TABLE-US-00012 SEQ ID No 51 Peptide LIV21b FVFALILALMLSMCG SEQ ID No 5 Peptide LIV21b KFFVFALILALMLSMCGADSHAKR

[0244] For example, the inventor obtained a very significant score of 81, hoped: 0.0012 for the histatin 3-2 variant with 52% of overlapping of sequences between the tested sample and histatin, this sequence SEQ ID No 5 is commune to Liv21 and HIS3-HUMAN (FIGS. 6 and 7). Using different database and a ppm which differed to 20 to 50 ppm, we obtain the same sequence for the commune part: SEQ ID No 51.

Example 4

[0245] Reverse Transcriptions:

[0246] After MCF7 cells (ATCC passage 15) had been thawed and cultured up to 2 00 million, they were trypsinized and frozen at -80.degree. C. The RNA was extracted from two pools of 50 million cells with the Nucleospin RNA L kit (Macherey Nagel) ref. 740.962.20, resulting in a pool 1 of 318 .mu.g and a second of 182 .mu.g.

[0247] The poly A+ RNA was extracted from 313 .mu.g of total RNA of pool 1 using the oligo Tex mRNA Midi kit (Qiagen) ref.70042.

[0248] I Reverse Transcription:

[0249] The RNA was reverse transcribed with the Fermentas Revert Aid H minus M MuLV Reverse Transcriptase, ref. EP0451 batch 1124, with 3.64 .mu.g of total RNA and 0.45 .mu.g of mRNA, 0according to the supplier's conditions, with an oligo dT primer. Reactions were carried out at 2 different temperatures at 45.degree. C. and 55.degree. C. so as to eliminate the RNA structures that may hinder reverse transcription.

[0250] IPCR

[0251] The PCRs were carried out with the reverse transcriptions as templates, initially with the primers Al+oligo dT. Nested PCRs were subsequently carried out on these first PCRs, with the primers Al+Splicing, Al+GDBR1, or ATG+Splicing, ATG+GDBR1.

[0252] PCR amplification was then carried out with the primers specific for the genes to be detected, using the cDNAs obtained after oligo dT RT.

[0253] Enzyme: Fermentas Taq DNA polymerase. Thermocycler: Bio Rad iCycler.

[0254] The quality of the cDNAs was tested by amplification of GAPDH, b actin and Historic H3.3 housekeeping genes.

TABLE-US-00013 TABLE 1 Primers Amplified fragment Reference 5'-3' sequence size Histone N 5'-gtg gta aag cac cca gga a-3' (SEQ ID NO: 324) 347 bp Histone I (reverse) 5'-gct agc tgg atg tct ttt gc-3'(SEQ ID NO: 325) Hum GAPDH sense 5'-TGA AGG TCG GAG TCA ACC G-3' (SEQ 983 bp ID NO: 326) Hum GAPDH 5'-CAT CTG GGC CAT GAG GTC-3' (SEQ ID antisense NO: 327) Hum b-actin sense 5'-GGA CTT CGA GCA AGA GATGG-3' (SEQ 234 bp ID NO: 328) Hu mb-actin 5*-AGC ACT GTG TTG GCG TAC AG-3' (SEQ antisense ID NO: 329) LIV21 (A1) 5*-TCCTATGCTTTGACTATTAG-3' (SEQ ID NO: 330) LIV21 (A2) 5'-CCTGACATCCCTACATCACCGCA-3* (SEQ ID NO: 331) odT ATG galgal 5*-ATGTATATTATATCTAA-3' (SEQ ID NO: 332) Splicing sense 5'-TGTTGGGATTGCTTATATTT-3' (SEQ ID histatin NO: 333) Splicing reverse 5;- AAATATAAGCAATCCC A AC A-3' (SEQ ID histatin NO: 334) GDBR1 reverse 5'-CTTTATTATTTTGTAAAAT-3 * (SEQ ID NO: 335) Forward Reverse 25 M Mg 10 mM primer primer 10X (1.5 mM final dNTP 10 uM 10 uM Taq (ul) cDNA H.sub.2O buffer concentration) (MI) (MI) (MI) 5 U/ul (MO 18.3 2.5 1.5 0.5 0.5 0.5 0.2 1

[0255] Other oligonucleotides (Ie patent in listing of Trail. PCR

[0256] Cycles Denaturation: 94.degree. C. 2 minutes Denaturation: 94.degree. C. 3 0 seconds 5 Annealing: 52-55.degree. C. 1 minute 35 cycles Elongation: 72.degree. C. 1 minute 3 0 Final elongation: 72.degree. C. 7 minutes Conservation:4.degree. C.

[0257] III Controls

[0258] The PCR Products were Subsequently Controlled on Agarose Gels and Analysed with the Biocapt 11.01 Software from Vilber Lourmat

[0259] Gel 1 (ie FIG. 7): control of RNA on agarose gel 15 FIG. 8: RNA pool

[0260] FIG. 9: PCR with housekeeping genes and analysis of molecular masses.

[0261] FIG. 10: PCR with the primers showing a band of 1400

[0262] bp. 20 FIG. 11: Gel 2 with analysis of molecular masses

[0263] FIG. 12 : Gel 3 at 55.degree. and analysis of molecular masses

[0264] FIG. 13: Gel 4 at 45.degree. and at 55.degree. and analysis of molecular masses. 25 FIG. 14: screening ligation of 400 pb band, clones B1 to B10.

[0265] FIG. 1.5: screening ligation of 1400 pb band, clones CI to C10.

[0266] FIG. 16: Gel 5: ligation screening on the five new clones.

[0267] FIG. 17: Gel 6: Screening of the S55T and S55M recombinant clones and analysis of molecular masses (i.e. ptenting listing for oligonucleotidic sequences).

[0268] Gel2: PCRs carried out using templates from PCRs performed with the primers Al+oligo dT on the RTs carried out at 45.degree. C. on the total RNA and the poly A+RNA (messenger RNA). The primers used for these PCRs are Al+GDBR1 or Al+Splicing reverse.

[0269] On the RTs carried out using the total RNA, a band of 1178 1253 bp is amplified with, the primers Al+GDBR1 and Al+Splicing reverse. The poly A RNA was used to early out the RT and is weakly observed at the size (FIG. 10) of 1400 bp for amplification with the primers Al+G, and of 415 bp with the primers Al+Splicing reverse. In the Al+splicing PCR product, there are other hands, of 860 and 233 bp (FIG. 11).

[0270] Gel 3: PCRs carried out using templates from PCRs performed with be primers Al+oligo dT on the RTs carried out at 45.degree. C. on the total RNA and the poly A+RNA (messenger RNA). The primers used for these PCRs are Al+GDBR1 or 25 Al+Splicing reverse (FIG. 12). For the PCRs carried out on RTs performed at 55.degree. C., the same overall pattern of bands as that obtained on the RTs performed at 45.degree. C. is found.

[0271] No specific amplification is observed when the poly A RNA was used to carry out the RT. On the RTs carried out on the total RNA, a major band of 1554 1609 bp is found with the primers Al+GDBR1 and Al+Splicing reverse. A band at the theoretical size of 1455 bp is expected for an amplification with the primers Al+GDBR1 and a band with the theoretical size of 415 bp is expected with the primers Al+Splicing reverse. In the 2 profiles, very clear bands of 1900-2100 bp and of 1000-1300 bp are found, but with a weaker intensity than that of the band of 1500-1600 bp.

[0272] In the Al+splicing reverse PCR product, there is another major band, of 263 bp.

[0273] Gel14: Nested PCRs carried out using templates from PCRs 10 performed with the primers Al+GDBR1 or Al+Splicing reverse on the RTs carried out at 45.degree. C. on the total RNA and the poly A+RNA (messenger RNA). The primers used for these PCRs are ATG+GDBR1 or ATG+Splicing reverse (FIG. 13).

[0274] The nested PCRs carried out with the primers ATG+GDBR1 give bands at 1213 by (RT 45.degree. C.) and 1559+1315 bp (RT at 55.degree. C.); the expected theoretical size is 1455 bp. The PCRs carried with the primers ATG+Splice reverse give more varied band profiles. These PCRs carried out on other PCRs performed with the primers Al+GDBR1 or Al+Splicing reverse. The presence of a hand of 400 bp is noted in the profiles obtained from messenger RNA (the band obtained from the reverse transcription carried out at 55.degree. C. is of greater intensity).

[0275] The profiles of the ATG+Splice reverse PCRs carried with total RNA at the start give a band of 424 437 bp of very strong intensity. Bands of 614 and 783 bp of very strong intensity are also found in the profile of the RT 45 and a greater number of bands, but of weaker intensity, is found in the profile of the RT 55, bands at 1118, 936 and 749 bp.

[0276] The products of these various PCRs were cloned and sequenced.

Example 5

[0277] The PCR products of lanes 2, 4, 6, 7 and 8 were ligated with the plasmid pGEMT Easy, Promega, and the recombinant clones were screened (FIG. 16).

TABLE-US-00014 Lane 2: G45T ligations Lane 4: S45T ligations Lane 6: G55T ligations Lane 7: S55M ligations Lane 8: S55T ligations

[0278] The recombinant clones obtained were screened (after extraction of the plasmid DNA) by restriction with the Eco RI enzyme, the sites of which border the site of insertion of the PCR products into the pGEMT Easy vector.

[0279] Screening of the Recombinant Clones:

[0280] The first experiments had been carried out using the ten clones B and the ten clones C, FIGS. 14 and 15, and the results of the sequences of clones B2 and C8 are given in the following example, and exhibit, by sequence comparison between clones, great homology with the clones of the second series of experiments.

[0281] Gel 5: screening of the S45T and G45T recombinant clones

[0282] Analysis of Molecular Masses

[0283] The screening of the clones with Eco RI shows that, out of the 9 S45T clones, 3 have inserts of 100 bp, 216 bp and 410 bp. On the G45T clones, out of the 6 clones tested, 3 have inserts of 57, 71 and 148 bp.

[0284] FIG. 17: screening of the S55T and S55M recombinant clones

[0285] Analysis of molecular masses

[0286] The screening with Eco RI shows that, out of the 13 clones screened, 7 have inserts of sizes between 239 and 637 bp. The clones G45T5 (148 bp), S45T9 (410 bp), S45T3 (100 bp), S55M1 (491 bp), S55T6 (251 bp) and S55T9 (637 bp) were extracted so as to be sequenced. Primers used for determining the sequences of the 15 various clones and are described in the patent listing:

TABLE-US-00015 (SEQ ID NO: 119) ATG galgal 5'atgtatattatatatctan 3' (SEQ ID NO: 120) INV COMP ttagatatataatatacat (SEQ ID NO: 336) Splicing reverse 5' AAATATAAGCAATCCCAACA 3' (SEQ ID NO: 337) Splicing reverse 5' TGTTGGGATTGCTTATATTt 3' (SEQ ID NO: 338) inv comp GDBR1 reverse 5' CTTTATTATTTTGTAAAAT 3' (SEQ ID NO: 339) GDBR1 reverse 5' ATTTACAAAATAATAAAG 3' inverse complement

Cloned fragments

[0287] The test of the bio-markers on extracts of neuroblastomas and cell cultures SHSY reveals by RT PCR the play of under expression and of on expression following in this example of analysis: Example of 16 biomarkers of interest analyzed by RT PCR which recuts the results obtained by biochip on sensor-chip making it possible to see by SPR the over expression and the under-expression of certain genes of the Liv21 complex and its partners of interaction for example. An under expression of DKK1, SKP2, DKK3, ID2, p21, SKP2, TP53INP1, ID2, P73 is observed whereas an over expression of MYCN, ALK, NLRR1 (the neuronal leucine rich repeat is transactivated), CRABPII, DDX1, LIV21K, AURORA kinase A is observed.

Example 6

[0288] From the cloning of the LIV21 gene described above, the new sequences are studied in order to design the most specific and effective siRNAs (ie. listing of siRNAs and FIG. 19) for creating "silencing" of the gene, i.e. inhibiting its expression. In the knowledge that the effect of the inhibition at each injection of siRNA remains short, i.e. most commonly less than one hour, the inventor has developed diagnostic products and therapeutic products from this same tool, namely the siRNA.

Example 6.1

[0289] The inventor uses siRNAs labeled with rhodamine or fluorescein or any other label that can be revealed and followed by optical observation with a microscope in order to localize the site, in the cells, tissues or sample labeled, that the labeled siRNA will go to in order to attach to the specific sequence which characterizes it, and thus to indicate the site of the expression of the messenger RNA of the gene of interest. Thus, the specific siRNA can be used as a diagnostic marker as an antibody would be, and can make it possible to localize, in a specific case such as on extemporaneous samples or any other type of sample taken from a patient, for example a cancerous tissue sample, the fluorescence or any other labeling used on the siRNA and found in a cell compartment on the sample.

[0290] Thus, a labelled siRNA of LIV21 (FIG. 19) that is found, under a microscope, in the cell nuclei at the periphery of a surgical exeresis, would indicate a diagnosis of complete exeresis of the cancerous tissue; on the other hand, this same marker found in the cytoplasm or the membranes of this same sample would mean that the surgeon would have to perform an enlarged exeresis, immediately if this test can be carried out directly in the operating theatre, which would be the best situation for removing all the cancer cells visible only on this molecular and cellular scale by virtue is the siRNA marker. This could be a more rapid implementation alternative than the other application that the inventor has developed with the antibody or the LIV21 peptide, which can be used in the same manner.

Example 6.2

[0291] For the treatment products which rise directly from the observations made thanks to the results of expression of the biomarkers on the biochips, the interest is well illustrated for the example of the TGF Beta and p27:

[0292] The publication of Mr. Lecanda J and Gold Li of March 2009 is very well rich of teaching and famous all the interest of the pharmaco diagnostic biochips as described above.

[0293] TGF Beta inhibits cell proliferation by increasing the level of p27 via the activation of the factors of transcription smad 2/3.

[0294] TGF Beta thus increases the total level of translocation of p27 in the core accumulates p27 in the cellular core through the activation of smad 2 and smad 3.

[0295] All these events are locked by an inhibiter of TGF Beta IH: serine kinase SD208: new centers therapeutic targeted for the carriers.

[0296] TGF Beta decreases the level of the components skp2 compared to protein but not the level of mRNA.

[0297] TGF Beta thus can mediate the degradation of p27 in the proteasome at the proteinic level because it maintains it in the core but on the other hand the inhibition of the transcription of p27 with a specific siRNA locks TGF beta.

[0298] TGFBeta prevents degradation proteasomale kinase cycles dependant inhibiter on p27. (Alvarez Rodriguez R Pon S J that sci 2009 March 1-122).

[0299] The gene expression proneural coding for Mash 1 abolishes MYCN (mitotic activity). (2009 Liu W Wuz Guan M, Lu Y).

[0300] The inventor uses first labelled siRNAs of the Liv21 complex in order to evidence their expected presence in the cellular compartment and to visualize them. Then the inventor will use non-labelled Liv21 siRNAs solely for their therapeutic role. In a specific case, the injection of siRNA (FIG. 19) directly in a neurodegenerating tissue or any other mean of administration allowing to the siRNA to get to the neurodegenerating tissue (for example the ear, the eye, cephaloraehidian liquid, etc.) and to act allowing proliferation until apoptosis and therefore the death of the neurodegenerating cell.

[0301] An experiment on human cell cultures then on animal models having a retinopathy generating a vitreo-retinal degeneration (direct injection of the siRNA in the eye) makes it possible to illustrate this method.

[0302] The siRNA are also transfected in the cells according to the Invitrogen protocol using the lipofectamine 2000.

[0303] The study of the specific role of the PKC epsilon on the nuclear translocation of Liv 21F can use a peptide which inhibits function PKC epsilon and the translocation like previously described but also according to the protocol of reference of Si RNA of PKC epsilon. The profile of expression observed corresponds to a doublet of tapes in the cytoplasm with approximately 51 KD (and with a tape of 64 kD according to the siRNA used) whereas it corresponds only to one simple tape with 50 kD in the nuclear fraction.

[0304] The molecules of siRNA resulting from the nucleotidic sequences of the Liv21 complex can be selected in the group made up of the molecules of siRNA understanding any of sequences SEQ ID N.degree. 119 to 126 and 171 to 175, and SEQ ID N.degree.--the use of a multitherapy based on the combination of several of these siRNA for the processing of cancerous or neurodegenerative pathology. These siRNA and the useful combination deduced from the results from on expression and from under expression of the biochips and RT PCR constitute an auxiliary processing of pathology and can be combined with small doses of chemical molecules having already proven reliable in the processing of pathology.

Example 6.3

[0305] The present invention, relates to methods and reagents useful in modulating gene expression associated with Alzheimer disease in a variety of applications, including use in validating therapeutic, diagnostic, target, and applications genomic discovery.

[0306] The invention concerns compounds, compositions and methods for the study, diagnosis and treatment of diseases that respond to the modulation of beta secretase (BACE) amyloid, expression and/or activity of protein gene the precursor APP, of pin 1 of presenillin 1 (PS-1) and/or of presenillin 2 (PS-2) in association with modulation of gene and protein complex Liv21. The invention concerns compounds, compositions and methods for the study, diagnosis and treatment of diseases that respond to the modulation of the expression and/or activity of genes involved in complex liv21 and in combination with the genes of the betasecretase (BACE), amyloid protein of precursor APP, pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2).

[0307] Specifically, the invention relates to small nucleic acid molecules, such as short nucleic acid interferent (siRNA), bicatener RNA (dsRNA), micro RNA (miRNA), short double spin RNA (shRNA) be able to interfere with RNA of mediation (RNAi) against beta secretase (BACE) mediation, gene expression of the protein precursor APP, of pin-1, of presenillin (PS-1) and/ presenillin 2 (PS-2).

[0308] Vectors to produce siRNAs are described.

[0309] Vectors are also commercially available. For example, the psilencer is available in Gene Therapy System, Inc. and the RNAi system of pSUPER is available in Oligoengine. They deliver compositions of siRNA with coding RNA part.

[0310] Xia et all 2002 Zeng et all 2002 Thijn et all 2002 Lee et all Biotechnology 19 Nature Mc Manus et all.

[0311] Sui et all PNAS 2002, Yu et all 2002 PNAS 99. Shi et all 2003.

[0312] The pharmaceutical compositions comprise a pharmaceutically acceptable carrier.

[0313] The compositions are also provided with a device for administering the composition in a cell or in a subject or a tumor. For example, a composition may be in a syringe or to a stent.

Example 7

Pharmaco-Diagnostic Test

[0314] Based on the observations that follow in annex at the end of the description of the example concerning the properties of the Liv21 complex, the inventor conceived a design for a pharmacodiagnostic test clinically applicable by known technologically means, which can differ according to users and correspond for each mean to a new product. The invention consists in the fabrication of diagnostic DNA, protein and antibody arrays, including the antibodies already known for the different proteins of the complex associated with Liv21 according to the phase of the cell cycle, that is the antibodies, peptides or nucleotide sequences of the following genes: RBP2, E2F4, E2F1, SUMO, INT2, CRB2, HDAC1, TGFbeta, integrin_alpha5 beta2, Myob, MyoD, cycE/cdk2, cdkl, chkl, chk2, TNFalpha, CREB1 and p300, Rb, pl07, pl30 from the pocket protein family. But also NFkB, cdc2A, mdm2, p21, p53, p65, p73 RAS, Ki67, CAF1. The protein arrays (FIG. 20) will allow the study of over or under expression of the gene products, the protein interactions and the post-translational modifications, more particularly phosphorylations and methylations of certain proteins, which indicate a specific state of the unhealthy cell that is different form the protein interactions and the metabolism of an healthy cell. The expression and silencing state of certain genes is different.

[0315] Example 7.1: pharmacodiagnostic biochip (FIG. 20) conceived based on nucleotide or peptide sequences fixed on classical supports and according to known techniques such as Agilent or Affymetrix or Caliper without restriction thereof and corresponding to known sequences of following genes and proteins listed in the patent, preferably using sequences that, by 3D analysis, show preferably a loop or helix-loop-helix or basic loop or zinc finger 3D structure or a 3D conformation similar to an helix corresponding in most cases to functional sites, or nucleotide sequences corresponding to a region of cystein methylation, methylation of the promoter region of the gene inducing a potential silencing (see general bibliography), as well as new sequences of Liv21F et Liv21K listed in the description and in annex, but also sequences common to certain genes and certain virus thought to be implicated in particular in breast cancer of Chinese population;

[0316] Mdm2 and HIV1:

[0317] GAVTSSNIAA; DLDQSV; EGF and HPV16; EWWRLD; KNSLD; MHIESLDS; BCAS3; BCAS4

[0318] These sequences may be tested by microfluidic techniques upon fixation on a gold coverslip in order to study the protein interactions with the cell extracts of the patient.

[0319] But which can also be studied by a MICAM technique implemented of the biochips which (cavities) bio-markers by piezo electric effect and not by physicochemical fixation.

[0320] Example 7.2: microfluidic test, for example type Biacore, using the SPR (plasmonic surface resonance) technique known by those skilled in the art based on a support fixed with a gold film, which allows, once the light beam has been sent to the interface, to obtain an adsorbed energy as a function of the presence and the size of protein complexes (in the case of protein protein or protein antibody interactions) or of protein DNA complexes (in the case of protein DNA interactions) or RNA, or protein or peptide and an evanescent wave perpendicular to the interface axis (use of a prism). The inventor fixes the selected peptide or DNA sequences on gold particles and calculates the rU number as a function of the size of molecules cited in this patent for each interaction complex studied. In microfluidic, the liquid flowing over these gold film arrays may be a cell extract (or a selective one, meaning that it is only made of cell nuclei, or solely cell cytoplasms or solely cytoskeletal proteins etc.) according to extraction, separation and fractionation techniques such as Calbiochem: subcellular proteome extraction or tissue or cell extracts without any other preparation than anti-proteases or cephalorachidian liquid or serum issued from a patient sample in order to study the circling marker (i.e. described nucleotide or peptide sequence list and/or known sequences of genes involved in the proliferation cycle listed).

[0321] EXAMPLE 8: biochip of sequences SEQ ID N.degree. 119 to 127 and 180 with compounds with the sequences of microRNA of interest in studied cancer: mir 21, mir 34a, etc . . . without the biochip being limited to these. The technique of fixing of RNUMS on the supports defers according to the form of mediums, of revelation and biochip used. For example one uses the sequences RNUMS quoted in solution biothynilees then fixed on sensor-chips at the streptavidine, if one tests their interactions with the cellular or plasmatic extracts or of the rachidian fluid cephalo passing in the channels (fluidic microcomputer) of a A100 or T100. It can also be used as described in the US patent 2008 045418 A1 RNAs locked in end 3' and added a ligase T4 RNA and a "labeled nucleic acid adapter" having a residue 5' phosphates.

[0322] EXAMPLE 9: Study of the expression of LIV21 in breast cancer and Colon cancer biopsies In order to determine whether the observations obtained above are applicable to human tissues, a large number of cancer biopsies obtained from patients were studied by immunohistochemical reaction with LIV21 specific antibodies. The immunohistochemical determination of LIV21 protein expression was carried out on several biopsies from patients. Moreover, some paraffin slides from patients suffering from bladder cancer and from breast cancer were also studied. The improvement of the invention is due to the fact of standardizing the biopsies or the punctures by a technique of taking away standardized and gauged in order to then allow reliable comparisons between cellular extracts of patients and witnesses or between cytoplasmic and nuclear and membrane fractions. This same standardization implemented to the taking away making it possible to compare the results of overexpression or of under expressions of the bio-markers by RTPCR is essential to obtain reliable and comparable results.

[0323] Immunocytochemical Analysis Protocol:

[0324] 1) Deparaffinize the slides, Rehydrate the tissues.

[0325] 2) Saturate the nonspecific sites and permeabilize the membranes.

[0326] 3) Add the antibody in a humid chamber, Reveal the antibody.

[0327] Deparaffinize the slides under a hood.

[0328] Two successive baths of toluene (rectapur Prolabo) 2.times.30' min or 2.times.20 min; then dehydrate the tissues with rectapur alcohol at 100% for 15 min; then rectapur ethanol at 95% for 10 min; then rectapur 70% for a further 10 min.

[0329] Thaw the antibody at the same time. Rehydrate the tissues gently in PBS supplemented with 10% fetal calf serum and 0.1% Triton.

[0330] Saturate the nonspecific sites (for example, with ovalbumin) and permeabilize the membranes, Rehydrate for one hour.

[0331] Deposit one ml of this "PBS" per section order to cover the slide without it drying out at any moment (when it is a slide with cells and not tissues, half an hour is sufficient).

[0332] Place the pane and the stainless steel cover and water below so as to create a humid chamber. Add the antibody in the humid chamber.

[0333] Dilute the rabbit serum to 1/200 in 4 ml of PBS triton, so as to continue to permeabilize the membranes and HCS.

[0334] Place 1 ml on each slide and keep away from the light and avoid evaporation. Leave overnight or for a minimum of three hours.

[0335] Then rinse with 1.times. normal PBS pH 7, carry out two washes of 5 to 10 min so that no trace of the first antibody remains.

[0336] While preparing the Alexa 488 green probe (in the cold at 4.degree. and in the dark) diluted to 1/250, therefore 10 .mu.liter in 2.5 ml of PBS, still with 10% FCS and 0.1% Triton.

[0337] Rest the slides on the plate. Cover the section again with 2.5 ml in order to maintain a humid chamber for one hour, and then wash with 1.times. PBS pH 7.

[0338] Wash with propidium iodide at 0.5 microgram per microliter to be diluted to 20 microgram per ml and then again to 1/50, but this time, diluted in 1.times. PBS alone (50 microliters per-2.5 ml of PBS). Drain while taking them out of the PBS and then dispense 2.5 ml of propidium iodide over the four slides for one minute, followed by two rinses with simple PBS. Mount the slides in Moviol before reading.

[0339] For an immunolabelling with peroxidase it is mandatory to mask the antigenic sites by a 20 minutes water bath step in order to obtain meaningful results when one is working with paraffined covers lips.

[0340] All these results show that the cytoplasmic localization of LIV21 is an indicator of the aggressiveness and of the metastatic potential of the cancer. The detection of LIV21 expression indicates the presence of invasive, aggressive and metastatic cancer cells. These results also show that the nuclear localization of LIV21 is an indicator of normal quiescent cells, that is of well-differentiated tissues.

[0341] Annex: Study of the nuclear translocation of LIV21 in MCF-7 and SHSY5Y cells

[0342] The study of the subcellular distribution of LIV21 in different tumor lines of various origins showed an plasmonic surface resonance exclusively cytoplasmic localization of this protein. The presence of putative phosphorylation sites by protein kinases C (PKCs) in the Liv21 sequence directed the study toward an involvement of these proteins with respect to its nuclear translocation. The MCF-7 line treated with TPA modulates PKCs and is used in the present study.

[0343] The effect of TPA on the MCF-7 line

[0344] TPA is a known activator of PKCs. It activates the growth of normal breast cells, does not modify the proliferation of the cells of benign tumors from this same tissue, but drastically inhibits the proliferation of the cells of human mammary tumor lines such as the MCF-7 line. It reduces the cell growth of this line by positively controlling the c-erb-2 receptor and negatively controlling the retinoic acid receptor a, which are both expressed in particularly large amount in these cells. The TPA greatly and rapidly inhibits the expression and the function of estrogen receptors (ERs) and it induces the time- and dose-dependent translocation of protein kinases C (PKCs) from the cytosol to the membranes. Furthermore, TPA increases the migratory capacity of MCF-7 cells in vitro and a short period of treatment of these cells with TPA induces cellular expansion and microtubule organization characteristic of their differentiation.

[0345] Expression of LIV21 in MCF-7 Cells and in the SHSY5Y Cells

[0346] Firstly, the inventor verified the expression of LIV21 in these cells at the transcriptional level and at the protein level.

[0347] The expression of the LIV21 mRNA was demonstrated by RT-PCR sense primer: (CCTGACATCCCTACATCACCCAT SEQ ID NO: 340) (SEQ ID No 3, SEQ ID No 217 and SEQ ID No 127 to 171) and antisense primer; (TCCTATGCTTGACTATTGC SEQ ID NO: 341) (SEQ ID No 4) in these cells compared with the cells from breast tissues (FIG. 2A). An mRNA of the same size as the mRNA detected in the breast tissues and specific for LIV21 was detected. However, the level of expression of LIV21 in the MCF 7 cells is lower than in the breast tissues. This first result shows that the MCF 7 line expresses the LIV21 mRNA.

[0348] The inventor tackled the study of the expression of the LIV21 protein through the Western blotting technique, with an anti-LIV21 antibody, in MCF-7 cells compared with mammary tissues. The anti-LIV21 antibodies were obtained by the method described below. In this line, LIV21 is expressed, both in the mammary tissues and in the MCF-7 cells, in the form of a doublet which migrates at an apparent molecular weight of 51 kDa.

[0349] Production of Purified Anti-LIV21 Serum

[0350] The specific peptide sequences are the sequences No. 1 and No. 2 and No. 180.

[0351] These peptides were injected into rabbits (NZ W ESD 75 female, 2.3 kg at day 0), in agreement with standard immunization procedures,

[0352] The effect of the inhibitors on the cells of neuroblastomas

[0353] Study of the influence of PKCs on the nuclear translocation of LIV21

[0354] Effect of TPA on PKC.epsilon. Expression

[0355] Western blotting study: Given that the protein sequence of LIV21 has putative PKC.epsilon. phosphorylation sites, including two specific for PKC.epsilon., the inventor tested the variation in the expression of this PKC as a function of the duration of TPA treatment. It was observed that TPA acts very rapidly on PKC.epsilon. expression, which decreases from 30 min. The expression of PKCzeta (PKC.zeta.) is used as an internal control since it is not sensitive to TPA.

[0356] P65L26 IMMUNOCYTO . . . P66L4 NUCLEAIRE DE LIV21

[0357] Study of the specific role of PKC.epsilon. on the nuclear translocation of LIV21 using an inhibiting peptide of the function and translocation of PKC.epsilon..

[0358] To determine the specific action of PKC.epsilon. on the translocation of LIV21, the crops were discussed with a peptide, selective antagonist of the function and translocation of this PKC (EAVSLKPT (SEQ ID No 6), and the results were compared with those obtained by processing with TP A. This peptide is recognized by the enzyme and links themselves as a substrate amended to the level of its catalytic site. Not phosphorylable, he acts as a specific inhibiter of the activity of PKC.epsilon..

[0359] The effect of the selective inhibition of the activity of PKC.epsilon. on the nuclear translocation of LIV21 was studied by immunocytochemistry. These experiments were carried out on nontreated cultures or cultures treated for 12 h with TPA at 25 nM or with the peptide at two different concentrations, 1 and 2 .mu.M (the peptide used at the concentration of 2 .mu.M has an effect identical to that of TPA on the nuclear translocation of LIV21).

[0360] These results were supported by cell fractionation experiments on cultures treated with the PKC inhibiting peptide at 2 .mu.M, compared with TPA-treated cultures. The same LIV21 expression profile was observed in the form of a doublet in the cytoplasm and of a single band in the nuclear fraction.

[0361] The specific inhibition of PKC.epsilon. induces a nuclear translocation of LIV21, which suggests that LIV21 could be the target of PKC.epsilon., which would maintain it in the cytoplasm in a phosphorylated form.

[0362] Example: Western Blotting Analysis

[0363] This example describes the conditions used for a Western blotting analysis of cancerous brain cells.

[0364] The protein extracts are heated at 80.degree. C. for 5 minutes in a Laemmli buffer (pH 7.4, 0.06 M Tris, 3% SDS, 10% 3 5 glycerol, 1 mM PMSF, .beta.-mercaptoethanol). The migration is carried out by SDS-PAGE (sodium dodecyl sulfates-polyacrylamide gel electrophoresis). 10 to 20 .mu.g of proteins migrate in a 12% polyacrylamide gel for 1 h under denaturing conditions (migration buffer: 25 mM Tris base, 192 mM glycine, 1% SDS, pH 8.3). The proteins are then transferred onto a nitrocellulose membrane (Schleicher & Schnell) for one hour by liquid 5 transfer, in a transfer membrane (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3). The membranes, saturated in PBS-0.1% Tween-0.1% Triton XIOO-5% skimmed milk for one hour, are brought into contact with the primary antibody diluted in PBS-0.1% Tween-0.1% Triton X100-1% milk at ambient temperature with gentle agitation for one hour to two hours. After washing, the peroxidase-coupled secondary antibody is incubated with the membranes for 1 h. Revelation is carried out by means of a chemiluminescence reaction using the ECL kit according to the supplier's protocol (Amersham).

[0365] The primary antibodies used are:

[0366] The anti-LIV21 serum which was produced using two synthetic peptides based on the sequence of LIV21F: peptide LIV21a (SEQ ID No 1) and peptide LIV21b (SEQ ID No 2) and/or peptide Liv21e (SEQ ID No 51). The peptides were coupled to hemocyanin before being injected into rabbits for the immunization. The polyclonal antibody was obtained from these two peptides by having immunized two rabbits and having bled one rabbit so as to have a preimmune serum (in order to be sure that this antibody did not already exist in this rabbit).

[0367] The rabbit anti-CDK2 polyclonal antibody (Santa-Cruz technology sc-163) diluted to 1/200.

[0368] The mouse anti-p21 monoclonal antibody (Dako, M72 02) diluted to 1/150.

[0369] The mouse anti-p27 monoclonal antibody (Santa-Cruz technology sc-1641) diluted to 1/100. It was shown before that protein LIV21 is associated with bodies PML and that, at the time of the sumoylation, LIV21 passes from a molecular weight of 50 kd to 60 kd. By immuno-precipitation, the inventor showed a Co-localization of LIV21 with SUMO in complex PML--SUMO/LIV21. (FIG. 12)

[0370] Antitumor role of PML bodies: At the proliferation stage, there are visualized modifications in the PML bodies since these PML bodies dissociate and degrade: (speckles), proteins then become available in the nucleus for ensuring transcription, proliferation, immune reactions and everything that is required for gene transcription. It has been shown that PML associates with SUMO and with HDAC-1 (histone deacetylase 1) and that its complex acts on the expression of E2F1 and PML thus acts on the arrest of proliferation by blocking E2F1. Thus, the PML/HDAC-1 complex down-regulates E2F1 expression. PML associated with Rh (pl30) binds to the deacetylated histones and blocks E2F1 by binding to the chromatin.

[0371] In acute promyelocytic leukemias, PML is truncated and becomes a fusion protein with the retinoic acid receptor. This fusion protein (PMLRARalpha) is due to a 15/17 chromosomal translocation. A new treatment for this disease by combining arsenic and retinoic acid in order to induce cancer cells into apoptosis has been reported in the literature. The PML protein is thought to regulate proliferation in cancers and lymphomas. The inventor has shown, by immunoprecipitation, the association SUMO-PML in which LW21 is located.

[0372] In the above patents, it was shown that LIV21 is phosphorylated by PKC. The TPA-treated MCF-7 lines show an inhibition of cancerous proliferation and a cell differentiation, and LIV21 is translocated into the nucleus. If a PKC-specific inhibitory peptide was used, it was the activity and not the expression of PKC which was inhibited.

[0373] During this TPA treatment (25 nM), when E2F4, pl30 and LIV21 were studied (green fluorescence) in the nuclei labelled (DNA) with propidium iodide (red fluorescence), the fallowing were observed:

[0374] After 12 h, intranuclear green fluorescence signals with the same pattern for E2F4, pl30 and LIV21;

[0375] After 48 h, when the proliferation begins, E2F4 has a comparable localization; but at 72 h, it disappears from the nucleus (to the benefit of E2F1).

[0376] By observing, by double labeling, the co-localization of PML and of LIV21 at 24 h of PKC treatment (i.e. merge: yellow fluorescence), it was observed that they are co-localized in the nuclei. At 48 h, the co-localization between LIV21 and SUMO (i.e.). The hypothesis is that SUMO, which binds to LIV21, in fact targets LIV21 into the PML bodies and that LIV21 is involved in the PML/SUMO/Rb/HDAC-1 complexes. LIV21 is physically associated with PML and SUMO in the nuclear bodies, by immunoprecipitation and by colocalization by immuno cytochemistry (Rb, pl30 and pl07 are pocket proteins which have the same binding site). The Rb proteins repress cell growth (Fabbro, Regazzi R, Bioch Biophys Res Comm 1986 Feb. 2; 135 (1.): 65-73).

[0377] Physical interaction of LIV21 with the proteins of the E2F family

[0378] Coimmunoprecipitation experiments carried out using anti-LIV21, anti-E2F1 and anti-E2F4 antibodies made it possible to demonstrate that LIV21 associates with E2F4.

[0379] It was shown that BRCA1 also re-entered in nteraction with family members E2F and thus complex LIV21. Indeed, E2F1 interacts with BRCA1 and Brca1 interacts with MYC, ESR1, CHEK1 and MAP3K3.

[0380] The members of the E2F family are transcription factors whose role has been widely described in the literature as being key molecules in the positive or negative control of the cell cycle (Slansky J E and Farnham P J 1996; Helin K 1998 and Yamasaki L, 1998), by virtue of their association with the pRb protein (WuCL, Zukerberg L R) or pocket proteins. E2F1 positively controls the cell cycle by transactivating 3 5 the promoter of the genes responsible for cell proliferation (DNA polymerase alpha, thymidine kinase, DHFR, etc.), whereas E2F4 is described as one of the members of the EF family which negatively controls the cycle. Furthermore, a high expression of E2F1 in embryonic mammary tissues has been shown (Espanel X, Gillet G 1998), whereas it is no longer expressed in post-mitotic mammary tissues, to the benefit of a large increase in E2F4 expression (Kastner A Brun G 1998).

[0381] The identification of antigens has been carried out in cell lysates by immunoprecipitation. The analysis of the physical interaction of various proteins associated with E2F4 and E2F1 was demonstrated by coimmuno-precipitation of protein complexes. The complex was studied using U. MACS PROTEIN with MICROBEADS (MILTENYIBIOTEC). When lysates of S aureus are added, the proteins A interact with the Fc portion of the specific antibodies and the immunocomplexes become insoluble and are therefore recovered by centrifugation. After breaking of the bonds (heating) between AG/AC and protein A-rich membranes. Western blotting was carried out. These results suggest that the LIV21/E2F4 complex appears to play an important Role in establishing cell quiescence. A study of co immunoprecipitation is following also with the profound mammalian kit Pierce.

[0382] Functional interaction of LIV2i with the proteins of the E2F family

[0383] It was demonstrated that blocking the expression of the LIV21 protein was correlated with a decrease in the expression of E2F4 and with an increase in the expression of E2F1. In parallel, the functional aspect of the increase in E2F1 was verified by studying the transcription of two of its target genes, DHFR and DNA polymerase a.

[0384] In conclusion, these results suggest that the LIV21/E2F4 complex acts as a complex which inhibits the expression of the E2F1 gene. This complex could 3 5 correspond to a new point of control in the arrest of cell proliferation.

REFERENCES

[0385] Arya R, Kedar V, Hwang J R, McDonough H, Li H H, Taylor J, Patterson C. Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy. J Cell Biol. 2004 Dec. 20; 167(6): 1147-59. Epub 2004 December

[0386] Aurelian Radu, Nicolae Ghinea (2010)

[0387] Expression of FSH receptor in tuymor blood vessels N England J Med (363:1621-16802010)

[0388] Stevaux O, Dyson N J. A revised picture of the E2F transcriptional network and RB function. (2002) Curr Opin Cell Biol, 14 (6): 684-91.

[0389] Yamasaki L, Growth regulation by the E2F and DP transcription factor families. (1998) Results Probl Cell Differ, 22 :199-227.

Sequence CWU 1

1

377113PRTHomo Sapiens 1Pro Ala Ser Ala Gly Ile Thr Gly Val Ser Cys Ala Arg1 5 10228PRTHomo Sapiens 2Gly Phe Thr Val Leu Ala Arg Met Val Ser Ile Ser Pro Arg Asp Pro1 5 10 15Pro Ala Ser Ala Ser Gln Ser Val Gly Ile Ala Tyr 20 25313PRTHomo Sapiens 3Phe Tyr Cys Arg Ser Leu Gln Ser Ser Trp Asp Tyr Arg1 5 10424PRTHomo Sapiens 4Ser Val Thr Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Arg Leu1 5 10 15Gln Pro Leu Pro Pro Gly Phe Lys 20536PRTHomo Sapiens 5Ser Val Thr Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln1 5 10 15Pro Leu Pro Pro Gly Phe Lys Phe Ser Cys Arg Ser Leu Gln Ser Ser 20 25 30Trp Asp Tyr Arg 35619PRTHomo Sapiens 6Ser Ile Ser Pro His Asp Leu Pro Ala Ser Ala Ser Gln Ser Ala Gly1 5 10 15Ile Thr Gly746PRTArtificial SequenceTraduction of clone C8T7 come from microorganism ref CNCM I-3940misc_featureSynthetic 7Asp Phe Leu Cys Leu Thr Ile Ser Ser Phe Ser Leu Pro Ile Ile Ile1 5 10 15Ile Tyr Phe Ser Asp Gly Val Ser His Cys Arg Gln Ala Gly Val Gly 20 25 30Gln Trp Arg Asn Leu Gly Ser Pro Pro Pro Thr Gly Phe Lys 35 40 45846PRTArtificial SequenceTraduction of clone S45T9 come from microorganism ref CNCM I-3941misc_featureSynthetic 8Met Glu Ser Arg Ser Val Ala Gln Ala Gly Val Gln Trp His Asn Leu1 5 10 15Gly Ser Ala Leu Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu 20 25 30Gln Ser Ser Trp Asp Tyr Arg His Ala Pro Pro Arg Pro Ala 35 40 45915PRTHomo sapiens 9Pro Pro Arg Pro Ala Thr Phe Leu Tyr Phe Pro Arg Gln Gly Phe1 5 10 151015PRTHomo sapiens 10Arg Arg Phe Leu Tyr Ser Ser Asn Leu Phe Pro Ser Asn Gly Thr1 5 10 15119PRTHomo sapiens 11Arg Tyr Val Pro Ser Ser Asn Pro Leu1 5129PRTHomo sapiens 12Arg Tyr Val Pro Ser Ser Asn Leu Pro1 5139PRTHomo sapiens 13Arg Tyr Leu Val Thr Pro Val Asn Ala1 5148PRTHomo sapiens 14Arg Tyr Val Leu Ser Pro Val Lys1 5159PRTHomo sapiens 15Lys Pro Ser His Pro Lys Pro Ser Lys1 5166PRTHomo sapiens 16Thr Phe Lys Asn Leu Cys1 5178PRTHomo sapiens 17Lys Ala His Asn Leu Phe Lys Thr1 5189PRTHomo sapiens 18Arg Tyr Leu Pro Ala Asn Pro Arg Tyr1 51913PRTHomo sapiens 19Phe Tyr Cys Arg Ser Leu Gln Ser Ser Trp Asp Tyr Arg1 5 102013PRTHomo sapiens 20Lys Thr Leu Pro Ser Ser Ser Cys Leu Val Ala Tyr Lys1 5 102114PRTHomo sapiens 21Lys Val Ile Ile Val Ala Val Asp Trp Asp Leu Ser Lys Glu1 5 102216PRTHomo sapiens 22Lys Ile Phe Ser Pro Ala Thr Val Phe Phe Thr Ser Ile Glu Lys His1 5 10 152318PRTHomo sapiens 23Lys Asn Val Trp Ile Leu Thr Gly Phe Gln Gln Gly Gln Glu Phe Pro1 5 10 15Lys Phe2412PRTHomo sapiens 24Arg Phe Asn Leu Phe Ala Gly Gly Ser Asn Lys Ala1 5 102512PRTHomo sapiens 25Arg Ala Tyr Ser Leu Leu Gly Thr Ser Glu Arg Thr1 5 102612PRTHomo sapiens 26Ala Met Ala Ala Asn Asp Thr Gly Gly Phe Val Lys1 5 102711PRTHomo sapiens 27Ala Ser Glu Glu Gly Ile Met Val Val Glu Arg1 5 102818PRTHomo sapiens 28Phe Asp Val Val Val Ile Gly Ala Gly Pro Gly Gly Tyr Val Ala Ala1 5 10 15Ile Lys2919PRTHomo sapiens 29Arg Pro Val Thr Thr Asp Leu Leu Ala Ser Asp Ser Gly Val Thr Ile1 5 10 15Asp Glu Arg307PRTHomo sapiens 30Phe Tyr Cys Gly Trp Asp Arg1 5318PRTHomo sapiens 31Asp Val Ala Gln Glu Glu Gly Lys1 5328PRTHomo sapiens 32Ser Gly Ile Pro Ser Glu Leu Arg1 5337PRTHomo sapiens 33Glu Ala His Ile Gln Met Lys1 5347PRTHomo sapiens 34Glu Gly Ile Trp Ile Pro Lys1 5356PRTHomo sapiens 35Tyr Thr Phe Asp Ser Arg1 5366PRTHomo sapiens 36Leu Thr His Glu Ile Arg1 5375PRTHomo sapiens 37Leu Tyr Leu Asp Lys1 5385PRTHomo sapiens 38Tyr Gly Leu Gln Arg1 5395PRTHomo sapiens 39Asp Ser Ile Ile Arg1 54016PRTHomo sapiens 40Leu Glu Ala Ile Cys Ala Ala Met Ile Glu Ser Trp Gly Tyr Asp Lys1 5 10 154112PRTHomo sapiens 41Gly Asp Leu Trp Phe Met Ser His Gln Gly His Lys1 5 104211PRTHomo sapiens 42Tyr Ala Phe Asp Phe Tyr Glu Met Thr Ser Arg1 5 104314PRTHomo sapiens 43Glu Val Asn Ala Gly Thr Ser Gly Thr Phe Ser Val Pro Arg1 5 10449PRTHomo sapiens 44Asn Gln Asp Arg Pro Tyr Met Pro Arg1 5459PRTHomo sapiens 45Ile Val Ser Ile Leu Glu Trp Asp Arg1 54610PRTHomo sapiens 46Ala Pro Tyr Ile Ala Glu Thr Ala Leu Arg1 5 10479PRTHomo sapiens 47Asn Met His Asn Leu Leu Gly Val Lys1 5489PRTHomo sapiens 48Asn Leu Thr Asp Met Ser Leu Ala Arg1 5498PRTHomo sapiens 49His Thr Thr Glu Asp Val Asn Arg1 5507PRTHomo sapiens 50Lys Phe Phe Val Phe Ala Leu1 55115PRTHomo sapiens 51Phe Val Phe Ala Leu Ile Leu Ala Leu Met Leu Ser Met Cys Gly1 5 10 155212PRTHomo sapiens 52Thr Leu Gln Ile Phe Asn Ile Glu Met Lys Ser Lys1 5 105317PRTHomo sapiens 53Lys Asp Pro Glu Leu Trp Ala His Val Leu Glu Glu Thr Asn Thr Ser1 5 10 15Arg5412PRTHomo sapiens 54Lys Ser Trp Glu Val Tyr Gln Gly Val Cys Gln Lys1 5 105513PRTHomo sapiens 55His Thr Ser Leu Val Gly Cys Gln Val Ile His Tyr Arg1 5 105611PRTHomo sapiens 56Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser1 5 105715PRTHomo sapiens 57Ser Leu Gln Ser Ser Trp Asp Tyr Arg Arg His Pro Pro Pro Thr1 5 10 155821PRTHomo sapiens 58Phe Leu Tyr Phe Leu Arg Trp Glu Phe Thr Gly Pro Thr Ala Ser Ala1 5 10 15Gly Ser Pro Pro Arg 205914PRTHomo sapiens 59Gly Phe Thr Met Met Ala Arg Met Val Ser Ile Ser Pro His1 5 106049RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 60ggaggccauu cauauuuauu ucaauuccuc cgguaaguau aaauaagag 496149RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 61gagaggauug guccaauaau ucaauucucu ccuaaccagg uuauuagag 496249RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 62gcaggcggcc gcgaauucau ucaauucguc cgccggcgcu uaaguagag 496349RNAArtificial SequencesiRNA seq 173 63gguggcacac gcccguaauu ucaauuccac cgugugcggg cauuaagag 496449RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 64gaauggaggc cauucauauu ucaauucuua ccuccgguaa guauaagag 496549RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 65ggccauucau auuuauguau ucaauuccgg uaaguauaaa uacauagag 496649RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 66ggcaagacuc ugucucaaau ucaauuccgu ucugagacag aguuuagag 496749RNAArtificial SequencesiRNA seq 173misc_featureSynthetic 67guuaagcuga gaucugaauu ucaauucaau ucgacucuag acuuaagag 496820RNAArtificial Sequenceoligonucleotide first strain 5'-3'of siRNA sequence of SEQ ID NO 173misc_featureSynthetic 68gggaguagcc caagaaucau 206925RNAArtificial Sequencesecond strand antisens of double helix of siRNA stop by AAmisc_featureSynthetic 69gagaugauuc uugggcuacu cccuu 257025RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 70gagaauaugg gagagcuccc aacuu 257125RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 71gagauugaga cagagucuug cccuu 257225RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 72gagauucaga ucucagcuua accuu 257325RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 73gagaagugau ucuugggcua cucuu 257425RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 74gagaugaugu ggucuuggcu cacuu 257525RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 75gagaagaucu cagcuuaacc aucuu 257625RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 76gagaaucuca gcuuaaccau cacuu 257725RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 77gagauaguga auucgcggcc gccuu 257825RNAArtificial SequencesiRNA seq 173misc_featureantisense strand of siRNAmisc_featureSynthetic 78gagaucacua gugaauucgc ggcuu 257925RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 79gagaaccaua ugggagagcu cccuu 258025RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 80gagauuugcc auguuggcca ggcuu 258125RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 81gagaagaguc uugcccuguu accuu 258225RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 82gagaaguagc ugggauuacg ggcuu 258325RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 83gagauggucu ugaacuccug gccuu 258425RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 84gagaucagcu uaaccaucac uucuu 258525RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 85gagaugggau uacgggcgug ugcuu 258625RNAArtificial SequencesiRNA seq 173misc_featureSyntheticmisc_featureantisense strand of siRNA 86gagaaugcca aagguaaggu agcuu 258753DNAArtificial Sequenceprimers siRNA 1 sequence of seq 173misc_featureSynthetic 87tctcggaggc cattcatatt tatttcaaga gaataaatat gaatggcctc cct 538853DNAArtificial Sequenceprimers antisens 3' to 5' of siRNA1 of seq 173misc_featureSynthetic 88cctccggtaa gtataaataa agttctctta tttatactta ccggagggac gtc 5389788DNAArtificial Sequencereverse complement of C8 clonemisc_featureSyntheticmisc_feature(11)..(11)n is a, c, g, or tmisc_feature(16)..(16)n is a, c, g, or tmisc_feature(22)..(22)n is a, c, g, or tmisc_feature(29)..(29)n is a, c, g, or tmisc_feature(60)..(60)n is a, c, g, or t 89agagtcatct ntactncaga gncatttant tcaatattaa gaattaatac atcatcatan 60tcaagacaaa cccatgtacc atttcacaac aactaataaa aattatagga agaatctcat 120ctcagaataa ttgatttcta tttttcattc attaacgaga taagactctc agctttaggt 180gtatttcatt gaattaactt tgtggaaata catactgcct gataaaaagc aaagatattt 240aaatggaaaa agattacttt attaggagta taggaatctc ctacattgcc taataaagga 300cattagaccc ataagtaggg tctggaattg aattaatgga gtcataggca aatataatcc 360tgctgattaa tcttgtatcc tccacaggca tttcagcgtt ccattggatg aattcttgtt 420attggatgaa ttcttgttat ttttaaaata ggtaggccta gcacagtggc tcatgcccgt 480aatcccagca ctttgggagg ctgaggcagg cagatcatga ggtcaagaga tcgagaccat 540cctggccatc atggtgaaac cccatctcaa ctaaaaatac aaaaaattag ctgggtgtgg 600tagtgcatgc ctgtagtccc agctactctg gagactgcgg cagtagaatc acttgaaccc 660ggtaggtgga gggttcagtg agccgagatg gcgccactgt actccagcct ggcgacagtg 720tgagactcca tctgaaaaat aaataataat aataggtaaa gaaaaggagc taatagtcaa 780gcatagga 78890299DNAArtificial Sequenceoligonucleotidic probe which correspond to SEQ ID N0 194misc_featureSyntheticmisc_feature(63)..(63)n is a, c, g, or t 90cccccacccc acccagccgt gtactgcctg ggctcccctc aaagggaaat ttttacggaa 60acntcttggc agcaagtgga aaaagatcta tggcccatga accaactgaa aactccaaga 120accctctgtc tgcctctgcc agcagcgagt cctaagcgca gaatccagag ctcgtagctg 180tcctcagctg taactactgt ttcagaatgt tgctgctgca tacatttgtc atgtcagccg 240ccagctccgt gggtgagagt gtgcgtgtgc gcgtgtctgt gtgtgtgtgc gtgtctgtg 29991299RNAArtificial Sequenceribonucleotidic probe which correspond to SEQ ID N0 194misc_featureSyntheticmisc_feature(63)..(63)n is a, c, g, or u 91cccccacccc acccagccgu guacugccug ggcuccccuc aaagggaaau uuuuacggaa 60acnucuuggc agcaagugga aaaagaucua uggcccauga accaacugaa aacuccaaga 120acccucuguc ugccucugcc agcagcgagu ccuaagcgca gaauccagag cucguagcug 180uccucagcug uaacuacugu uucagaaugu ugcugcugca uacauuuguc augucagccg 240ccagcuccgu gggugagagu gugcgugugc gcgugucugu gugugugugc gugucugug 2999249RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 92gggucuggaa uugaauuaau ucaauuccca gaccuuaacu uaauuagag 499349RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 93ggucuggaau ugaauuaauu ucaauuccag accuuaacuu aauuaagag 499449RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 94ggagucauag gcaaauauau ucaauuccuc aguauccguu uauauagag 499549RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 95gagucauagg caaauauaau ucaauucuca guauccguuu auauuagag 499649RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 96gaaucucauc ucagaauaau ucaauucuua gaguagaguc uuauuagag 499749RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 97guuccauugg augaauucuu ucaauucaag guaaccuacu uaagaagag 499849RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 98guagggucug gaauugaauu ucaauucauc ccagaccuua acuuaagag 499949RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 99ggacauuaga cccauaaguu ucaauuccug uaaucugggu auucaagag 4910049RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 100gacaaagaga gucaucuuau ucaauucugu uucucucagu agaauagag 4910149RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 101gagacugcgg caguagaauu ucaauucucu gacgccguca ucuuaagag 4910249RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 102gacauuagac ccauaaguau ucaauucugu aaucugggua uucauagag 4910349RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 103ggcaguagaa ucacuugaau ucaauuccgu caucuuagug aacuuagag 4910449RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 104gauaagacuc ucagcuuuau ucaauucuau ucugagaguc gaaauagag 4910549RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 105gacugcggca guagaaucau ucaauucuga cgccgucauc uuaguagag 4910649RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 106guauaggaau cuccuacauu ucaauucaua uccuuagagg auguaagag 4910749RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 107ggagacugcg gcaguagaau ucaauuccuc ugacgccguc aucuuagag 4910849RNAArtificial Sequenceprimers of siRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 108gcugaggcag gcagaucauu ucaauucgac uccguccguc uaguaagag 4910949RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 109guaccauuuc acaacaacuu ucaauucaug guaaaguguu guugaagag 4911049RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 110ggagcuaaua gucaagcauu ucaauuccuc gauuaucagu ucguaagag 4911149RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 111gguaggugga ggguucaguu ucaauuccau ccaccuccca agucaagag

4911249RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 112gcagaucaug aggucaagau ucaauucguc uaguacucca guucuagag 4911349RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 113gaagaaucuc aucucagaau ucaauucuuc uuagaguaga gucuuagag 4911449RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 114gugugagacu ccaucugaau ucaauucaca cucugaggua gacuuagag 4911549RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 115gaucaugagg ucaagagauu ucaauucuag uacuccaguu cucuaagag 4911649RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 116ggcugaggca ggcagaucau ucaauuccga cuccguccgu cuaguagag 4911749RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 117gguagugcau gccuguaguu ucaauuccau cacguacgga caucaagag 4911849RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 118gagauggcgc cacuguacuu ucaauucucu accgcgguga caugaagag 4911930DNAArtificial Sequenceoligonucleotidic probemisc_featureSynthetic 119atgtatatta tatatctaaa gttatactaa 3012036DNAArtificial Sequenceoligonucleotidic probemisc_featureSynthetic 120tttcctgcta agcttatgtt gggattgctt atattt 3612136DNAArtificial Sequenceantisens oligonucleotide (histatine)misc_featureSynthetic 121aaatataagc aatcccaaca taagcttagc aggaaa 3612219RNAArtificial Sequenceinsert of siRNA (PKC epsilon)misc_featureSynthetic 122guuguagccu ggaccuuga 19123420DNAHomo Sapiensmisc_feature(1)..(420)insert S45T9T7 come from clone extract to cells in culture MCF7misc_feature(420)..(420)n is a, c, g, or t 123taaatataag caatcccaac actttgggag gccgaggcgg gcggatcacg aggtcaggag 60atggagacca tcctggctaa cacagtgaaa ccctgtctct actgaaaata caaaaaagta 120gccgggcgtg gcggcaggcg cctgtagccc cagctactca ggaggctgag gcaggagaat 180ggcatgaacc caggaggcag agcttgcagt gagccgagat tgtgccactg cactccagcc 240tgggcaacag agcgagactc catctcaaaa aaaaaaaaaa aatcacccca aagcaataag 300gagaactaga acaggacata cactccaaca ctggtgaaac taggaaaaca tatgtaaccc 360caaaccacaa tatatacaca caaaactata cgagatgttg ggattgctta tatttaatcn 420124456DNAHomo Sapiensmisc_featureS55M1 450 pb M13 come from clone extract to cells in MCF7 culturemisc_feature(1)..(6)n is a, c, g, or tmisc_feature(8)..(8)n is a, c, g, or t 124nnnnnngntc cggccgccat ggcggccgcg ggattcgatt aaatataagc aatcccaaca 60ctttgggagg ccgaggcggg cggatcacga ggtcaggaga tggagaccat cctggctaac 120acagtgaaac cctgtctcta cggaaaatac aaaaaagtag ccgggcgtgg cggcaggcgc 180ctgtagtccc agctactcag gaggctgagg caggagaatg gcatgaaccc aggaggcaga 240gcttgcagtg agccgagatt gtgccactgc actccagcct gggcaacaga gcgagactcc 300atctcaaaaa aaaaaaaaaa tcaccccaaa gcaataagga gaactagaac aggacataca 360ctccaacact ggtgaaacta ggaaaacata tgtaacccca aaccacaata tatacacaca 420aaactatacg agatgttggg attgcttata tttaat 456125587DNAHomo Sapiensmisc_featureS55T9 M13 reverse 700 pb come from clone extract to cells in culture MCF7misc_feature(1)..(9)n is a, c, g, or tmisc_feature(11)..(15)n is a, c, g, or tmisc_feature(17)..(18)n is a, c, g, or tmisc_feature(21)..(21)n is a, c, g, or t 125nnnnnnnnng nnnnngnncc ntggcggccg cgggattcga ttaaatataa gcaatcccaa 60cactttgggg gggtgaggcg gacagatcac ttgaggtcag gggtttgaga ccagcatggc 120caacgtggtg aaaactcaac tactcaaaat agaaaaatta gctggacatg gtggcacaca 180cctgtgaagc cagctactca ggaggctgaa gcatgagaat tgcttgaacc ctggagatgg 240aggttacagt gagcccacgt cgcgtccctg cacgcaagcc taggcaagaa agcaagaccc 300tgtctcaaaa aaagaaaaga gatgctgata catgctacaa catagatgaa ccttgaggac 360attattctaa gtgaaatgag cttgtcacaa aagaacaaat attgcatgat tccagttata 420tgaggtgccc atagttgtca aattcacaaa gacaaaaagt ggcatggtcg ttaccaaggg 480ctgggagaaa agaggaatgg tgagttagtg tttaattggt acagagtttc agttttgcaa 540gatgaaaaga gttctggaga tgaatgttgg gattgcttat atttaat 587126514DNAHomo Sapiensmisc_featureinsert of clone extract from MCF7 cellsmisc_feature(1)..(8)n is a, c, g, or tmisc_feature(10)..(11)n is a, c, g, or tmisc_feature(13)..(16)n is a, c, g, or tmisc_feature(18)..(19)n is a, c, g, or tmisc_feature(21)..(21)n is a, c, g, or tmisc_feature(23)..(25)n is a, c, g, or tmisc_feature(27)..(27)n is a, c, g, or tmisc_feature(35)..(36)n is a, c, g, or tmisc_feature(74)..(75)n is a, c, g, or tmisc_feature(77)..(80)n is a, c, g, or t 126nnnnnnnngn ncnnnnanng nannncnact cactnnaggg cgaattgggc ccgacgtcgc 60atgctcccgg ccgnnannnn ggccgcggga attcgattaa atataagcaa tcccaacact 120ttgggaggcc gaggcgggcg gatcacgagg tcaggagatg gagaccatcc tggctaacac 180agtgaaaccc tgtctctact gaaaatacaa aaaagtagcc gggcgtggcg gcaggcgcct 240gtagtcccag ctactcagga ggctgaggca ggagaatggc atgaacccag gaggcagagc 300ttgcagtgag ccgagattgt gccactgcac tccagcctgg gcaacagagc gagactccat 360ctcaaaaaaa aaaaaaaatc accccaaagc aataaggaga actagaacag gacatacact 420ccaacactgg tgaaactagg aaaacatatg taaccccaaa ccacaatata tacacacaaa 480actatacgag atgttgggat tgcttatatt taat 514127770DNAHomo Sapiensmisc_featureinsert C8 PGEMT M13 rev1605 come from clone extract of cells in MCF7 culturemisc_feature(711)..(711)n is a, c, g, or tmisc_feature(742)..(742)n is a, c, g, or tmisc_feature(749)..(749)n is a, c, g, or tmisc_feature(755)..(755)n is a, c, g, or tmisc_feature(760)..(760)n is a, c, g, or t 127tcctatgctt gactattagc tccttttctt tacctattat tattatttat ttttcagatg 60gagtctcaca ctgtcgccag gctggagtac agtggcgcca tctcggctca ctgaaccctc 120cacctaccgg gttcaagtga ttctactgcc gcagtctcca gagtagctgg gactacaggc 180atgcactacc acacccagct aattttttgt atttttagtt gagatggggt ttcaccatga 240tggccaggat ggtctcgatc tcttgacctc atgatctgcc tgcctcagcc tcccaaagtg 300ctgggattac gggcatgagc cactgtgcta ggcctaccta ttttaaaaat aacaagaatt 360catccaatgg aacgctgaaa tgcctgtgga ggatacaaga ttaatcagca ggattatatt 420tgcctatgac tccattaatt caattccaga ccctacttat gggtctaatg tcctttatta 480ggcaatgtag gagattccta tactcctaat aaagtaatct ttttccattt aaatatcttt 540gctttttatc aggcagtatg tatttccaca aagttaattc aatgaaatac acctaaagct 600gagagtctta tctcgttaat gaatgaaaaa tagaaatcaa ttattctgag atgagattct 660tcctataatt tttattagtt gttgtgaaat ggtacatggg tttgtcttga ntatgatgat 720gtattaattc ttaatattga antaaatgnc tctgnagtan agatgactct 77012818DNAArtificial Sequenceoligonucleotide BV1 S for PCRmisc_featureSynthetic 128atgtgcacca acgcccgc 1812919DNAArtificial Sequenceoligonucleotide BV2 AS for PCRmisc_featureSynthetic 129gttttcagtt ggttcatgg 1913020DNAArtificial Sequenceoligonucleotide BV3-A1Smisc_featureSynthetic 130gatgtctgca cctttatccc 2013120DNAArtificial Sequenceoligonucleotide BV4 ASmisc_featureSynthetic 131catggccatg aagcagagac 2013219DNAArtificial Sequenceoligonucleotide A2 Smisc_featureSynthetic 132cctgacatcc catcatccc 1913319DNAArtificial Sequenceoligonucleotide A2 ASmisc_featureSynthetic 133gggatgatgg gatgtcagg 1913422DNAArtificial Sequenceoligonucleotide GDBR1 Smisc_featureSynthetic 134gcgctttgta aaattcacat tt 2213523DNAArtificial Sequenceoligonucleotide NES 4 ASmisc_featureSynthetic 135tcagacgctt tgtagtgctt cag 2313619DNAArtificial Sequenceoligonucleotide NESB1 Smisc_featureSynthetic 136gcgttcgcaa gcgctggct 1913722DNAArtificial Sequenceoligonucleotide SPLIC ASmisc_featureSynthetic 137gtaaatataa gcaatcccaa ca 2213822DNAArtificial Sequenceoligonucleotide AVT SPLIC Smisc_featureSynthetic 138tcctcattcg acagctgaaa ct 2213925DNAArtificial Sequenceoligonucleotide HUM SPLIC Smisc_featureSynthetic 139atttttacgg aaacatcttg gcagc 2514025DNAArtificial Sequenceoligonucleotide HUM SPLIC ASmisc_featureSynthetic 140gctgccaaga tgtttccgta aaaat 2514119DNAArtificial Sequenceoligonucleotide humA2Smisc_featureSynthetic 141cagatactgt gagcccggc 1914219DNAArtificial Sequenceoligonucleotide humA2ASmisc_featureSynthetic 142gccgggctca cagtatctg 1914324DNAArtificial Sequenceoligonucleotide POZ Smisc_featureSynthetic 143acctactgaa ctgctactgt tgcc 2414424DNAArtificial Sequenceoligonucleotide POZ ASmisc_featureSynthetic 144ggcaacagta gcagttcagt aggt 24145806DNAArtificial SequenceT7 antisens come from cells in MCF7 culturemisc_featureSyntheticmisc_feature(35)..(35)n is a, c, g, or tmisc_feature(745)..(745)n is a, c, g, or t 145cttatctcgt taatgaatga aaaatagaaa tcaanttatt ctgagatgag attcttccct 60ataattttta ttagttgttg tgaaatggta catgggtttg tcttgaagat atgatgatgt 120attaattctt aatattgaat taaatgcctc tgaagtagag atgactctct ttgtcatgga 180gttacagttg tttgattaaa ttgcattgaa ttttgaatgt taatgttata tattaactta 240aatgagattt tccaatataa atactctgtg aacctccagc cttgtgtttc tttctttttt 300tttttttttt tttttttttt ttgatacaga gtctcaatct gtcgcccagg ctggagtgca 360gtggcacgat ctcggctcac tgcaacctct gcctcccagg ttcaagcaat tctcctgcct 420cagcctccca agcagagtag ctggaactac aagtgcgcac caccatgcct ggctattttt 480tttatttttg gtagagacgg ggtttcacca tgttggccag gctagtctca aactcctgac 540atcggtgatc tgcctgcctt ggcctcccaa aatgctggaa ttacaagcat cagccactgc 600acccggcctc agataccctt ttaagaattg taggccatac atctcatgga aattgaatgg 660taatacctgc ctgcattcat actcttgtag agctaagacc agcatgactt tttctgtcct 720cttacttctt tggagaggaa accgncatct cagctaatag tcaagcatag gaaatcgaat 780tcccgcggcc gccatggcgg ccggag 806146720DNAHomo Sapiensmisc_feature2006M13rev2005 come from clone from cells in MCF7 culturemisc_feature(585)..(585)n is a, c, g, or tmisc_feature(610)..(610)n is a, c, g, or tmisc_feature(645)..(646)n is a, c, g, or tmisc_feature(664)..(664)n is a, c, g, or tmisc_feature(681)..(681)n is a, c, g, or tmisc_feature(707)..(708)n is a, c, g, or tmisc_feature(711)..(711)n is a, c, g, or tmisc_feature(713)..(713)n is a, c, g, or t 146tcaagctatg catccaacgc gttgggagct ctcccatatg gtcgacctgc aggcggccgc 60gaattcacta gtgatttcct atgcttgact attagctcct tttctttacc tattattatt 120atttattttt cagatggagt ctcacactgt cgccaggctg gagtacagtg gcgccatctc 180ggctcactga accctccacc taccgggttc aagtgattct actgccgcag tctccagagt 240agctgggact acaggcatgc actaccacac ccagctaatt ttttgtattt ttagttgaga 300tggggtttca ccatgatggc caggatggtc tcgatctctt gacctcatga tctgcctgcc 360tcagcctccc aaagtgctgg gattacgggc atgagccact gtgctaggcc tacctatttt 420aaaaataaca agaattcatc caatggaacg ctgaaatgcc tgtggaggat acaagattaa 480tcagcaggat tatatttgcc tatgactcca ttaattcaat tccagaccct acttatgggt 540ctaatgtcct ttattaggca atgtaggaga ttcctatact cctantaaag taatcttttt 600ccatttaaan atctttgctt tttatcaggc agtatgtatt ttccnnaaag ttaattcaat 660gaantacacc ctaaagctga nagtcttatc ctcgttaatg gaatggnnaa nanaaattca 720147783DNAHomo Sapiensmisc_featureC8sens1605 come from clone from cells in MCF7 culturemisc_feature(21)..(21)n is a, c, g, or tmisc_feature(26)..(26)n is a, c, g, or tmisc_feature(32)..(32)n is a, c, g, or tmisc_feature(39)..(39)n is a, c, g, or tmisc_feature(70)..(70)n is a, c, g, or t 147catgacaaag agagtcatct ntactncaga gncatttant tcaatattaa gaattaatac 60atcatcatan tcaagacaaa cccatgtacc atttcacaac aactaataaa aattatagga 120agaatctcat ctcagaataa ttgatttcta tttttcattc attaacgaga taagactctc 180agctttaggt gtatttcatt gaattaactt tgtggaaata catactgcct gataaaaagc 240aaagatattt aaatggaaaa agattacttt attaggagta taggaatctc ctacattgcc 300taataaagga cattagaccc ataagtaggg tctggaattg aattaatgga gtcataggca 360aatataatcc tgctgattaa tcttgtatcc tccacaggca tttcagcgtt ccattggatg 420aattcttgtt atttttaaaa taggtaggcc tagcacagtg gctcatgccc gtaatcccag 480cactttggga ggctgaggca ggcagatcat gaggtcaaga gatcgagacc atcctggcca 540tcatggtgaa accccatctc aactaaaaat acaaaaaatt agctgggtgt ggtagtgcat 600gcctgtagtc ccagctactc tggagactgc ggcagtagaa tcacttgaac ccggtaggtg 660gagggttcag tgagccgaga tggcgccact gtactccagc ctggcgacag tgtgagactc 720catctgaaaa ataaataata ataataggat aagaaaagga gctaatagtc aagcatagga 780aat 78314829PRTHomo SapiensMISC_FEATUREDomain zn finger example ZN 99misc_featureDomain zn finger example ZN 99misc_feature(10)..(10)Xaa can be any naturally occurring amino acidmisc_feature(13)..(13)Xaa can be any naturally occurring amino acidmisc_feature(18)..(19)Xaa can be any naturally occurring amino acidmisc_feature(22)..(23)Xaa can be any naturally occurring amino acid 148Phe Leu Val Glu Thr Gly Phe His His Xaa Gln Ala Xaa Leu Leu Thr1 5 10 15Ser Xaa Xaa Pro Pro Xaa Xaa Ala Ser Gln Ser Ala Pro 20 2514923PRTHomo Sapiensmisc_featuredomain kinase and zinc fingermisc_feature(5)..(7)Xaa can be any naturally occurring amino acidmisc_feature(9)..(9)Xaa can be any naturally occurring amino acidmisc_feature(11)..(11)Xaa can be any naturally occurring amino acidmisc_feature(20)..(20)Xaa can be any naturally occurring amino acid 149Phe Phe Phe Phe Xaa Xaa Xaa Val Xaa Trp Xaa Leu Pro Pro Ala Leu1 5 10 15Ala Ser Gln Xaa Ser Ala Pro 20150780DNAHomo Sapiensmisc_featureC8 sens come from clone from cells in MCF7 culturemisc_feature(21)..(21)n is a, c, g, or tmisc_feature(26)..(26)n is a, c, g, or tmisc_feature(32)..(32)n is a, c, g, or tmisc_feature(39)..(39)n is a, c, g, or tmisc_feature(70)..(70)n is a, c, g, or t 150catgacaaag agagtcatct ntactncaga gncatttant tcaatattaa gaattaatac 60atcatcatan tcaagacaaa cccatgtacc atttcacaac aactaataaa aattatagga 120agaatctcat ctcagaataa ttgatttcta tttttcattc attaacgaga taagactctc 180agctttaggt gtatttcatt gaattaactt tgtggaaata catactgcct gataaaaagc 240aaagatattt aaatggaaaa agattacttt attaggagta taggaatctc ctacattgcc 300taataaagga cattagaccc ataagtaggg tctggaattg aattaatgga gtcataggca 360aatataatcc tgctgattaa tcttgtatcc tccacaggca tttcagcgtt ccattggatg 420aattcttgtt atttttaaaa taggtaggcc tagcacagtg gctcatgccc gtaatcccag 480cactttggga ggctgaggca ggcagatcat gaggtcaaga gatcgagacc atcctggcca 540tcatggtgaa accccatctc aactaaaaat acaaaaaatt agctgggtgt ggtagtgcat 600gcctgtagtc ccagctactc tggagactgc ggcagtagaa tcacttgaac ccggtaggtg 660gagggttcag tgagccgaga tggcgccact gtactccagc ctggcgacag tgtgagactc 720catctgaaaa ataaataata ataataggat aagaaaagga gctaatagtc aagcatagga 78015119DNAArtificial Sequenceoligonucleotide BV12 S for PCRmisc_featureSynthetic 151gaggccgagg cggcgaatc 1915220DNAArtificial Sequenceoligonuclotide BV12 AS for PCRmisc_featureSynthetic 152gattcgcccg cctcggcctc 2015320DNAArtificial Sequenceoligonucleotide BV10 S for PCRmisc_featureSynthetic 153ggctgcccta tgctggctcc 2015422DNAArtificial Sequenceoligonucleotide GDBR1 ASmisc_featureSynthetic 154aaatgtgaat tttacaaagc gc 2215521DNAArtificial Sequenceoligonucleotide AVT BV1 Smisc_featureSynthetic 155ttgcagcccc atcacccggt c 2115624PRTHomo sapiens 156Ala Glu Ala Gly Gly Ser Arg Gly Gln Glu Met Glu Thr Ile Leu Ala1 5 10 15Asn Thr Val Lys Pro Cys Leu Tyr 2015735PRTHomo sapiens 157Leu Gly Leu Gln Ala Pro Ala Ala Thr Pro Gly Tyr Phe Phe Val Phe1 5 10 15Ser Val Glu Thr Gly Phe His Cys Val Ser Gln Asp Gly Leu His Leu 20 25 30Leu Thr Ser 3515826PRTHomo sapiens 158Val Ala Gly Ala Thr Gly Ala Cys Arg His Ala Arg Leu Leu Phe Cys1 5 10 15Ile Phe Ser Arg Asp Arg Val Ser Leu Cys 20 2515949PRTHomo sapiens 159Thr Gln Glu Ala Glu Leu Ala Val Ser Arg Asp Cys Ala Thr Ala Leu1 5 10 15Gln Pro Gly Gln Gln Ser Glu Thr Pro Ser Gln Lys Lys Lys Lys Asn 20 25 30His Pro Lys Ala Ile Arg Arg Thr Arg Thr Gly His Thr Leu Gln His 35 40 45Trp16028PRTHomo sapiens 160Ala Glu Ile Val Pro Leu His Ser Ser Leu Gly Asn Arg Ala Arg Leu1 5 10 15His Leu Lys Lys Lys Lys Lys Ile Thr Pro Lys Gln 20 2516150PRTHomo sapiens 161Gly Glu Leu Glu Gln Asp Ile His Ser Asn Thr Gly Glu Thr Arg Lys1 5 10 15Thr Tyr Val Thr Pro Asn His Asn Ile Tyr Thr Gln Asn Tyr Thr Arg 20 25 30Cys Trp Asp Cys Leu Ile Thr Ser Glu Phe Ala Ala Ala Cys Arg Ser 35 40 45Thr Ile 5016233PRTHomo sapiens 162Ala Ile Pro Thr Ser Arg Ile Val Leu Cys Val Tyr Ile Val Val Trp1 5

10 15Gly Tyr Ile Cys Phe Pro Ser Phe Thr Ser Val Gly Val Tyr Val Leu 20 25 30Phe16324PRTHomo sapiens 163Glu Asn Ile Cys Asn Pro Lys Pro Gln Tyr Ile His Thr Lys Leu Tyr1 5 10 15Glu Met Leu Gly Leu Leu Asn His 2016434PRTHomo sapiens 164Asn Thr Gln Ala Met His Pro Thr Arg Trp Glu Leu Ser His Met Val1 5 10 15Asp Leu Gln Ala Ala Ala Asn Ser Leu Val Ile Lys Gln Ser Gln His 20 25 30Leu Val16522PRTHomo sapiens 165Ser Leu Val Asn Ser Arg Pro Pro Ala Gly Arg Pro Tyr Gly Arg Ala1 5 10 15Pro Asn Ala Leu Asp Ala 2016627PRTHomo sapiens 166His Tyr Arg Ile Leu Lys Leu Cys Ile Gln Arg Val Gly Ser Ser Pro1 5 10 15Ile Trp Ser Thr Cys Arg Arg Pro Arg Ile His 20 2516724PRTHomo sapiens 167Ile Arg Gly Arg Leu Gln Val Asp His Met Gly Glu Leu Pro Thr Arg1 5 10 15Trp Met His Ser Leu Ser Ile Leu 2016829PRTHomo sapiens 168Ile Ala Trp Arg Asn His Gly His Ser Cys Phe Leu Cys Glu Ile Val1 5 10 15Ile Arg Ser Gln Phe His Thr Thr Tyr Glu Pro Glu Ala 20 2516930PRTHomo sapiens 169Leu Gly Val Ile Met Val Ile Ala Val Ser Cys Val Lys Leu Leu Ser1 5 10 15Ala His Asn Ser Thr Gln His Thr Ser Arg Lys His Lys Val 20 25 301701125PRTHomo Sapiens 170Met Ser Lys Thr Leu Lys Lys Lys Lys His Trp Leu Ser Lys Val Gln1 5 10 15Glu Cys Ala Val Ser Trp Ala Gly Pro Pro Gly Asp Phe Gly Ala Glu 20 25 30Ile Arg Gly Gly Ala Glu Arg Gly Glu Phe Pro Tyr Leu Gly Arg Leu 35 40 45Arg Glu Glu Pro Gly Gly Gly Thr Cys Cys Val Val Ser Gly Lys Ala 50 55 60Pro Ser Pro Gly Asp Val Leu Leu Glu Val Asn Gly Thr Pro Val Ser65 70 75 80Gly Leu Thr Asn Arg Asp Thr Leu Ala Val Ile Arg His Phe Arg Glu 85 90 95Pro Ile Arg Leu Lys Thr Val Lys Pro Gly Lys Val Ile Asn Lys Asp 100 105 110Leu Arg His Tyr Leu Ser Leu Gln Phe Gln Lys Gly Ser Ile Asp His 115 120 125Lys Leu Gln Gln Val Ile Arg Asp Asn Leu Tyr Leu Arg Thr Ile Pro 130 135 140Cys Thr Thr Arg Ala Pro Arg Asp Gly Glu Val Pro Gly Val Asp Tyr145 150 155 160Asn Phe Ile Ser Val Glu Gln Phe Lys Ala Leu Glu Glu Ser Gly Ala 165 170 175Leu Leu Glu Ser Gly Thr Tyr Asp Gly Asn Phe Tyr Gly Thr Pro Lys 180 185 190Pro Pro Ala Glu Pro Ser Pro Phe Gln Pro Asp Pro Val Asp Gln Val 195 200 205Leu Phe Asp Asn Glu Phe Asp Ala Glu Ser Gln Arg Lys Arg Thr Thr 210 215 220Ser Val Ser Lys Met Glu Arg Met Asp Ser Ser Leu Pro Glu Glu Glu225 230 235 240Glu Asp Glu Asp Lys Glu Ala Ile Asn Gly Ser Gly Asn Ala Glu Asn 245 250 255Arg Glu Arg His Ser Glu Ser Ser Asp Trp Met Lys Thr Val Pro Ser 260 265 270Tyr Asn Gln Thr Asn Ser Ser Met Asp Phe Arg Asn Tyr Met Met Arg 275 280 285Asp Glu Thr Leu Glu Pro Leu Pro Lys Asn Trp Glu Met Ala Tyr Thr 290 295 300Asp Thr Gly Met Ile Tyr Phe Ile Asp His Asn Thr Lys Thr Thr Thr305 310 315 320Trp Leu Asp Pro Arg Leu Cys Lys Lys Ala Lys Ala Pro Glu Asp Cys 325 330 335Glu Asp Gly Glu Leu Pro Tyr Gly Trp Glu Lys Ile Glu Asp Pro Gln 340 345 350Tyr Gly Thr Tyr Tyr Val Asp His Leu Asn Gln Lys Thr Gln Phe Glu 355 360 365Asn Pro Val Glu Glu Ala Lys Arg Lys Lys Gln Leu Gly Gln Val Glu 370 375 380Ile Gly Ser Ser Lys Pro Asp Met Glu Lys Ser His Phe Thr Arg Asp385 390 395 400Pro Ser Gln Leu Lys Gly Val Leu Val Arg Ala Ser Leu Lys Lys Ser 405 410 415Thr Met Gly Phe Gly Phe Thr Ile Ile Gly Gly Asp Arg Pro Asp Glu 420 425 430Phe Leu Gln Val Lys Asn Val Leu Lys Asp Gly Pro Ala Ala Gln Asp 435 440 445Gly Lys Ile Ala Pro Gly Asp Val Ile Val Asp Ile Asn Gly Asn Cys 450 455 460Val Leu Gly His Thr His Ala Asp Val Val Gln Met Phe Gln Leu Val465 470 475 480Pro Val Asn Gln Tyr Val Asn Leu Thr Leu Cys Arg Gly Tyr Pro Leu 485 490 495Pro Asp Asp Ser Glu Asp Pro Val Val Asp Ile Val Ala Ala Thr Pro 500 505 510Val Ile Asn Gly Gln Ser Leu Thr Lys Gly Glu Thr Cys Met Asn Pro 515 520 525Gln Asp Phe Lys Pro Gly Ala Met Val Leu Glu Gln Asn Gly Lys Ser 530 535 540Gly His Thr Leu Thr Gly Asp Gly Leu Asn Gly Pro Ser Asp Ala Ser545 550 555 560Glu Gln Arg Val Ser Met Ala Ser Ser Gly Ser Ser Gln Pro Glu Leu 565 570 575Val Thr Ile Pro Leu Ile Lys Gly Pro Lys Gly Phe Gly Phe Ala Ile 580 585 590Ala Asp Ser Pro Thr Gly Gln Lys Val Lys Met Ile Leu Asp Ser Gln 595 600 605Trp Cys Gln Gly Leu Gln Lys Gly Asp Ile Ile Lys Glu Ile Tyr His 610 615 620Gln Asn Val Gln Asn Leu Thr His Leu Gln Val Val Glu Val Leu Lys625 630 635 640Gln Phe Pro Val Gly Ala Asp Val Pro Leu Leu Ile Leu Arg Gly Gly 645 650 655Pro Pro Ser Pro Thr Lys Thr Ala Lys Met Lys Thr Asp Lys Lys Glu 660 665 670Asn Ala Gly Ser Leu Glu Ala Ile Asn Glu Pro Ile Pro Gln Pro Met 675 680 685Pro Phe Pro Pro Ser Ile Ile Arg Ser Gly Ser Pro Lys Leu Asp Pro 690 695 700Ser Glu Val Tyr Leu Lys Ser Lys Thr Leu Tyr Glu Asp Lys Pro Pro705 710 715 720Asn Thr Lys Asp Leu Asp Val Phe Leu Arg Lys Gln Glu Ser Gly Phe 725 730 735Gly Phe Arg Val Leu Gly Gly Asp Gly Pro Asp Gln Ser Ile Tyr Ile 740 745 750Gly Ala Ile Ile Pro Leu Gly Ala Ala Glu Lys Asp Gly Arg Leu Arg 755 760 765Ala Ala Asp Glu Leu Met Cys Ile Asp Gly Ile Pro Val Lys Gly Lys 770 775 780Ser His Lys Gln Val Leu Asp Leu Met Thr Thr Ala Ala Arg Asn Gly785 790 795 800His Val Leu Leu Thr Val Arg Arg Lys Ile Phe Tyr Gly Glu Lys Gln 805 810 815Pro Glu Asp Asp Ser Ser Gln Ala Phe Ile Ser Thr Gln Asn Gly Ser 820 825 830Pro Arg Leu Asn Arg Ala Glu Val Pro Ala Arg Pro Ala Pro Gln Glu 835 840 845Pro Tyr Asp Val Val Leu Gln Arg Lys Glu Asn Glu Gly Phe Gly Phe 850 855 860Val Ile Leu Thr Ser Lys Asn Lys Pro Pro Pro Gly Val Ile Pro His865 870 875 880Lys Ile Gly Arg Val Ile Glu Gly Ser Pro Ala Asp Arg Cys Gly Lys 885 890 895Leu Lys Val Gly Asp His Ile Ser Ala Val Asn Gly Gln Ser Ile Val 900 905 910Glu Leu Ser His Asp Asn Ile Val Gln Leu Ile Lys Asp Ala Gly Val 915 920 925Thr Val Thr Leu Thr Val Ile Ala Glu Glu Glu His His Gly Pro Pro 930 935 940Ser Gly Thr Asn Ser Ala Arg Gln Ser Pro Ala Leu Gln His Arg Pro945 950 955 960Met Gly Gln Ser Gln Ala Asn His Ile Pro Gly Asp Arg Ser Ala Leu 965 970 975Glu Gly Glu Ile Gly Lys Asp Val Ser Thr Ser Tyr Arg His Ser Trp 980 985 990Ser Asp His Lys His Leu Ala Gln Pro Asp Thr Ala Val Ile Ser Val 995 1000 1005Val Gly Ser Arg His Asn Gln Asn Leu Gly Cys Tyr Pro Val Glu 1010 1015 1020Leu Glu Arg Gly Pro Arg Gly Phe Gly Phe Ser Leu Arg Gly Gly 1025 1030 1035Lys Glu Tyr Asn Met Gly Leu Phe Ile Leu Arg Leu Ala Glu Asp 1040 1045 1050Gly Pro Ala Ile Lys Asp Gly Arg Ile His Val Gly Asp Gln Ile 1055 1060 1065Val Glu Ile Asn Gly Glu Pro Thr Gln Gly Ile Thr His Thr Arg 1070 1075 1080Ala Ile Glu Leu Ile Gln Ala Gly Gly Asn Lys Val Leu Leu Leu 1085 1090 1095Leu Arg Pro Gly Thr Gly Leu Ile Pro Asp His Gly Leu Ala Pro 1100 1105 1110Ser Gly Leu Cys Ser Tyr Val Lys Pro Glu Gln His 1115 1120 11251711202DNAHomo sapiensmisc_featureSequence of Liv21 complexmisc_feature(1070)..(1070)n is a, c, g, or t 171ggagaagggt ccccactgct cctgtcaagc cttgttgtgt cgggacttga actttattct 60aagcaggtga atgcggtgca tgcaagagag acagagagaa tgtggcagga ccaaggagga 120ggctatgcca cttatgtcac tcctggcaaa aataaggggg catggagtag gctgtttgtg 180gtgcagatgg tgagagcagt caggtccagc acagatttta aaggttggac ccagagaatt 240tgctgcagaa tcagatgtgg ggtgtaaggc agagaggagt caagggcaac ttcaggattt 300ggggccggaa ctgccattag acagacagag ggacactggg ggagaagcag gttaggtggg 360attaaaatca agagttcaag ttaagtttga gcagcctgtt agacctccaa cgagggccag 420atagaagaat ctggtttcca gggagaggtc aggatgagag atacacacgt gggaatgatt 480ggcattgggc ggactttata ttctctgggc cagtgagaca gctgggaagt gaccacggat 540agagaagaga caaagtcaca gaaaccaaga gaggtaatgt tgcaaggacg gaacactcaa 600ctctcaaatg ctgctgagac gtgggctgag ggctgagaat ggaattggga agaaccgagg 660tcactggtga tcctgagggt ttcagtggca agggcaggtg gactgcagtg gggcccggtg 720gggatcggtg gagcatgggc ccctctcccg gagagttgca ctgtaaacga gggcagacat 780atgggagtgc agctagaggg agggaacgta ggctcaaggg agagtttatt ctgaatgaga 840gagatcacag cttgttttta ggctgacggg catgatccat agaggggaaa gtaattaaga 900tgcagaagag aggccggggg tggtggctca cgcctgtaat ctcagcactt tgggaggctc 960gaggtgggtg gatcatttga ggacaggagt tcgagaccat cctggccagc atggtgaaac 1020ctcgcctcta ctaaaaataa aaataaaaaa aaattagctg ggtgcggtgn acgggcacct 1080gtagtaccag ctacttggga ggctgaggta acagaatcgc ttgaaccctg gaggcagggg 1140ttgcagtgag ctgagattgt gccactgcac tctagcctgg gcaacaaatt gagactccac 1200tc 12021721199DNAHomo sapiensmisc_featureSequence of LIV21 complex 172ggagaagggt ccccactgct cctgtcaagc cttgttgtgt cgggacttga actttattct 60aagcaggtga atgcggtgca tgcaagagag acagagagaa tgtggcacga ccaaggagga 120ggctatgcca cttatgtcac tcctggcaaa aataaggggg catggagtag gctgtttgtg 180gtgcagatgg tgagagcagt caggtccagc acagatttta aaggttggac ccagagaatt 240tgctgcagaa tcagatgtgg ggtgtaaggc agagaggagt caagggcaac ttcaggattt 300ggggccggaa ctgccattag acagacaggg acactggggg agaagcaggt taggtgggat 360taaaatcaag agttcaagtt aagtttgagc agcctgttag acctccaacg agggccagat 420agaagaatct ggtttccagg gagaggtcag gatgagagat acacacgtgg gaatgattgg 480cattgggcgg actttatatt ctctgggcca gtgagacagc tgggaagtga ccacggatag 540agaagagaca aagtcacaga aaccaagaga ggtaatgttg caaggacgga acactcaact 600ctcaaatgct gctgagacgt gggctgaggg ctgagaatgg aattgggaag aaccgaggtc 660actggtgatc ctgagggttt cagtggcaag ggcaggtgga ctgcagtggg gcccggtggg 720gatgggtgga gcatgggccc ctctcccgga gagttgcact gtaaacgagg gcagacatat 780gggagtgcag ctagagggag ggaacgtagg gtcaagggag agtttattct gaatgagaga 840gatcacagct tgtttttagg ctgacgggca tgatccatag aggggaaagt aattaagatg 900cagaagagag gccgggggtg gtggctcacg cctgtaatct cagcactttg ggaggctgag 960gtgggtggat catttgagga caggagttcg agaccatcct ggccagcatg gtgaaacctc 1020gcctctacta aaaataaaaa taaaaaaaaa ttagctgggt gcggtgacgg gcacctgtag 1080taccagctac ttgggaggct gaggtaacag aatcgcttga accctggagg caggggttgc 1140agtgagctga gattgtgcca ctgcactcta gcctgggcaa caaattgaga ctccatctc 119917320DNAArtificial Sequenceoligonucleotide for PCRmisc_featureSynthetic 173tttccgtcac gccgacctgc 2017420DNAArtificial Sequenceoligonucleotide reverse for PCRmisc_featureSynthetic 174gcaggtcggc gtgacggaaa 2017520DNAArtificial Sequenceoligonucleotide for PCRmisc_featureSynthetic 175cgccacgaac tccagcagca 2017620DNAArtificial Sequenceoligonucleotide for PCRmisc_featureSynthetic 176ggcctgcgct cgcctgtaaa 2017720DNAArtificial Sequenceoligonucleotide for PCRmisc_featureSynthetic 177cagtggagaa gcggcggcaa 2017819PRTArtificial Sequencesequence of Liv21 complexmisc_featureSynthetic 178Pro Pro Arg Ala Ser Gln Ser Ala Glu Ile Thr Gly Val Ser His His1 5 10 15Pro Arg Pro17919PRTArtificial Sequenceisoforme of sequence of complexe Liv21misc_featureSynthetic 179Pro Thr Leu Ala Ser Gln Ser Ala Gly Ile Thr Gly Val Ser His Arg1 5 10 15Ala Trp Pro180144PRTArtificial SequenceLiv 21Kmisc_featureSyntheticmisc_feature(83)..(83)Xaa is any amino acid 180Ser Val Ala Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln1 5 10 15Ala Leu Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Leu Ser 20 25 30Ser Trp Asp Tyr Arg Arg Leu Pro Pro Arg Pro Ala Asn Phe Leu Tyr 35 40 45Phe Pro Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val Ser Ile Ser 50 55 60Pro Arg Asp Pro Pro Ala Ser Ala Ser Gln Ser Ala Gly Ile Thr Tyr65 70 75 80Ile Ser Xaa Phe Phe Phe Phe Glu Met Glu Ser Arg Ser Ser Val Ala 85 90 95Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln Ala Leu Pro 100 105 110Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp Asp 115 120 125Tyr Arg Arg Leu Pro Pro Arg Pro Ala Thr Phe Leu Tyr Phe Pro Arg 130 135 14018195PRTArtificial SequenceLiv 21Fmisc_featureSyntheticmisc_feature(83)..(83)Xaa is any amino acid 181Ser Val Ala Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln1 5 10 15Ala Leu Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Leu Ser 20 25 30Ser Trp Asp Tyr Arg Arg Leu Pro Pro Arg Pro Ala Thr Phe Leu Tyr 35 40 45Phe Pro Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val Ser Ile Ser 50 55 60Pro Arg Asp Pro Pro Ala Ser Ala Ser Gln Ser Val Gly Ile Ala Tyr65 70 75 80Ile Ser Xaa Phe Phe Phe Phe Glu Met Glu Ser Arg Ser Val Ala 85 90 95182129PRTArtificial Sequencetraduction of clone C18misc_featureSyntheticmisc_feature(83)..(83)Xaa is any amino acid 182Ser Val Ala Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln1 5 10 15Ala Leu Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Leu Ser 20 25 30Ser Trp Asp Tyr Arg Arg Leu Pro Pro Arg Pro Ala Asn Phe Leu Tyr 35 40 45Phe Pro Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val Ser Ile Ser 50 55 60Pro Arg Asp Pro Pro Ala Ser Ala Ser Gln Ser Ala Gly Ile Thr Tyr65 70 75 80Ile Ser Xaa Phe Phe Phe Phe Glu Met Glu Ser Arg Ser Val Ala Phe 85 90 95Leu Tyr Phe Pro Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val Ser 100 105 110Ile Ser Pro Arg Asp Pro Pro Ala Ser Ala Ser Gln Ser Ala Gly Ile 115 120 125Thr18378PRTArtificial Sequenceisoforme of sequence NO 180misc_featureSyntheticmisc_feature(42)..(43)Xaa is any amino acidmisc_feature(48)..(48)Xaa is any amino acid 183Ser Leu Ala Leu Leu Pro Lys Leu Glu Cys Arg Gly Thr Ile Ser Ala1 5 10 15His Cys Asn Leu His Leu Pro Gly Ser Ser Asp Phe Pro Ala Ser Ala 20 25 30Ser Gln Val Ala Gly Thr Thr Gly Ala Xaa Xaa Cys His His Ala Xaa 35 40 45Trp Leu Ile Phe Val Phe Leu Val Glu Ala Arg Phe His His Val Gly 50 55 60Gln Asp Gly Leu Glu Leu Leu Thr Ser Asn Asp Pro Pro Thr65

70 7518478PRTArtificial Sequenceisoforme of sequence NO 183misc_featureSyntheticmisc_feature(43)..(43)Xaa is any amino acid 184Ser Leu Asn Leu Leu Pro Arg Leu Glu Cys Ser Gly Thr Ile Ser Ala1 5 10 15His Cys Asn Pro Cys Leu Gln Gly Ser Ser Asp Ser Val Thr Ser Ala 20 25 30Ser Gln Val Ala Gly Thr Thr Gly Ala Arg Xaa Pro His Pro Ala Asn 35 40 45Phe Phe Leu Phe Leu Phe Leu Val Glu Ala Arg Phe His His Ala Gly 50 55 60Gln Asp Gly Leu Glu Leu Leu Ser Ser Asn Asp Pro Pro Thr65 70 7518576PRTArtificial Sequenceisoforme of sequence NO 183misc_featureSynthetic 185Ser Leu Ala Leu Ser Pro Arg Leu Glu Cys Ser Gly Thr Ile Leu Ala1 5 10 15His Cys Asn Leu Cys Leu Leu Gly Ser Ser Asp Ser Pro Ala Ser Ala 20 25 30Ser Arg Val Ala Gly Thr Thr Gly Thr Cys His His Ala Gln Leu Ile 35 40 45Phe Val Phe Leu Val Glu Thr Arg Phe His His Ile Gly Gln Asp Gly 50 55 60Leu Asp Leu Leu Thr Tyr Asp Pro Pro Ala Ser Ala65 70 75186184PRTHomo sapiensmisc_featureAD7c NTP 060448 - HUMANmisc_featureSynthetic 186Leu Ile Phe Ile Phe Ile Phe Asn Phe Leu Arg Gln Ser Leu Asn Ser1 5 10 15Val Thr Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln Pro 20 25 30Leu Pro Pro Gly Phe Lys Leu Phe Ser Cys Pro Pro Ser Leu Leu Ser 35 40 45Ser Trp Asp Tyr Arg Arg Pro Pro Arg Leu Ala Asn Phe Phe Val Phe 50 55 60Leu Val Glu Met Gly Phe Thr Met Phe Ala Arg Leu Ile Leu Ile Ser65 70 75 80Gly Pro Cys Asp Leu Pro Ala Ser Ala Ser Gln Ser Ala Gly Ile Thr 85 90 95Gly Val Ser His His Ala Arg Leu Ile Phe Asn Phe Cys Leu Phe Glu 100 105 110Met Glu Ser His Ser Val Thr Gln Ala Gly Val Gln Trp Pro Asn Leu 115 120 125Gly Ser Leu Asp Pro Leu Pro Pro Gly Leu Lys Arg Phe Ser Cys Leu 130 135 140Ser Leu Pro Ser Ser Trp Asp Tyr Gly His Leu Pro Pro His Pro Ala145 150 155 160Asn Phe Cys Ile Phe Ile Arg Gly Gly Val Ser Pro Tyr Leu Ser Gly 165 170 175Trp Ser Gln Thr Pro Asp Leu Arg 18018760PRTArtificial Sequencepart of EAW88192.1 Figure 20misc_featureSynthetic 187Met Cys Val Ser Val Arg Val Cys Val Cys Val Cys Ala Ser Val Cys1 5 10 15Ala Cys Val Cys Ala Ser Val Cys Met Cys Ala Arg Ala Ser Val Cys 20 25 30Thr Cys Val Ser Leu His Ala Cys Leu Cys Met Cys Ala Arg Val Cys 35 40 45Leu Cys Val Cys Thr Arg Val His Val Thr Thr Gly 50 55 6018895PRTArtificial Sequenceisoforme of sequence 183 (1202 _ 915)misc_featureSyntheticmisc_feature(44)..(44)Xaa is any amino acidmisc_feature(86)..(86)Xaa is any amino acid 188Glu Trp Ser Leu Asn Leu Leu Pro Arg Leu Glu Cys Ser Gly Thr Ile1 5 10 15Ser Ala His Cys Asn Pro Cys Leu Gln Gly Ser Ser Asp Val Thr Ser 20 25 30Ala Ser Gln Val Ala Gly Thr Thr Gly Ala Arg Xaa Pro His Pro Ala 35 40 45Asn Phe Phe Leu Phe Leu Phe Leu Val Glu Ala Arg Phe His His Ala 50 55 60Gly Gln Asp Gly Leu Glu Leu Leu Ser Ser Asn Asp Pro Pro Thr Ser65 70 75 80Ser Leu Pro Lys Cys Xaa Asp Tyr Arg Arg Glu Pro Pro Pro Pro 85 90 9518980PRTArtificial Sequenceisoforme of sequence NO 183misc_featureSyntheticmisc_feature(43)..(43)Xaa is any amino acid 189Ser Leu Asn Leu Leu Pro Arg Leu Glu Cys Ser Gly Thr Ile Ser Ala1 5 10 15His Cys Asn Pro Cys Leu Gln Gly Ser Ser Asp Ser Val Thr Ser Ala 20 25 30Ser Gln Val Ala Gly Thr Thr Gly Ala Arg Xaa Pro His Pro Ala Asn 35 40 45Phe Phe Leu Phe Leu Phe Leu Val Glu Ala Arg Phe His His Ala Gly 50 55 60Gln Asp Gly Leu Glu Leu Leu Ser Ser Asn Asp Pro Pro Thr Ser Ser65 70 75 8019096PRTArtificial Sequencezinc finger (sbjt 97 - 192)misc_featureSynthetic 190Lys Trp Ser Leu Thr Leu Ser Pro Lys Leu Glu Cys Asn Gly Ala Ile1 5 10 15Ser Val His Cys Asn Leu Arg Leu Leu Gly Ser Ser Asp Ser Leu Ala 20 25 30Ser Thr Ser Gln Ala Ala Gly Ile Ala Gly Ala Cys His His Ala Gln 35 40 45Leu Ile Phe Val Phe Leu Val Glu Thr Gly Phe His His Phe Asp Gln 50 55 60Ala Gly Phe Glu Leu Leu Thr Ser Ser Asp Pro Pro Ala Leu Ala Ser65 70 75 80Gln Ser Ala Pro Lys Cys Trp Asp Tyr Lys His Glu Pro Leu Ser Pro 85 90 9519120PRTArtificial Sequencevariant Leucine reach repeatmisc_featureSynthetic 191Ile Ser Pro Arg Asp Pro Pro Ala Ser Ala Ser Gln Ser Val Glu Ile1 5 10 15Ala Tyr Ile Ser 2019220PRTArtificial SequenceLeucine reach repeatmisc_featureSynthetic 192Leu Ser Ser Glu Asp Pro Pro Ala Ser Ala Ser Gln Ser Val Gly Ile1 5 10 15Ile Gly Val Ser 2019343PRTArtificial Sequencevariant of sequence NO 186 (sbjct 19) unamed proteinmisc_featureSynthetic 193Ser Val Ala Gln Ala Gly Val Gln Trp Arg Asp Leu Gly Ser Leu Gln1 5 10 15Ala Pro Pro Pro Gly Phe Thr Pro Phe Ser Cys Leu Ser Leu Pro Ser 20 25 30Ser Trp Asp Tyr Arg Arg Pro Pro Leu Arg Pro 35 4019443PRTHomo sapiensmisc_featurepart of sequence N0 182 homologue at "unamed protein"misc_featureSynthetic 194Ser Val Ala Gln Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln1 5 10 15Ala Leu Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Leu Ser 20 25 30Ser Trp Asp Tyr Arg Arg Leu Pro Pro Arg Pro 35 4019541PRTArtificial Sequencevariant of sequence NO 186 (sbjct 15) unamed proteinmisc_featureSynthetic 195Ala Gln Ala Gly Val Gln Trp Arg Tyr Leu Gly Ser Leu Gln Pro Pro1 5 10 15Pro Pro Gly Phe Thr Arg Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp 20 25 30Asp Tyr Arg Arg Pro Pro Pro Arg Pro 35 4019643PRTArtificial Sequencevariant de la sequence N0 186 (sbjct 5) E2F2misc_featureSynthetic 196Ser Val Ala Gln Ala Gly Val Gln Trp Pro Asp Leu Gly Ser Leu Gln1 5 10 15Pro Leu Pro Pro Arg Phe Lys Arg Phe Phe Cys Leu Ser Leu Gln Ser 20 25 30Ser Trp Asp Tyr Arg His Ala Pro Pro Arg Pro 35 4019743PRTArtificial Sequencetranscription factor (sbjct 265) TFIIDmisc_featureSynthetic 197Ser Val Thr Gln Ala Gly Val Gln Trp Gln Asp Leu Gly Ser Leu Gln1 5 10 15Pro Pro Pro Pro Gly Phe Lys Arg Phe Ser Ser Leu Ser Leu Leu Ser 20 25 30Ser Trp Asn Tyr Arg Arg Ile Leu Glu Pro Arg 35 4019841PRTArtificial Sequencevariant (sbjct 565) vmybmisc_featureSynthetic 198Ala Pro Thr Gly Val Gln Trp His Asp Phe Gly Ser Leu Gln Pro Leu1 5 10 15Pro Pro Gly Phe Lys Arg Phe Ser Cys Leu Ser Leu Pro Arg Ser Trp 20 25 30Asp Tyr Arg His Pro Pro Pro Arg Pro 35 4019941PRTArtificial Sequencevariant (sbjct 20) macaquemisc_featureSynthetic 199Ser Val Ile Gln Ser Gly Val Gln Trp His Asn Leu Gly Ser Leu Gln1 5 10 15Pro Pro Pro Pro Glu Phe Asn Arg Phe Ser Cys Leu Ser Leu Pro Asn 20 25 30Ser Trp Asp Tyr Arg Cys Met Pro Pro 35 4020038PRTArtificial Sequenceinitiation of translation factor (sbjct 159)misc_featureSynthetic 200Gln Ala Gly Val Gln Trp His His Leu Gly Ser Leu Gln Ser Pro Pro1 5 10 15Pro Gly Phe Lys His Phe Thr Cys Leu Ser Leu Pro Ser Ser Trp Asp 20 25 30Tyr Met His Met Pro Pro 3520141PRTArtificial SequenceDNA polymerase transactivated (sbjct 9)misc_featureSynthetic 201Ser Val Pro His Ala Gly Val Gln Trp His Asn Leu Ser Ser Leu Gln1 5 10 15Pro Pro Pro Ser Gly Phe Lys Pro Phe Ser Tyr Leu Ser Leu Leu Ser 20 25 30Ser Arg Asp Gln Arg Arg Pro Leu Pro 35 4020232PRTArtificial Sequenceunamed protein (sbjct 15)misc_featureSynthetic 202Ala Gly Val Gln Trp Arg Asn Leu Gly Ser Leu Gln Ala Leu Pro Pro1 5 10 15Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp Asp Tyr 20 25 3020335PRTArtificial SequenceRNA binding motif (sbjct 2)misc_featureSynthetic 203Ala Lys Ala Gly Val Gln Trp Arg Asp Leu Asp Ser Leu Gln Pro Leu1 5 10 15Pro Pro Arg Phe Lys Arg Phe Ser His Leu Cys Leu Leu Ser Ser Trp 20 25 30Asp Tyr Arg 3520432PRTArtificial Sequenceisoforme 3 mitogene activating protein kinasemisc_featureSynthetic 204Ala Gly Val Gln Trp His Asp Leu Gly Ser Leu Gln Pro Leu Pro Pro1 5 10 15Arg Phe Lys Arg Phe Ser Cys Leu Ser Leu Gln Ser Ser Trp Asp Tyr 20 25 3020539PRTArtificial SequencePP2121 ((Sbjct90) 76% of homology with SEQ NO 203)misc_featureSynthetic 205Ala Gly Val Gln Leu Ser Gly Leu Gly Ser Leu Gln Pro Leu Pro Pro1 5 10 15Gly Phe Gln Arg Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp Asp Tyr 20 25 30Arg Cys Met Leu Pro Arg Pro 352069PRTArtificial SequenceSequence of Figure 4B (Obtain by spectrometry ESI MS MS)misc_featureSynthetic 206Tyr Arg Pro Gly Thr Val Ala Leu Arg1 52079PRTArtificial SequenceSequence obtain by spectrometry ESI MS MS analysismisc_featureSynthetic 207Lys Ala Val Ala Phe Pro Val Gly Arg1 5208939DNAArtificial SequenceSequence of genemisc_featureSynthetic 208ggcagctggg ttgcatggag aggtccagga gggaccggag gtgtgacaga tactgtgagc 60ggcagctggg ttgcatggag aggtccagga gggaccggag gtgtgacaga tactgtgagc 120ccggcgggcc gcgcctggct gggtgcctcg gtacttgaat tctgtcttgt tttccgcatt 180gtgtctgtcc acccgagttc tctgtcgtca cttaactttg cattggattt ggttgttgta 240ctttgcccct gaatgtggac aaagctgtgg gcaagaggtc agcaggaccc gcctgggggt 300gccggcgttg gtgactgcgg gtcggggctc ctagaacata ggagccggct gcctggcctc 360ctttctcctc caggaagagt cattctttgg catttgtgtt tagagccagg aggaaggcgg 420aaggtaggga gggagggctg gtccccctct gagggggctc tagtgcctga ccctgacctg 480tcctcattcg acagctgaaa ctgttaagcg ctggcccagt ccccccaccc cacccagccg 540tgtactgcct gggctcccct caaagggaaa tttttacgga aacatcttgg cagcaagtgg 600aaaaagatct atggcccatg aaccaactga aaactccaag aaccctctgt ctgcctctgc 660cagcagcgag tcctaagcgc agaatccaga gctcgtagct gtcctcagct gtaactactg 720tttcagaatg ttgctgctgc atacatttgt catgtcagcc agccagctcc gtgggtgaaa 780gtgtgcgtgt gcgcgtgtct gtgtgtgtgt gcgtgtctgt gtgtgtgcac gtctgtgcgt 840gcgcgtccgt gcatgtgtgt gtctgtgcgt gtgtgcgtcc gtgtgtgtgc gtctgtgtgc 900gcgtgtgtgt cccccttctg tatgtgtgca cgccgcgtc 93920920DNAArtificial Sequenceoligonucleotide BV9 S for PCRmisc_featureSynthetic 209tgggaggttg cctgcgggtc 2021021DNAArtificial Sequenceoligonucleotide BV8 S for PCRmisc_featureSynthetic 210gcattcctag ggccgcaggt g 2121122DNAArticial Sequencemisc_featureoligonucleotide BV7 S for PCRmisc_featureSynthetic 211ggaggcctgt gtccttgtcc ag 2221221DNAArtificial Sequenceoligonucleotide BV6 S for PCRmisc_featureSynthetic 212agggacagtg gaggaagggc c 2121321DNAArtificial Sequenceoligonucleotide BV5 S for PCRmisc_featureSynthetic 213gagggggctg agctgtgcgt c 2121475RNAArtificial SequenceStem loop domain NO 100492041_1 / 19_10049183misc_featureSyntheticmisc_feature(42)..(42)n is a, c, g, or umisc_feature(47)..(47)n is a, c, g, or umisc_feature(59)..(59)n is a, c, g, or u 214ugucggguag cuuaucagac ugauguugac uguugaaucu cnauggncaa caccagucng 60augggcuguc ugaca 7521525PRTArtificial SequenceSyntheticmisc_featureSyntheticMISC_FEATUREBreast cancer suppressor Liv21 215Gly Trp Trp Leu Thr Pro Val Ile Ser Ala Leu Trp Glu Ala Glu Val1 5 10 15Gly Gly Ser Phe Glu Asp Arg Ser Ser 20 2521686PRTHomo sapiensmisc_featureVMYB v-myb myeloblastosis viral oncogene homolog (avian) Homo sapiensmisc_feature(19)..(19)Xaa can be any naturally occurring amino acidmisc_feature(56)..(56)Xaa can be any naturally occurring amino acid 216Gly Val Gln Trp Arg His Leu Gly Ser Leu Asn Pro Pro Pro Thr Gly1 5 10 15Phe Leu Xaa Phe Tyr Cys Arg Ser Leu Gln Ser Ser Trp Asp Tyr Arg 20 25 30His Ala Leu Pro His Pro Ala Asn Phe Leu Tyr Phe Leu Arg Trp Gly 35 40 45Phe Thr Met Met Ala Arg Met Xaa Val Ser Ile Ser Pro His Asp Leu 50 55 60Pro Ala Ser Ala Ser Gln Ser Ala Gly Ile Thr Gly Met Ser His Cys65 70 75 80Ala Arg Pro Thr Tyr Phe 85217906DNAHomo sapiensmisc_featureA1S1 M13 Rev Clone from MCF7 cellsmisc_feature(2)..(2)n is a, c, g, or tmisc_feature(5)..(5)n is a, c, g, or tmisc_feature(7)..(7)n is a, c, g, or tmisc_feature(10)..(11)n is a, c, g, or tmisc_feature(17)..(17)n is a, c, g, or tmisc_feature(751)..(751)n is a, c, g, or tmisc_feature(768)..(768)n is a, c, g, or tmisc_feature(824)..(824)n is a, c, g, or tmisc_feature(828)..(832)n is a, c, g, or tmisc_feature(848)..(848)n is a, c, g, or tmisc_feature(873)..(873)n is a, c, g, or tmisc_feature(881)..(881)n is a, c, g, or tmisc_feature(887)..(888)n is a, c, g, or tmisc_feature(894)..(894)n is a, c, g, or tmisc_feature(898)..(898)n is a, c, g, or tmisc_feature(900)..(901)n is a, c, g, or tmisc_feature(904)..(904)n is a, c, g, or tmisc_feature(906)..(906)n is a, c, g, or t 217tntangngan nataganact caagctatgc atccaacgcg ttgggagctc tcccatatgg 60tcgacctgca ggcggccgcg aattcactag tgatttccta tgcttgacta ttagcctttc 120tgtgagagca gttgctcaga gttgaggaca ctcggaacaa ccatcaactg tcaattagaa 180atatggcaaa ttatttcagt ggttttccct ggctcttgct gagtttatta ccacaatgct 240tagttgttgt ttacttaggg aatcaatgcc aagtttgaag tgactgaaga accagcctgt 300ttgaacagtc catgtggaag agctacgtgt gagagtattt cagagaagct gagaaaacgc 360taaatgagta cagcctaaac tggaatatgc taggcagtgt tacaactgtg gtggtaaaaa 420tgcgcggaac agaaaggggg tcaaacatcc aaaacctgtg taagggttac tcactgcatt 480attactcatg agcatgtacc ttgtgggaaa cacatgaatc tattgtgctc atgaacgagt 540aatgtcagtg atgaatttaa cacgctcctg tgaacctgac catcagcagg tcatgagttt 600ctgtcagaaa caaaaagtga aaattctgac acagttcgat gtcttagcag cgctaaagtt 660ttactgactt ttttctgagc acagggatgg aactgatttc ttttcctgaa caagaactac 720ccttaaccac tattgttgaa cgctgaatgg nttcggaaat tagccttngg gcagacttga 780tttgatttct gaatgaattc aacctaaaat tacaaggcaa acgnactnnn nnaaacttac 840actctggnaa agtcatttcg acagctagca tantttttaa ncaaaannat gtcnaacngn 900nttnan 90621845PRTHomo sapiensmisc_featureVMYB DNA binding domain tandem repeats GC rich motifs 218Arg Trp Thr Arg Glu Glu Asp Glu Lys Leu Lys Lys Leu Val Glu Gln1 5 10 15Asn Gly Thr Asp Asp Trp Lys Val Ile Ala Asn Tyr Leu Pro Asn Arg 20 25 30Thr Asp Val Gln Cys Gln His Arg Trp Gln Lys Val Leu 35 40 45219211PRTHomo sapiensmisc_featurebcas4 sequence 1 starting following 219Met Gln Arg Thr Gly Gly Gly Ala Pro Arg Pro Gly Arg Asn His Gly1 5 10 15Leu Pro Gly Ser Leu Arg Gln Pro Asp Pro Val Ala Leu Leu Met Leu 20 25 30Leu Val Asp Ala Asp Gln Pro Glu Pro Met Arg Ser Gly

Ala Arg Glu 35 40 45Leu Ala Leu Phe Leu Thr Pro Glu Pro Gly Ala Glu Ala Lys Glu Val 50 55 60Glu Glu Thr Ile Glu Gly Met Leu Leu Arg Leu Glu Glu Phe Cys Ser65 70 75 80Leu Ala Asp Leu Ile Arg Ser Asp Thr Ser Gln Ile Leu Glu Glu Asn 85 90 95Ile Pro Val Leu Lys Ala Lys Leu Thr Glu Met Arg Gly Ile Tyr Ala 100 105 110Lys Val Asp Arg Leu Glu Ala Phe Val Lys Met Val Gly His His Val 115 120 125Ala Phe Leu Glu Ala Asp Val Leu Gln Ala Glu Arg Asp His Gly Ala 130 135 140Phe Pro Gln Ala Leu Arg Arg Trp Leu Gly Ser Ala Gly Leu Pro Ser145 150 155 160Phe Arg Asn Val Glu Cys Ser Gly Thr Ile Pro Ala Arg Cys Asn Leu 165 170 175Arg Leu Pro Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser Gln Val Ala 180 185 190Gly Ile Thr Glu Val Thr Cys Thr Gly Ala Arg Asp Val Arg Ala Ala 195 200 205His Thr Val 21022023PRTHomo sapiens 220Thr Asp Thr Ala Leu Asp Val Ala Val Lys Thr Phe Pro Pro Glu Arg1 5 10 15His Val Ala Val Lys Cys Phe 2022110PRTHomo sapiens 221Glu Leu Gln Arg Glu Gly Ser Ile Glu Thr1 5 1022210PRTHomo sapiens 222Pro Leu Ser Leu Phe Pro Thr Gly Phe Pro1 5 1022310PRTHomo sapiens 223Asp Thr Ala Leu Asp Val Ala Val Lys Thr1 5 1022410PRTHomo sapiens 224Ser Ala Arg Gly Lys His Arg Asp Ser Glu1 5 1022546PRTHomo sapiensmisc_featuresp|Q9H6U6|69-114 3 WD repeat 225Asp Leu Asn Asp Thr Ser Arg Asn Leu Glu Phe His Glu Ile His Ser1 5 10 15Thr Gly Asn Glu Pro Pro Leu Leu Ile Met Ile Gly Tyr Ser Asp Gly 20 25 30Met Gln Val Trp Ser Ile Pro Ile Ser Gly Glu Ala Gln Glu 35 40 4522641PRTHomo sapiensmisc_featuresp|Q9H6U6|349-389 226Ala His Glu Lys Pro Val Cys Cys Met Ala Phe Asn Thr Ser Gly Met1 5 10 15Leu Leu Val Thr Thr Asp Thr Leu Gly His Asp Phe His Val Phe Gln 20 25 30Ile Leu Thr His Pro Trp Ser Ser Ser 35 4022745PRTHomo sapiensmisc_featuresp|Q9H6U6|403-447 227Glu Thr Glu Ala Lys Val Gln Asp Ile Cys Phe Ser His Asp Cys Arg1 5 10 15Trp Val Val Val Ser Thr Leu Arg Gly Thr Ser His Val Phe Pro Ile 20 25 30Asn Pro Tyr Gly Gly Gln Pro Cys Val Arg Thr His Met 35 40 4522820PRTHomo sapiens 228Cys Phe Gly Lys Lys Lys Gly Lys Lys Lys Gln Cys Gln Gln Pro Ser1 5 10 15Val Arg Glu Gln 2022924PRTHomo sapiensmisc_featuresp|Q9H6U6|403-447 sequence in isoform 5 229Pro Asn Ser Asn Lys Ala Cys Val Arg Asp Gly Gly Arg Thr Ser Ala1 5 10 15Arg Gly Lys His Arg Asp Ser Glu 2023087PRTHomo sapiens 230Gln Val Gln Trp His Asp Phe Gly Ser Leu Gln Pro Leu Pro Pro Gly1 5 10 15Phe Lys Arg Phe Ser Cys Leu Ser Leu Pro Arg Ser Trp Asp Tyr Arg 20 25 30His Pro Pro Pro Arg Pro Ala Asn Phe Glu Phe Leu Val Glu Thr Gly 35 40 45Phe Leu His Val Gly Gln Ala Gly Leu Gln Leu Leu Thr Ser Gly Asp 50 55 60Leu Pro Ala Ser Ala Ser Gln Ser Ala Arg Ile Thr Gly Val Ser His65 70 75 80Arg Ala Arg Pro Gly Ile Phe 8523128PRTHomo sapiens 231Ala Asp Asn Asn Phe Thr Gln Glu Thr Ala Met Thr Met Ile Thr Pro1 5 10 15Ser Tyr Leu Gly Asp Thr Ile Glu Tyr Ser Ser Tyr 20 2523222PRTHomo sapiens 232Ala Ser Asn Ala Leu Gly Ala Leu Pro Tyr Gly Arg Pro Ala Gly Gly1 5 10 15Arg Glu Phe Thr Ser Asp 20233151PRTHomo sapiensmisc_featuresp|Q6AI08|HEAT6_HUMAN HEAT repeat-containing protein 6 OS=Homo sapiens GN=HEATR6 PE=1 SV=1 Sequence 2 233Met Ala Ala Val Gln Val Val Gly Ser Trp Pro Ser Val Gln Pro Arg1 5 10 15Glu Ala Pro Arg Glu Ala Ile Pro Glu Arg Gly Asn Gly Phe Arg Leu 20 25 30Leu Ser Ala Arg Leu Cys Ala Leu Arg Pro Asp Asp Ser Ser Ser Ala 35 40 45Arg Thr Glu Ile Pro Gln Gln Ser Glu Ser Ser Ala Ser Arg Pro Thr 50 55 60Leu Asn Lys Lys Lys Lys Ser Lys Val Lys Pro Lys Lys Ile Gln Gln65 70 75 80Gly Glu Glu Glu Glu Lys Glu Ser Ser Gly Glu Ile Glu Ala Ala Pro 85 90 95Val Thr Leu Ser Ala Ile Leu Glu Gly Ser Lys Gln Phe Leu Ser Val 100 105 110Ala Glu Asp Thr Ser Asp His Arg Arg Ala Phe Thr Pro Phe Ser Val 115 120 125Met Ile Ala Cys Ser Ile Arg Glu Leu His Arg Cys Leu Leu Leu Ala 130 135 140Leu Val Ala Glu Ser Ser Ser145 1502345PRTHomo sapiensmisc_featureNatural variations Alternative sequence 1 162 162 MEIPN 234Met Glu Ile Pro Asn1 52355PRTHomo sapiensmisc_featureNatural variations Alternative sequence 1 162 VHGEE 235Val His Gly Glu Glu1 523623PRTHomo sapiensmisc_featureNatural variations in isoform 5 VSP_036384 236Met Glu Glu Ala Ser Cys Pro Thr Cys Ser Val Asn Glu Ala Cys Glu1 5 10 15Trp Thr Pro Phe Ser Gln Lys 202377PRTHomo sapiensmisc_featureAlternative sequence 1 ? 70 70 Missing in isoform 4. VSP_036385 MEDYSKM in isoform 2 conflict 535 4 DSTC / EAL in BAA25019. Ref.2 237Met Glu Asp Tyr Ser Lys Met1 52385PRTHomo sapiensmisc_featureSequence conflict 591 / 602 ASEHW 238Ala Ser Glu His Trp1 52395PRTHomo sapiensmisc_featureSequence conflict 591 / 602 12 KVVSC 239Lys Val Val Ser Cys1 524012PRTHomo sapiensmisc_featurePQSTGTARWFPV in BAA25019 240Pro Gln Ser Thr Gly Thr Ala Arg Trp Phe Pro Val1 5 1024153PRTHomo sapiensmisc_featureHELICASE Probable ATP-dependent RNA helicase DHX40 779 aas 241Gln Gln Arg Arg Ile Phe Leu Pro Pro Pro Pro Gly Ile Arg Lys Cys1 5 10 15Val Ile Ser Thr Asn Ile Ser Ala Thr Ser Leu Thr Ile Asp Gly Ile 20 25 30Arg Tyr Val Val Asp Gly Gly Phe Val Lys Gln Leu Asn His Asn Pro 35 40 45Arg Leu Gly Leu Glu 502427PRTHomo sapiensmisc_featureIsoform 3 (identifier Q8IX18-3) 716-722 REDARRR The sequence of this isoform differs from the canonical sequence as follows 242Arg Glu Asp Ala Arg Arg Arg1 52437PRTHomo sapiensmisc_featureIsoform 3 (identifier Q8IX18-3) The sequence of this isoform differs from the canonical sequence as follows 243Met Lys Ile Tyr Tyr Phe Gln1 524425PRTHomo sapiensmisc_featureglobular part of proteinmisc_feature(2)..(2)Xaa is any naturally occurring amino acidmisc_feature(9)..(10)Xaa is any naturally occurring amino acidmisc_feature(15)..(16)Xaa is any naturally occurring amino acidmisc_feature(20)..(20)Xaa is any naturally occurring amino acidmisc_feature(22)..(22)Xaa can be any naturally occurring amino acid 244Gly Xaa Trp Leu Thr Pro Val Ile Xaa Xaa Leu Trp Glu Ala Xaa Xaa1 5 10 15Gly Gly Ser Xaa Glu Xaa Arg Ser Ser 20 2524512PRTHomo sapiensmisc_featuresecond important domain 245Leu Arg Gly Arg Gly Trp Trp Leu Trp Pro Val Ile1 5 1024619PRTHomo sapiensmisc_featuredomain variantmisc_feature(2)..(2)Xaa is any naturally occurring amino acidmisc_feature(13)..(13)Xaa is any naturally occurring amino acid 246Leu Xaa Gly Arg Ala Arg Trp Leu Trp Pro Val Ile Xaa Ala Leu Thr1 5 10 15Glu Ala Glu247904DNAHomo Sapiensmisc_featureA1S6 clone extracted from MCF7 cellsmisc_feature(2)..(2)n is a, c, g, or tmisc_feature(5)..(5)n is a, c, g, or tmisc_feature(7)..(7)n is a, c, g, or tmisc_feature(10)..(11)n is a, c, g, or tmisc_feature(17)..(17)n is a, c, g, or tmisc_feature(751)..(751)n is a, c, g, or tmisc_feature(768)..(768)n is a, c, g, or tmisc_feature(824)..(824)n is a, c, g, or tmisc_feature(828)..(832)n is a, c, g, or tmisc_feature(848)..(848)n is a, c, g, or tmisc_feature(873)..(873)n is a, c, g, or tmisc_feature(881)..(881)n is a, c, g, or tmisc_feature(887)..(888)n is a, c, g, or tmisc_feature(894)..(894)n is a, c, g, or tmisc_feature(898)..(898)n is a, c, g, or tmisc_feature(900)..(901)n is a, c, g, or t 247tntangngan nataganact caagctatgc atccaacgcg ttgggagctc tcccatatgg 60tcgacctgca ggcggccgcg aattcactag tgatttccta tgcttgacta ttagcctttc 120agtgagagca gttgctcaga gttgaggaca ctcggaacaa ccatcaactg tcaattaaga 180aacatggcaa attatttcag tggttttccc tggctcttgc tgagtttatt accacaatgc 240tcagttgttg tttacttagg gaatcaatgc caagtttgaa gtgactgaag aaccagcctg 300tatgaacagt ccatgtggaa gagctacgtg tgagagtatt ttcagagaag ctgagaaaac 360gctaaatgag tacagcctaa actggaatat gctaggcagt gttacaactg atggtggtaa 420aaatgcgcgg aacagaaagg gggtcaaaca tgcaaaacct gtgtaagggt tactcactgc 480attactcatg agcatgtacc ttgtgggaaa cacatgaatc tattgtgctc atgaacgagt 540aatgtcagtg atgaatttaa cacgctcctg tgaacctgac catcagcagg tcatgagttt 600ctgtcagaaa caaaaagtga aaattctgac acagttcgat gtcttagcag cgctaaagtt 660ttactgactt ttttctgagc acagggatgg aactgatttc ttttcctgaa caagaactac 720ccttaaccac tattgttgaa cgctgaatgg nttcggaaat tagccttngg gcagacttga 780tttgatttct gaatgaattc aacctaaaat tacaaggcaa acgnactnnn nnaaacttac 840actctggnaa agtcatttcg acagctagca tantttttaa ncaaaannat gtcnaacngn 900nttt 90424820RNAArtificial Sequenceoligonucleotide siRNA sequence of seq NO 150misc_featureSynthetic 248gagcuaauag ucaagcauau 2024946PRTHomo sapiens 249Met Lys Phe Phe Val Phe Ala Leu Ile Leu Ala Leu Met Leu Ser Met1 5 10 15Thr Gly Ala Asp Ser His Ala Lys Arg His His Gly Tyr Lys Arg Lys 20 25 30Phe His Glu Lys His His Ser His Gln Gly Tyr Arg Ser Asn 35 40 4525020RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 250gagcuaauag ucaagcauau 2025120RNAArtificial SequencesiRNA reverse complement of sequence 250 of seq NO 150misc_featureSynthetic 251auaugcuuga cuauuagcuc 2025220RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 252ggaagaaucu caucucagau 2025320RNAArtificial SequencesiRNA reverse complement of sequence 252 of seq NO 150misc_featureSynthetic 253aucugagaug agauucuucc 2025420RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 254gagagucauc uuacucagau 2025520RNAArtificial SequencesiRNA reverse complement of sequence 254 of seq NO 150 255aucugaguaa gaugacucuc 2025620RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 256gcugggugug guagugcauu 2025720RNAArtificial SequencesiRNA reverse complement of sequence 256 of seq NO 150misc_featureSynthetic 257aaugcacuac cacacccagc 2025820RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 258gucaagagau cgagaccauu 2025920RNAArtificial SequencesiRNA reverse complement of sequence 258 of seq NO 150misc_featureSynthetic 259aauggucucg aucucuugac 2026020RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 260gucaucuuac ucagagcauu 2026120RNAArtificial SequencesiRNA reverse complement of sequence 260 of seq NO 150misc_featureSynthetic 261aaugcucuga guaagauguc 2026220RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 262ggaguauagg aaucuccuau 2026320RNAArtificial SequencesiRNA reverse complement of sequence 262 of seq NO 150misc_featureSynthetic 263auaggagauu ccuauacucc 2026420RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 264gccuggcgac agugugagau 2026522RNAArtificial SequencesiRNA reverse complement of sequence 264 of seq NO 150misc_featureSynthetic 265aucucacaca cugucgccag gc 2226620RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 266gccuguaguc ccagcuacuu 2026720RNAArtificial SequencesiRNA reverse complement of sequence 266 of seq NO 150misc_featureSynthetic 267aaguagcugg gacuacaggc 2026820RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 268ggaaucuccu acauugccuu 2026920RNAArtificial SequencesiRNA reverse complement of sequence 268 of seq NO 150misc_featureSynthetic 269aaggcaaugu aggagauucc 2027020RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 270gacucucagc uuuagguguu 2027120RNAArtificial SequencesiRNA reverse complement of sequence 270 of seq NO 150misc_featureSynthetic 271aacaccuaaa gcugagaguc 2027220RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 272gcucaugccc guaaucccau 2027320RNAArtificial SequencesiRNA reverse complement of sequence 272 of seq NO 150misc_featureSynthetic 273augggauuac gggcaugagc 2027420RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 274ggaauugaau uaauggaguu 2027520RNAArtificial SequencesiRNA reverse complement of sequence 274 of seq NO 150misc_featureSynthetic 275aacuccauua auucaauucc 2027620RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 276ggcaggcaga ucaugagguu 2027720RNAArtificial SequencesiRNA reverse complement of sequence 276 of seq NO 150misc_featureSynthetic 277aaccacauga ucugccugcc 2027820RNAArtificial SequencesiRNA sequence of seq NO 150 (ex118)misc_featureSynthetic 278gaaucuccua cauugccuau 2027920RNAArtificial SequencesiRNA reverse complement of sequence 278 of seq NO 150misc_featureSynthetic 279auaggcaaug uaggagauuc 2028049RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 280gagauggcgc cacuguacuu ucaauucucu accgcgguga caugaagag 4928123RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0001787misc_featureSynthetic 281uagcuuauca gacugguguu ggc 2328273RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0003325misc_featureSynthetic 282ugucaaauag cuuaucagac ugguguuggc uguuaagauu gcaaggcgac aacagucugu 60aggcugucug aca 73283119RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0004994misc_featureSynthetic 283cugacauuuu gguaucucuc auguaccauc cugucggaua gcuuaucaga cugauguuga 60cuguuggauc ucauggcaac aacagucggu aggcugucug acauuuuugg uaucucuca 11928422RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0003774misc_featureSynthetic 284uagcuuauca gacugauguu ga 2228574RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0005275misc_featureSynthetic 285ugucggguag cuuaucagac ugauguugac uguuggaucu cauggcaaca gcagucgaug 60agcugucuga cauu 7428622RNAArtificial SequenceSyntheticmisc_featureSyntheticmisc_featureMicroRNA mIR-21 MIMAT 0002320 286uagcuuauca gacugauguu ga 2228792RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0000569misc_featureSynthetic 287uguaccaccu ugucggauag cuuaucagac ugauguugac uguugaaucu cauggcaaca 60gcagucgaug ggcugucuga cauuuuggua

uc 9228822RNAArtificial SequenceMicroRNA mIR-21 MIMAT 0004628misc_featureSynthetic 288caacagcagu cgaugggcug uc 2228949RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 289gagcuaauag ucaagcauau ucaauucucg auuaucaguu cguauagag 4929049RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 290ggaagaaucu caucucagau ucaauuccuu cuuagaguag agucuagag 4929149RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 291gagagucauc uuacucagau ucaauucucu caguagaaug agucuagag 4929249RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 292gcugggugug guagugcauu ucaauucgac ccacaccauc acguaagag 4929349RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 293gucaagagau cgagaccauu ucaauucagu ucucuagcuc ugguaagag 4929449RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 294gucaucuuac ucagagcauu ucaauucagu agaaugaguc ucguaagag 4929549RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 295ggaguauagg aaucuccuau ucaauuccuc auauccuuag aggauagag 4929649RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 296gccuggcgac agugugagau ucaauucgga ccgcugucac acucuagag 4929749RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 297gccuguaguc ccagcuacuu ucaauucgga caucaggguc gaugaagag 4929849RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 298ggaaucuccu acauugccuu ucaauuccuu agaggaugua acggaagag 4929949RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 299gacucucagc uuuagguguu ucaauucuga gagucgaaau ccacaagag 4930049RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 300gcucaugccc guaaucccau ucaauucgag uacgggcauu aggguagag 4930149RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 301ggaauugaau uaauggaguu ucaauuccuu aacuuaauua ccucaagag 4930249RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 302ggcaggcaga ucaugagguu ucaauuccgu ccgucuagua cuccaagag 4930349RNAArtificial SequencesiRNA sequence of seq NO 150misc_featureSynthetic 303gaaucuccua cauugccuau ucaauucuua gaggauguaa cggauagag 4930423PRTHomo sapiens 304Leu Ser Asn Pro Asn Ile Ser Tyr Ser Phe Val Cys Ile Tyr Cys Gly1 5 10 15Leu Gly Leu His Met Phe Ser 20305121PRTHomo sapiensMISC_FEATUREDomain 612 / 732 SET Motif of Histone-lysine N-methyltransferase EZH1 305Lys Lys His Leu Leu Leu Ala Pro Ser Asp Val Ala Gly Trp Gly Thr1 5 10 15Phe Ile Lys Glu Ser Val Gln Lys Asn Glu Phe Ile Ser Glu Tyr Cys 20 25 30Gly Glu Leu Ile Ser Gln Asp Glu Ala Asp Arg Arg Gly Lys Val Tyr 35 40 45Asp Lys Tyr Met Ser Ser Phe Leu Phe Asn Leu Asn Asn Asp Phe Val 50 55 60Val Asp Ala Thr Arg Lys Gly Asn Lys Ile Arg Phe Ala Asn His Ser65 70 75 80Val Asn Pro Asn Cys Tyr Ala Lys Val Val Met Val Asn Gly Asp His 85 90 95Arg Ile Gly Ile Phe Ala Lys Arg Ala Ile Gln Ala Gly Glu Glu Leu 100 105 110Phe Phe Asp Tyr Arg Tyr Ser Gln Ala 115 12030619RNAArtificial Sequenceoligonucleotidic probemisc_featureSynthetic 306uugguaacga ccaugccac 1930719RNAArtificial Sequenceoligonucleotide probemisc_featureSynthetic 307uucacuuaga auaaugucc 1930819RNAArtificial Sequenceoligonucleotide probemisc_featureSynthetic 308ucuuugugaa uuugacaac 1930919RNAArtificial Sequenceoligonucleotide probemisc_featureSynthetic 309ucaaggucca ggcuacaac 1931019RNAArtificial SequencesiRNA sequence of SEQ ID NO 150misc_featureSynthetic 310guggcauggu cguuaccaa 1931119RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 311caccguacca gcaaugguu 1931219RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 312ggacauuauu cuaagugaa 1931319RNAArtificial SequencesiRNA 1 sequence of SEQ ID NO 150misc_featureSynthetic 313ccuguaauaa gauucacuu 1931446PRTArtificial SequenceSubsection of Liv21K of SEQ ID NO 180misc_featureSyntheticmisc_feature(3)..(3)Xaa can be any naturally occurring amino acidmisc_feature(10)..(10)Xaa can be any naturally occurring amino acidmisc_feature(17)..(17)Xaa can be any naturally occurring amino acidmisc_feature(22)..(24)Xaa can be any naturally occurring amino acidmisc_feature(31)..(31)Xaa can be any naturally occurring amino acidmisc_feature(37)..(38)Xaa can be any naturally occurring amino acidmisc_feature(42)..(42)Xaa can be any naturally occurring amino acidmisc_feature(45)..(45)Xaa can be any naturally occurring amino acid 314Ser Val Xaa Gln Ala Gly Val Gln Trp Xaa Asn Leu Gly Ser Leu Gln1 5 10 15Xaa Leu Pro Pro Gly Xaa Xaa Xaa Phe Ser Cys Leu Ser Leu Xaa Ser 20 25 30Ser Trp Asp Tyr Xaa Xaa Leu Pro Pro Xaa Pro Ala Xaa Phe 35 40 4531543PRTArtificial SequenceSubsection of Liv21K SEQ ID NO 180misc_featureSyntheticmisc_feature(3)..(3)Xaa can be any naturally occurring amino acidmisc_feature(10)..(10)Xaa can be any naturally occurring amino acidmisc_feature(17)..(17)Xaa can be any naturally occurring amino acidmisc_feature(23)..(24)Xaa can be any naturally occurring amino acidmisc_feature(28)..(28)Xaa can be any naturally occurring amino acidmisc_feature(38)..(38)Xaa can be any naturally occurring amino acidmisc_feature(42)..(42)Xaa can be any naturally occurring amino acid 315Ser Val Xaa Gln Ala Gly Val Gln Trp Xaa Asn Leu Gly Ser Leu Gln1 5 10 15Xaa Leu Pro Pro Gly Phe Xaa Xaa Phe Ser Cys Xaa Ser Leu Ser Ser 20 25 30Trp Asp Tyr Arg Arg Xaa Pro Pro Arg Xaa Ala 35 4031621PRTArtificial SequencePreserved Region between SEQ ID NO 314 and 315 of Liv21Kmisc_featureSyntheticmisc_feature(4)..(4)Xaa can be any naturally occurring amino acidmisc_feature(6)..(6)Xaa can be any naturally occurring amino acidmisc_feature(14)..(14)Xaa can be any naturally occurring amino acidmisc_feature(17)..(19)Xaa can be any naturally occurring amino acidmisc_feature(21)..(21)Xaa can be any naturally occurring amino acid 316Ile Ser Pro Xaa Asp Xaa Pro Ala Ser Ala Ser Gln Ser Xaa Gly Ile1 5 10 15Xaa Xaa Xaa Ser Xaa 2031738PRTArtificial SequenceSequence of Liv21I Complexmisc_featureSynthetic 317Phe Leu Tyr Phe Pro Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val1 5 10 15Ser Ile Ser Pro Arg Asp Pro Pro Ala Ser Ala Ser Gln Ser Val Gly 20 25 30Ile Ala Tyr Ile Ser Asn 3531811PRTArtificial SequenceVariation of end region of Liv21I of SEQ ID 317misc_featureSynthetic 318Pro Ala Ser Ala Ser Gln Ser Ala Gly Ile Thr1 5 1031912PRTArtificial SequenceVariation of end region of Liv 21I of SEQ ID 317misc_featureSynthetic 319Asp Pro Pro Thr Ser Ala Ser Gln Ser Val Gly Ile1 5 1032025PRTArtificial SequenceVariation for Liv21F or Liv21Kmisc_featureSynthetic 320Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp Asp Tyr Arg Arg Leu Pro1 5 10 15Pro Arg Pro Ala Thr Phe Leu Tyr Phe 20 2532125PRTArtificial SequenceVariation of Liv21F and Liv21Kmisc_featureSynthetic 321Phe Ser Cys Leu Ser Leu Pro Ser Ser Trp Asp Tyr Arg Arg Pro Pro1 5 10 15Pro Arg Pro Ala Asn Phe Leu Tyr Phe 20 2532224PRTArtificial SequenceHomologous region between Liv21e and Liv21Kmisc_featureSynthetic 322Lys Phe Phe Val Phe Ala Leu Ile Leu Ala Leu Met Leu Ser Met Cys1 5 10 15Gly Ala Asp Ser His Ala Lys Arg 203239PRTHomo Sapiens 323Phe Ala Val Ala Phe Pro Val Gly Arg1 532419DNAHomo sapiensmisc_featureOlilgonucleotide Primer 324gtggtaaagc acccaggaa 1932520DNAHomo sapiensmisc_featureOligonucleotide Primer 325gctagctgga tgtcttttgc 2032619DNAHomo sapiensmisc_featureOligonucleotide Primer 326tgaaggtcgg agtcaacgg 1932718DNAHomo sapiensmisc_featureoligonucleotide primer 327catgtgggcc atgaggtc 1832820DNAHomo sapiensmisc_featureoligonucleotide primer 328ggacttcgag caagagatgg 2032920DNAHomo sapiensmisc_featureoligonucleotide primer 329agcactgtgt tggcgtacag 2033020DNAHomo sapiensmisc_featureoligonucleotide primer 330tcctatgctt tgactattag 2033123DNAHomo sapiensmisc_featureoligonucleotide primer 331cctgacatcc ctacatcacc gca 2333217DNAHomo sapiensmisc_featureoligonucleotide primer 332atgtatatta tatctaa 1733320DNAHomo sapiensmisc_featureoligonucleotide primer 333tgttgggatt gcttatattt 2033420DNAHomo sapiensmisc_featureoligonucleotide primer 334aaatataagc aatcccaaca 2033519DNAHomo sapiensmisc_featureoligonucleotide primer 335ctttattatt ttgtaaaat 1933620DNAHomo sapiensmisc_featureoligonucleotide primer 336aaatataagc aatcccaaca 2033720DNAHomo sapiensmisc_featureoligonucleotide primer 337tgttgggatt gcttatattt 2033819DNAHomo sapiensmisc_featureoligonucleotide primer 338ctttattatt ttgtaaaat 1933918DNAHomo sapiensmisc_featureoligonucleotide primer 339atttacaaaa taataaag 1834023DNAHomo sapiensmisc_featureoligonucleotide primer 340cctgacatcc ctacatcacc cat 2334119DNAHomo sapiensmisc_featureoligonucleotide primer 341tcctatgctt gactattgc 193429PRTHomo Sapiens 342Arg Tyr Leu Pro Ser Ala Asn Pro Asp1 53437PRTHomo sapiens 343Leu Ala His Tyr Asn Lys Arg1 534410PRTHomo sapiens 344Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys1 5 103459PRTHomo sapiens 345Met Glu Glu Ala Leu Gly Arg Val Lys1 53468PRTHomo sapiens 346Glu Glu Ala Leu Gly Arg Val Lys1 53478PRTHomo sapiens 347Glu Thr Pro Ala Ser Asp Lys Lys1 534824RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 348gggaguagcc caagaaucau ucaa 2434924RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 349guugggagcu cucccauauu ucaa 2435024RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 350gggcaagacu cugucucaau ucaa 2435124RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 351gguuaagcug agaucugaau ucaa 2435224RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 352gaguagccca agaaucacuu ucaa 2435324RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 353gugagccaag accacaucau ucaa 2435424RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 354gaugguuaag cugagaucuu ucaa 2435524RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 355gugaugguua agcugagauu ucaa 2435624RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 356ggcggccgcg aauucacuau ucaa 2435724RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 357gccgcgaauu cacuagugau ucaa 2435824RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 358gggagcucuc ccauaugguu ucaa 2435924RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 359gccuggccaa cauggcaaau ucaa 2436024RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 360gguaacaggg caagacucuu ucaa 2436124RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 361gcccguaauc ccagcuacuu ucaa 2436224RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 362ggccaggagu ucaagaccau ucaa 2436324RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 363gaagugaugg uuaagcugau ucaa 2436424RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 364gcacacgccc guaaucccau ucaa 2436524RNAArtificial SequenceSyntheticmisc_featuresense strand of siRNA 365gcuaccuuac cuuuggcauu ucaa 2436624DNAArtificial SequenceSynthetic 366ggaaucuccu acauugccuu ucaa 2436725DNAArtificial SequenceSynthetic 367gagaaggcaa uguaggagau uccuu 2536824DNAArtificial SequenceSynthetic 368gacucucagc uuuagguguu ucaa 2436925DNAArtificial SequenceSynthetic 369gagaacaccu aaagcugaga gucuu 2537024DNAArtificial SequenceSynthetic 370gcucaugccc guaaucccau ucaa 2437125DNAArtificial SequenceSynthetic 371gagaugggau uacgggcaug agcuu 2537224DNAArtificial SequenceSynthetic 372ggaauugaau uaauggaguu ucaa 2437325DNAArtificial SequenceSynthetic 373gagaacucca uuaauucaau uccuu 2537424DNAArtificial SequenceSynthetic 374ggcaggcaga ucaugagguu ucaa 2437525DNAArtificial SequenceSynthetic 375gagaaccuca ugaucugccu gccuu 2537624DNAArtificial SequenceSynthetic 376gaaucuccua cauugccuau ucaa 2437725DNAArtificial SequenceSynthetic 377gagauaggca auguaggaga uucuu 25

Claims

1. A Human Liv 21 complex characterized in that it comprises: a nucleotide sequences selected from SEQ ID N.degree. 171 to 175 and SEQ ID 217 an siRNA sequence derived from one of the RNA sequences seq120 and 121 and 171 to 175 and all siRNA sequences (SEQ ID 91 to 118) a protein fraction comprising at least sequence SEQ ID 1 to 181 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said SEQ ID 1 to 181 and SEQ ID N.degree. 183 and SEQ ID N.degree. 215 to 220 or a sequence having 70, 80 or 90% identity with said sequence SEQ ID 183 and 215 to 220 and SEQ ID 230.

2. Liv 21 human complex according to claim 1, further comprising: A nucleotide sequences SEQ ID N.degree. 123, 124, 127 and the protein fractions comprising at least sequence SEQ ID No. 1 or a sequence having 70, 80 or 90% identity with said sequence SEQ ID N.degree. 1 and the sequences 181 to 185.

3. The Liv21 human complex according to claim 1 further comprising: The nucleotide sequences of any one or ribonucleotide sequence SEQ ID N.degree. 119 to 126 or 127, or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID N.degree. 119 to 127, or sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID N.degree. 119 to 127, or UUGGUAACGACCAUGCCAC or UUCACUUAGAAUAAUGUCC or UCUUUGUGAAUUUGACAAC or UCAAGGUCCAGGCUACAAC or any of the following siRNA sequences SEQ ID IN.degree. 60 to 88 and 92 to 118, and TABLE-US-00016 GUGGCAUGGUCGUUACCAA dTdT DTdT CACCGUACCAGCAAUGGUU GGACAUUAUUCUAAGUGAA dTdT

4. Liv21 human complex according to claim 1, further comprising at least one of: Any one of the nucleotide sequences SEQ ID No. 123, 124 and SEQ ID N.degree. 127 to 149 or Any one of amino acid sequences SEQ ID N.degree. 1 to 118 and SEQ ID N.degree. 150 to 170 and SEQ ID N.degree. 180 to 185: or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequences SEQ ID N.degree.: 1 to 185.

5. Liv21 human complex according to claim 1, characterized in that it interacts with at least one associated partners, said at least one associated partners being selected from the group consisting of; any of the following proteins: RBP2, TNF alpha crb2, cmd2, cycE/cdk2, cdk1, CREB1 and p300, Rb, p107, p130 of family of pocket proteins, NFkB, cdc2A, mdm2, p21, p53, p65, p'73, CyclinA and D1, BCAS3, BCAS4, Solute Carrier; or a antibody of any one of the following proteins: RBP2, E2F4, E2F1, E2F2, SUMO, HDAC1, crb2, Int2, cmd2, cycE/cdk2, cdk1, CREB1 and p300, Rb, p107, p130 of family of pocket proteins, NFkB, cdc2A, mdm2, p21, p53, p65, Ki67, CAF1, CyclinA and D1, CHUK, BCAS3, BCAS4,Solute Carrier.

6. A method of detecting the complex human Liv21, characterized in that it comprises the implementation of at least one probe specific for at least one sequence of said human Liv21 complex selected from: a nucleotide sequences selected from SEQ ID NO: 171 to 175 and. SEQ ID NO: 217 a siRNA sequence derived from one of the RNA sequences SEQ ID NO: 120 and SEQ ID NO: 121 and SEQ ID NO: 171 to 175 and all siRNA sequences (SEQ ID NO: 91 to 118) a protein fraction comprising at least sequence SEQ ID NO: 1 to 181 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said SEQ ID NO: 1 to 181 and SEQ ID NO: 183 and SEQ ID NO: 215 to 220 or a sequence having 70, 80 or 90% identity with said sequence SEQ ID NO: 183 and 215 to 220 and SEQ ID NO: 230, or nucleotide sequences SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 127 and the protein fractions comprising at least sequence SEQ ID NO: 1 or a sequence having 70, 80 or 90% identity with said sequence SEQ ID NO: 1 and the sequences SEQ ID NO: 181 to 185, a nucleotide sequences of any one or ribonucleotide sequence SEQ ID NO: 119 to 126 or SEQ ID NO: 127, or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID NO: 119 to 127, or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID NO: 119 to 127, or UUGGUAACGACCAUGCCAC or UUCACUUAGAAUAAUGUCC or UCUUUGUGAAUUUGACAAC or UCAAGGUCCAGGCUACAAC or any of the following siRNA sequences SEQ ID NO: 60 to 88 and SEQ ID NO: 92 to 118, and TABLE-US-00017 GUGGCAUGGUCGUUACCAA dTdT dTdT CACCGUACCAGCAAUGGUU GGACAUUAUUCUAAGUGAA dTdT,

any one of the nucleotide sequences SEQ ID NO: 123, SEQ ID NO: 124 and SEQ ID NO: 127 to 149 or any one of amino acid sequences SEQ ID NO: 1 to 118 and SEQ ID NO: 150 to 170 and SEQ ID NO: 180 to 185: or a sequence having 90%, and preferably 80%, and more preferably 70% identity with the sequences SEQ ID NO: 1 to 185.

7. (canceled)

8. Method of detecting the human complex Liv21 according to claim 6, further comprising the implementation of at least one probe specific for at least one of associated partners selected from the group consisting of: any of the following proteins: RBP2, TNF alpha crb2, cmd2, cycE/cdk2, cdk1, CREBI and p300, Rb, p1 07, p130 of family of pocket proteins, NFkB, cdc2A, mdm2, p21, p52, p65, p73, CyclinA and D1, BCAS3, BCAS4, Solute Carrier; or a antibody of any one of the following proteins: RBP2, E2E4, E2F1, E2F2, SUMO, HDACI, crb2, Int2, cmd2, cycE/cdk2, cdk1, CREBI and p300, Rb, p1 07, p130 of family of pocket proteins, NFkB, cdc2A, mdm2, p21, p53, p65, Ki67, CAFI, CyclinA and DI, CHUK, BCAS3 BCAS4, Solute Carrier.

9. (canceled)

10. The method of detecting the human complex Liv21 according to claim 6, comprising the following steps: A step of extracting biological material from a biological sample taken. from a patient, A step of contacting said biological material with at least said specific probe of any one of said. sequences of said human complex Liv21 and its associated partners, and at least one control and A step of detecting the expression products of gene expression said human Liv21 complex and its associated partners, said products being comprised of expression of messenger RNA, or peptides, or proteins.

11. Method of detecting the human complex Liv 21 according to claim 10, comprising a step of screening a candidate compound capable of modulating the activity of said human. complex Liv21, wherein said step of screening comprises a step of contacting said biological material with said candidate compound, and a step of selecting said candidate compound.

12. Method of detecting the human complex Liv21 according to claim 11, wherein said biological sample is taken from a cancer patient and from a healthy patient, and wherein said biological material comprises nuclear cell extracts, cell extracts and cytoplasmic or cell extracts membrane, and wherein the emthod further comprises a step of determining the sub-expression and overexpression of the gene products of said complex or said complex Liv21 or said Liv21 human. complex and. associated partners said biological extracts.

13. The method of detecting the human complex. Liv21 according to claim 12 further comprising a step of determining ratios of said sub-expression and overexpression of the gene products of said cell nuclear extracts and said cytoplasmic cell extracts, or said membrane cell extracts, and wherein the method further comprises a step of combined analysis of said ratios of said biological material taken from a cancer patient and in a healthy patient

14. The method of detecting the human complex Liv21 according to claim 10, characterized in that it uses a biochip on which is deposited at least one sequence-specific probe from said human Liv21 complex comprising a nucleotide sequences selected from SE ID NO: 171 to 175 and SEQ ID NO: 217 a siRNA sequence derived from one of the RNA sequences SEQ ID NO: 120 and SEQ ID NO: 121 and SEQ ID NO: 171 to 175 and all siRNA sequences (SEQ ID NO: 91 to 118 and SEQ ID NO: 248 to 303) a protein fraction comprising at least sequence SEQ ID NO: 1 to 181 or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said SEQ ID NO: 1 to 181 and SEQ ID NO: 183 and SEQ ID NO: 215 to 220 or a sequence having 70, 80 or 90% identity with said sequence SEQ ID NO: 183 and 215 to 220 and SEQ ID NO: 230, a nucleotide sequences SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 127 and the protein fractions comprising at least. sequence SEQ ID NO: 1 or a sequence having 70, 80 or 90% identity with said sequence SEQ ID NO: 1 and the sequences SEQ ID NO: 181 to 185, a nucleotide sequences of any one or ribonucleotide sequence SEQ ID NO: 119 to 126 or SEQ ID NO: 127, or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID NO: 119 to 127, or a sequence having 90%, and preferably 80%, and more preferably 70% identity with said sequence SEQ ID NO: 119 to 127, or UUGGUAACGACCAUGCCAC or UUCACUUAGAAUAAUGUCC or UCUUUGUGAAUUUGACAAC or UCAAGGUCCAGGCUACAAC or any of the following siRNA sequences SEQ ID NO: 60 to 88 and SEQ ID NO: 92 to 118, and TABLE-US-00018 GUGGCAUGGUCGUUACCAA dTdT dTdT CACCGUACCAGCAAUGGUU GGACAUUAUUCUAAGUGAA dTdT,

any one of the nucleotide sequences SEQ ID NO: 123, SEQ ID NO: 124 and SEQ ID NO: 127 to 149 or any one of amino acid sequences SEQ ID NO: 1 to 118 and SEQ ID NO: 150 to 170 and SEQ ID NO: 180 to 185: or a sequence having 90%, and preferably 80%, and more preferably 70% identity with the sequences SEQ ID NO: 1 to 185.

15. The method according to claim 10, characterized in that it applies to brain cancer, neuroblastoma, glioblastoma, without being limited there and breast cancer, bladder, skin and prostate and Alzheimer's disease.

16. (canceled)

17. A method of treating cancers comprising the injection of a peptide selected from a vectorized peptide of SEQ ID N.degree.: 215 to 220.

18. The method according to claim 6, wherein said probe is specific of the SEC) ID NO: 150 or to a sequence having 90%, and preferably 80%, and more preferably 70% identity with the SEQ ID NO:150.

19. The method according to claim 14, wherein said sequence-specific probe is specific of the SEQ ID NO: 150 or to a sequence having 90%, and preferably 80%, and more preferably 70% identity with the SEQ ID NO: 150.